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Résumé 
L'objectif de cette étude était de préparer et de caractériser les particules submicroniques 
multifonctionnelles utilisables simultanément pour le diagnostic et le traitement de plusieurs 
maladies mortelles telles que le cancer. Pour ce faire, une étude systématique a été réalisée afin 
de comprendre les mécanismes impliqués et d'optimiser les paramètres du procédé  de double 
émulsion-évaporation de solvant pour la préparation de ces particules. Pour l’imagerie in vitro, 
des nanoparticules polymériques fluorescentes (FluoSpheres®) ont  été encapsulées dans une 
matrice polycaprolactone dégradable en utilisant le procédé de l’émulsion double-évaporation de 
solvant. Pour l’imagerie in-vivo, des nanoparticules d'or colloïdal ont été préparées et 
encapsulées via le même procédé et parfaitement caractérisées. Enfin, pour application 
theranostic, les nanoparticules d'or (comme agent de contraste) et un actif moléculaire 
(hydrophile Nefopam et hydrophobe benzoate de benzyle) ont été encapsulés simultanément 
dans des  particules de polycaprolactone. Ces particules multifonctionnelles ont été caractérisées 
et évaluées in vitro comme model de pénétration cutané. 
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GENERAL INTRODUCTION 
 
 
 
  
1
The application of nanotechnology in biomedical field for therapy of various diseases has 
received substantial attention in recent years. It offers a unique approach against fatal diseases like 
cancer, CVS, HIV and diabetes, through early diagnosis, prediction, prevention and personalized 
therapy1,2. It plays a vital role in target-specific drug therapy and techniques for early diagnosis of 
tumor cells. Nanomedicine has potential for revolutionizing cancer therapy and diagnosis by 
developing new biocompatible nanocarrier systems for drug delivery purposes. These nanosystem 
have four unique properties unlike conventional therapeutics.  
(i) It can be attached to targeting ligands, which have high affinity and specificity for target cells. (ii) 
It can themselves possess therapeutic or diagnostic properties and can be utilize to carry therapeutic 
agents. (iii) It can be designed for loading multiple therapeutic agents simultaneously. (iv) It can 
bypass traditional drug resistance mechanism. 
Due to targeting strategies nanocarrier can achieve high drug concentration in tumor cells while 
minimizing toxicity in normal cells, so enhancing the therapeutic effects and reducing systemic 
toxicity3,4. Combining diagnosis and therapy in one process is referred as theranostic, the basic goal 
of theranostic is to target specific tissue selectively, to monitor the response to the treatment, to 
increase drug efficacy and safety, to increase therapeutic and diagnostic accuracy5. This strategy can 
enable us to make the treatment shorter, safer and more efficient for fetal disease like cancer, HIV, 
diabetes etc. Biocompatible theranostic particles for cancer therapy are under development, which 
would accelerate the therapy, reduce the drug toxicity and side effects. Presently, most of the 
research in theranostic has been focused on the management of cancer, since it is the major disease 
and leading cause of mortality. 
Cancer, also known as malignant tumor is a term used for a group of almost 100 diseases. Its 
two main characteristics are uncontrolled growth of the cells in the human body and the ability of 
these cells to migrate from the original site and spread to distant sites of the body through blood or 
lymph, the process is termed as metastasis.  The most common cancers are skin cancer, lung cancer, 
colon cancer, breast cancer (in women), and prostate cancer (in men). Cancer is a major cause of 
mortality worldwide. In United States, one out of every four deaths is from cancer. About 1.2 million 
Americans are diagnosed with cancer annually; more than 500,000 die of cancer annually6. Normally 
cells (the structural and functional unit of life) grow and divide in a controlled way as they are 
needed to keep the body healthy. However, sometime this orderly process goes wrong. When the 
genetic material of cell (DNA) become damaged or abnormal due to the environmental and genetic 
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factors; consequently, there is uncontrolled proliferation of cells. These cells form a mass of tissue 
called "tumor" or neoplasm (new growth). All tumors are not cancerous; tumors are of two types, 
benign and malignant. (i) Benign tumors aren't cancerous. It is slow growing, does not spread or 
invade surrounding tissue, and once it is removed, doesn't usually recur. (ii) Malignant tumors are 
cancerous. Cells in these tumors can invade nearby tissues and spread to other parts of the body. The 
spread of cancer from one part of the body to another is called metastasis. Some cancers do not form 
tumors. For example, leukemia is a cancer of the bone marrow and blood. 
In spite of many advances in conventional cancer therapy such as chemotherapy and 
radiation7, it is still facing many challenges e.g nonspecific systemic distribution of therapeutic 
agents, inadequate drug concentrations reaching the tumor site, unbearable cytotoxicity, poor 
therapeutic drug response monitoring and development of multiple drug resistance8–10. Therefore, 
there is need of innovative technologies development that could overcome these challenges and help 
to properly identify residual tumor cells, outlines of tumor margins and determine whether a tumor 
has been totally removed11. For effective cancer therapy, the key issue is to achieve the appropriate 
concentration of antitumor agent in cancerous tissue with minimal loss of activity in blood 
circulation, and after reaching the target site, drug should have the ability to destroying tumor cell 
selectively with minimum damage to normal cells12,13. The efficacy of the cancer’s treatment and the 
degree of change in the patient's quality of life is directly related to the treatment's capability to target 
and to kill the tumor cells while affecting as few healthy cells as possible. With this idea, it is 
essential to fabricate a single agent that could contribute potentially in cancer prevention, detection 
and treatment. Various types of tools/carriers have been developed to the date including liposomes, 
polymeric micelles, dendrimers, carbon nanotubes, quantum dots and submicron particles. 
Submicron-size colloidal particles are widely studied due to their numerous applications in 
oncology. Therapeutic and diagnostic agent of interest are encapsulated within their polymeric 
matrix or adsorbed onto the surface of the particle14, and targeted to specific sites by surface 
modifications, to interact with the receptor expressed on tumor cells. By coating the particles with 
polysorbates, they can deliver the drug across the blood-brain barrier, enabling brain targeting after 
intravenous administration of drug. Similarly the efficiency of protein anticancer drug can be 
enhanced by encapsulation of active molecule in polymeric particles and targeting to specific sites. 
Moreover, sub-micron particle can be loaded with multiple types of drugs (both lipophilic and 
hydrophilic) for efficient treatment of tumors , can be loaded with multimodal imaging contrast 
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agents15 and additionally, specific ligands can be attached to their surfaces in order to target surface-
bound molecules on cancer cells. Typically, polymeric theranostic particle can be consisting of three 
main components, i.e. biomedical payload, polymeric carrier, and surface modifier. Biomedical 
“payloads” comprise imaging agents such as, organic dyes, quantum dot, optical contrast agents, 
MRI contrast agents, CT contrast agents, etc and therapeutic agents include anticancer drugs, DNA, 
proteins etc. while, carrier should provide physical support and protection to payload during its 
delivery to specific target. Modifiers are attached to the surface of carrier particle in order to enhance 
its circulation time, increased barrier penetration ability and to provide target specific binding 
abilities16. The submicron carriers can be targeted to cancerous cells by using various targeting 
strategies. The most commonly used approach is to identify a specific biomarker that is aberrantly 
expressed on the surface of cancer cells, and then to load its related binding vector onto carriers to 
achieve recognition and tumor binding.  The unique size scale of the polymeric particles allows 
achievement of an enhanced-permeability-and-retention (EPR) effect in tumor cells targeting. 
Nanoparticle-based imaging and therapy have been widely investigated, which have the 
ability to co-deliver therapeutic and imaging functions. It allows for imaging to be performed not 
only before and after, but also during a treatment regimen. Being non-invasive, imaging techniques 
are considered advantageous over repetitive biopsies of multiple tumor lesions in cancer patients. 
Numerous imaging techniques such as, computed X-ray tomography (CT), optical imaging, magnetic 
resonance imaging (MRI), positron emission tomography (PET), single-photon-emission computed 
tomography (SPECT), and ultrasound have been used for diagnosis of disease including cancer and 
neurodegenerative diseases 5,17,18. These techniques make the visualization of target tissues possible. 
Techniques such as MRI and optical imaging depend on contrast agent to visualize the organ of 
interest, which highlighting the differences between tissues and could augment the efficiency of 
imaging techniques19,20. Iron oxide nanoparticles (IONP), quantum dots, carbon nanotubes, 
fluorescent dyes, gold nanoparticles and silica nanoparticles, have been investigated in the imaging 
setting and are good candidate  for building up nanoparticle-based theranostics.  Gold nanoparticles 
(AuNPs) have also been used as a contrast agent in MRI and other imaging techniques. They possess 
many unique features such as surface plasmon resonance , bioconjugation, chemical stability and 
biocompatibility and have been studied in a variety of imaging field, including, computed tomography 
(CT), photoacoustics and surface-enhanced raman spectroscopy (SERS)21,22. Gold nanoparticles can 
be synthesized in various forms such as, spheres, cubes, rods, cages and wires with accurate quality 
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control and in large capacity. Their particle size and morphology is very important since, it influence 
the physical properties e.g surface plasmon absorption etc of AuNPs23. For example, 10 nm spherical 
Au NPs have maximum absorbance at about 520 nm with characteristic red color, while changing the 
sphere shape to rod-like, on the other hand, can push the absorption to the NIR region (650–900 nm). 
The aim of this work is to prepare sub-micron particle for theranostic applications i.e for 
diagnosis and therapy. For this purpose, initially an optimized particle was prepared by using 
polycaprolactone (PCL) as polymer and polyvinyl alcohol as a stabilizer via double emulsion solvent 
evaporation technique using ultra turrax. All parameters affecting the colloidal property of the 
particles during the process were investigated and optimized. Additionally, the submicron particles 
were also prepared and optimized via double emulsion evaporation technique using power 
ultrasound. In the next step, PCL particles were loaded with fluorescent contrast agent in the 
guidance of the optimized parameters obtained from our previous study, and characterized in term of 
morphology, loading efficiency, size and distribution of fluorescent material in PCL particles. And 
finally gold nanoparticle were prepared to be used as contrast agent and loaded into PCL particles 
along with active drug simultaneously for in-vitro evaluation. 
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General summary 
 
Over the past decade, biodegradable and biocompatible polymers are widely used for
biomedical applications.  Various polymer carriers with different characteristics have been 
developed by different techniques for drug encapsulation but only biodegradable and 
biocompatible polymers are suitable for drug delivery system. Polymeric encapsulation of active 
drug permits enhancement of drug bioavailability, targeted delivery of drug, sustained release of
drug and thus, minimizing the toxicity and side effects. These formulations can protect sensitive 
drug like proteins from degradation when administered via oral route. Thus, they enhance the 
drug efficiency, patient compliance and allow better management of disease. In this review, we
report the commonly used polymers and techniques for micro and nano- encapsulation of active 
molecules, the principal of each technique, their operating conditions and application in drug 
delivery system. 
The choice of technique and selection of suitable polymer is crucial step. It depends on 
the physicochemical properties of the drug to be encapsulated and the polymer to be used. 
Polymers can be either natural or synthetic. Generally, synthetic polymers have more advantages
over natural ones by offering wide range of modifications in properties. The selection criteria of 
polymer for a carrier system depend upon their mechanical properties and degradation rate 
needed for a particular application. Among natural polymers, chitosan, cyclodextrins and dextran
and its derivatives are frequently used. Chitosan is a nontoxic biodegradable polymer and can be 
digested by liposome or chitinases, which are present in human intestine and blood. It has
mucoadhesive properties due to its positive charge that enable it to interact with negatively charged 
mucosal surface. Dextran can also be used for mucosal drug delivery, its nasal microspheres can
release drug for extended period of time due to bioadhesive properties. Cyclodextrins are widely 
used in drug formulations with poor water solubility and poor stability. Synthetic derivatives of
cyclodextrins (amphiphilic cyclodextrins) have been used recently for preparation of 
nanoparticles with high drug-loading capacity and targeting properties. In synthetic biodegradable 
polymers, the polyester-based like poly(lactic acid), poly (glycolic acid), poly(lactic co-glycolic 
acid) (PLGA) and polycaprolactone (PCL) are widely investigated for drug delivery 
applications. PLGA is approved by US FDA for drug delivery systems in humans. It is used to
improve the controlled drug delivery formulations. The degradation time can vary from several 
months to several years depending on the weight and copolymer ratio. For example, lactide is more
10
hydrophobic than glycolic acid, so lactide-rich PLGA are more hydrophobic, absorb less water, and 
so degrade more slowly. PCL is a biodegradable polymer first identified in 1973. The surface 
hydrophobicity depends on the molecular weight of PCL, and undergoes slower biodegradation. 
Lipophilic drugs are generally distributed uniformly in the matrix while hydrophilic tends to
remain on the surface of the PCL formulation in adsorbed state. Different techniques have been 
used for encapsulation of active drug via polymers. For example, nanoprecipitation,   emulsion   
diffusion,   double   emulsion   evaporation,   and   spray   drying techniques. 
Nanoprecipitation is a simple, fastest and reproducible method. It require two miscible
phases  i.e   organic  phase  (good  solvent  for  polymer)  and  aqueous  phase  (bad  solvent  for 
polymer), the organic phase containing dissolved polymer is slowly added to the aqueous phase 
under magnetic stirring, which leads displacement of organic solvent from organic solution, 
consequently  results in polymeric suspension at the end. Commonly used solvent for 
nanoprecipitation are ethanol and acetone etc, while frequently studied polymers include PCL, 
PLA and PLGA. For emulsion diffusion method, three liquid phases are required: an organic phase, 
aqueous phase and dilution phase. The organic phase containing hydrophobic drug is homogenized 
with aqueous phase comprising stabilizer, and subsequent addition of large volume of dilution
phase enables the diffusion of organic phase from the dispersed phase, hence results in polymeric 
suspension. 
Double emulsion evaporation (DEE) technique can be used for encapsulation of both 
lipophilic and hydrophilic drugs. There are two types of DEE: water in oil in water emulsion 
(w/o/w) and oil in water in oil emulsion (o/w/o). In case of w/o/w, aqueous solution of hydrophilic
drug is homogenized with organic phase containing polymer to form first emulsion (w/o). This 
step is followed by dispersion of first emulsion into second aqueous phase containing appropriate
stabilize under high shear homogenization or sonication to form w/o/w emulsion. Subsequent 
evaporation of organic solvent from emulsion under ambient temperature or by rotary
evaporator leads to formation of particulate carrier suspension. Spray drying is a very cost 
effective method. In which, polymer containing drug solution is atomized and sprayed into a drying
chamber where droplets are dried by hot air, the subsequent precipitation of polymer leads to
the encapsulation of drug. The evaporation of solvent occurs in a very short period of time so this 
technique can be utilized for encapsulation of heat-sensitive drug molecules.
11
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ABSTRACT 
Biodegradable and biocompatible polymers are widely used for the encapsulation of drug 
molecules. Various particulate carriers with different sizes and characteristics have been pre-
pared by miscellaneous techniques. In this review, we reported the commonly used preformed 
polymer based techniques for the preparation of micro and nano-structured materials intended 
for drug encapsulation. A description of polymer-solvent interaction was provided. The most 
widely used polymers were reported and described and their related research studies were 
mentioned. Moreover, principles of each technique and its crucial operating conditions were 
described and discussed. Recent applications of all the reported techniques in drug delivery 
were also reviewed. 
 
Keywords: Drug delivery, particles, polymer, encapsulation, carriers, operating conditions 
 
 
 
INTRODUCTION
Particulate carriers have gained tremen-
dous interest during the last decades which 
permitted to deliver many hydrophilic and 
hydrophobic molecules. Obtained particles 
present small size which facilitates their 
absorption. These drug delivery systems 
protect active pharmaceutical ingredients 
from degradation, enhance biopharmaceuti-
cal properties and could provide passive or 
active targeting or sustained delivery. Bio-
medical applications of the developed carri-
ers are continuously growing (Ahmad, 
2013; Soares, 2013; Miladi et al., 2013). 
Although, they present different physico-
chemical properties, the used polymers are 
mainly biocompatible and biodegradable. A 
multitude of techniques are used to obtain 
these particles. These methods differ by 
their principles and the nature of drug mol-
ecules that could be encapsulated. Some 
successfully marketed products led to an 
enlargement of the applications and the in-
terest given by researchers to these drug 
delivery systems. Choice of the technique 
and operating conditions is crucial to obtain 
formulations bearing good properties for in
vitro and in vivo applications. In this re-
view, we will focus on polymeric particles 
and give a scope about the most used poly-
mers. We will also describe the common 
preformed polymer based techniques used 
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for the encapsulation of drug molecules. 
We will also review the major applications 
of the developed particles during the last 
years and their main properties. 
 
1. POLYMER-SOLVENT INTERAC-
TIONS
Many techniques that rely on preformed 
polymers have been used for the prepara-
tion of particulate carriers. Although these 
methods are quite different, they generally 
share a unique principle which is polymer 
precipitation. Precipitation of the polymer 
occurs either when a non solvent is added 
or after subsequent decrease of its solubility 
in a solvent. Many parameters could influ-
ence polymer solubility such as, solvent 
nature, pH, salinity and temperature of the 
dispersion medium. Solubility of polyelec-
trolytes in water, for example, is highly pH 
and salinity dependent (Gennes, 1979), 
while that of poly(alkyl acrylamide) and 
poly(alkyl methacrylamide), is mainly tem-
perature dependent (Elaissari, 2002). In 
fact, nanoprecipitation and emulsion based 
techniques are based on the addition of a 
non solvent to the polymer which causes its 
precipitation. However, ionic gelation tech-
nique, for instance, in which generally a 
polyelectrolyte is used as polymer, is based 
on the addition of a salt or an oppositely 
charged polymer. This results in a change 
in the salinity of the medium and the ap-
pearance of electrostatic interactions and 
thus, leads to polymer precipitation. The 
thermodynamic behavior of the polymer in 
a given solution is highly dependent on the 
Flory F-parameter. This parameter is de-
fined as the free energy change per solvent 
molecule (in kBT units) when a solvent-
solvent contact is shifted to a solvent-
polymer contact. It is expressed by the fol-
lowing mathematical equations: 
Fൌ οீ௞ಳ் ൌ
οுି்οௌ
௞ಳ் ൌ
ଵ
ଶ െ ܣሺͳ െ
ఏ
்ሻ 
Equation (1) 
where kB and T are Boltzmann constant 
and temperature, respectively; A and T pa-
rameters are defined as follows: 
ܣ ൌ ଶ୼ௌା௞ಳଶ௞ಳ   Equation (2) 
ߠ ൌ ଶοுଶοௌା௞ಳ Equation (3) 
 
It can be seen that the A parameter is di-
rectly related to entropy changes, whereas T 
temperature is a function of both entropic 
and enthalpic variations. When T tempera-
ture = T, the corresponding Flory F-
parameter = 1/2, at which the second Virial 
coefficient is equal zero (Elias, 2003). The 
latter can be easily determined from light 
scattering measurements of a diluted poly-
mer solution. At T temperature conditions, 
the binary interactions among constituents 
will be negligible and only the excluded 
volume effects will be predominant. Con-
sequently, the solvent will be a good sol-
vent for the polymer when F < 1/2 and a 
poor one when F > 1/2 (Minost et al., 
2012). 
 
2. COMMONLY USED POLYMERS 
FOR ENCAPSULATION 
Several polymers have been used for 
drug encapsulation but only biodegradable 
and biocompatible ones are suitable for bi-
omedical applications. The biodegradability 
of a polymer is acquired by the presence of 
a labile function such as ester, orthoester, 
anhydride, carbonate, amide, urea or ure-
thane in their backbone. These polymers 
could be of natural (polysaccharides and 
protein based polymers) or synthetic (poly-
esters) nature (Pillai and Panchagnula, 
2001). The most commonly used polymers 
for drug encapsulation are polyesters (lac-
tide and glycolide copolymers, poly-H-
caprolactone), acrylic polymers (polymeth-
acrylates) and polyamides (gelatin and al-
bumin). The selection of the right polymer 
is a crucial step to obtain particles that are 
suitable for a well-defined application. In 
fact, polymers’ structures are highly differ-
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ent and their surface and bulk properties are 
highly relevant for the obtaining of the de-
sirable biological application. Copolymers 
could be also used to monitor the hydro-
phobicity of the materials. Some polymers 
are poly(ethyleneglycol) (PEG) copolymer-
ized in order to decrease nanoparticle 
recognition by the reticular endothelial sys-
tem. Table 1 contains examples of the most 
used biocompatible and biodegradable pol-
ymers in encapsulation. Some polymers, 
especially those having mucoadhesive 
properties, could also be used for coating 
the nanocarriers (Mazzaferro et al., 2012; 
Zandanel and Vauthier, 2012).  
 
Table 1: Commonly used polymers 
Materials References 
Polymers 
Natural polymers 
Chitosan Elmizadeh et al., 2013; Fàbregas et al., 2013; Khalil et al., 2012; Konecsni et al., 2012; 
Du et al., 2009; Bernkop-Schnürch et al., 2006; Gan et al., 2005; Asada et al., 2004 
Dextran Liang et al., 2013; Dai et al., 2012; Sajadi Tabassi et al., 2008; Koten et al., 2003 
Dextran derivatives Kanthamneni et al., 2012; Kauffman et al., 2012; Aumelas et al., 2007; Miyazaki et al., 
2006 
Cyclodextrins Çirpanli et al., 2009; Memiúo÷lu et al., 2003; Pariot et al., 2002; Lemos-Senna et al., 
1998 
Gelatin Nahar et al., 2008; Balthasar et al., 2005; Vandervoort and Ludwig, 2004; Bruschi et al., 
2003 
Synthetic polymers 
Biodegradable polyesters 
PLGA Gyulai et al., 2013; Beck-Broichsitter et al., 2012; Morales-Cruz et al., 2012; Beck-
Broichsitter et al., 2011; Nehilla et al., 2008; Song et al., 2008; Budhian et al., 2007; 
Bozkir and Saka, 2005; Fonseca et al., 2002;Yang et al., 1999; Govender et al., 1999 
PLA BazyliĔska et al., 2013; Fredriksen and Grip 2012; Kadam et al., 2012; Kumari et al., 
2011; Ataman-Önal et al., 2006; Lamalle-Bernard et al., 2006; Hyvönen et al., 2005; 
Katare et al., 2005; Chorny et al., 2002; Leo et al., 2000  
PCL Behera and Swain, 2012; Guerreiro et al., 2012; Hernán Pérez de la Ossa et al., 2012; 
Khayata et al., 2012; Arias et al., 2010; Wang et al., 2008; Limayem Blouza et al., 2006; 
Tewa-Tagne et al., 2006; Yang et al., 2006; Le Ray et al., 2003; Chawla and Amiji 2002; 
Raval et al., 2011; Hombreiro Pérez et al., 2000; Benoit et al., 1999; Masson et al., 1997 
Poly(lactide-co-
glycolide-co-
caprolactone) 
Zhang et al., 2006  
Acrylic polymers 
Eudragit  Hao et al., 2013; Das et al., 2010; Eidi et al., 2010; Trapani et al., 2007; Galindo-
Rodríguez et al., 2005; Haznedar and Dortunç 2004; Pignatello et al., 2002 
Others
Polyvinylbenzoate Labruère et al., 2010 
Pegylated polymers 
Chitosan-PEG Seo et al., 2009 
MPEG-PCL Falamarzian and Lavasanifar, 2010; Xin et al., 2010  
PCL-PEG-PCL Suksiriworapong et al., 2012; Huang et al., 2010; Gou et al., 2009  
Poly(caprolactone)-
poly(ethylene ox-
ide)-polylactide 
Hu et al., 2003 
PLA-PEG Sacchetin et al., 2013; Essa et al., 2010; Ishihara et al., 2010; Vila et al., 2005; Vila et al., 
2004; Govender et al., 2000; Huang et al., 1997  
PLA-PEG-PLA Chen et al., 2011; Ruan and Feng 2003 
MPEG-PLA Zheng et al., 2010; Dong and Feng, 2007; Dong and Feng, 2004 
14
EXCLI Journal 2014;13:28-57 – ISSN 1611-2156 
Received: November 05, 2013, accepted: January 25, 2014, published: February 03, 2014 
 
 
31 
2.1 Natural polymers 
2.1.1 Chitosan 
Chitosan is obtained by deacetylation of 
chitin, which is the structural element in the 
exoskeleton of crustaceans (crabs, shrimp, 
etc.) and cell walls of fungi. It is a cationic 
and biodegradable polysaccharide consist-
ing of repeating D-glucosamine and N-
acetyl-D-glucosamine units, linked via (1-
4) glycosidic bonds. Chitosan is non toxic 
and can be digested in the physiological 
environment, either by lysozymes or by chi-
tinases, which are present in the human in-
testine and in the blood. These properties 
led to increased interest for this polymer in 
pharmaceutical research and industry as a 
carrier for drug delivery (Mao et al., 2010). 
In addition, chitosan has mucoadhesive 
properties owing to its positive charge that 
allows interaction with the negatively-
charged mucosal surface. Consequently, the 
use of chitosan as a matrix (Patil and 
Sawant, 2011) or as a coating material 
(Mazzarino et al., 2012) in drug encapsula-
tion had become a promising strategy to 
prolong the residence time, to increase the 
absorption of active molecules through the 
mucosa (Mao et al., 2010; Alpar et al., 
2005) and also for targeted delivery (Park et 
al., 2010).  
 
2.1.2 Dextran and its derivatives 
Dextran polymers are produced by bac-
teria from sucrose. Chemical synthesis is 
also possible. These glucose polymers con-
sist predominantly of linear D-1,6-
glucosidic linkage with some degree of 
branching via 1,3-linkage. Dextran-based 
microspheres have got much attention be-
cause of their low toxicity, good biocom-
patibility and biodegradability, which are of 
interest for application in biomedical and 
pharmaceutical fields (Mehvar, 2000). 
Many detxran polymers such as Sephadex® 
(cross-linked dextran microspheres) as well 
as Spherex® (cross-linked starch micro-
spheres) were used as carriers for drug de-
livery. Other derivatives of dextran and 
starch including diethyl aminoethyl dextran 
and polyacryl starch have also been used 
for mucosal drug delivery. Illum et al. 
(2001) proposed some mechanisms to ex-
plain absorption enhancement effects of 
cross-linked starch and dextran micro-
spheres intended to nasal delivery which 
are: (1) Deposition of the microspheres in 
the less or non ciliated anterior part of the 
nasal cavity and slower nasal clearance; (2) 
Retention of the formulation in the nasal 
cavity for an extended time period because 
of the bioadhesive properties of the micro-
spheres and (3) The local high drug concen-
tration provided by the gelled system in 
close contact with the epithelial absorptive 
surface (Illum et al., 2001). 
 
2.1.3 Cyclodextrins 
Cyclodextrins (CDs) are cyclic oligo-
saccharides that contain at least six D-(+) 
glucopyranose units which are attached by 
D-(1,4) glucosidic bonds. They have been 
widely used for the formulation of drugs 
with bioavailability concerns resulting from 
poor solubility, poor stability and severe 
side effects. There are 3 natural CDs which 
are Į-, ȕ-, and Ȗ-CDs (with 6, 7, or 8 glu-
cose units respectively) (Challa et al., 
2005). In addition, amphiphilic cyclodex-
trins are synthetic derivatives of natural cy-
clodextrins. Such derivatives are able to 
self-organize in water to form micelles and 
nano-aggregates, which is interesting for 
pharmaceutical applications, mainly, encap-
sulation (Gèze et al., 2002). In fact, am-
phiphilic cyclodextrins have recently been 
used to prepare nanoparticles and nanocap-
sules without surfactants and have shown 
high drug-loading capacity with favorable 
release properties (Lemos-Senna et al., 
1998; Çirpanli et al., 2009; Duchêne, 1999). 
They have also been used for targeting and 
for increasing drug loading (Duchêne et al., 
1999).  
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2.1.4 Gelatin 
Gelatin is a natural polymer that is de-
rived from collagen. It is commonly used 
for pharmaceutical and medical applica-
tions because of its biodegradability and 
biocompatibility in physiological environ-
ments. Gelatin is attractive for use in con-
trolled release due to its nontoxic, bioactive 
properties and inexpensive price. It is also a 
polyampholyte having both cationic and 
anionic groups along with hydrophilic 
groups. Mechanical properties, swelling 
behavior and thermal properties of gelatin 
depend significantly on its crosslinking de-
gree (Young et al., 2005). 
 
2.2 Biodegradable polyesters 
Polyester-based polymers are among of 
the most widely investigated materials for 
drug delivery. Poly(lactic acid) (PLA), 
poly(glycolic acid) (PGA) and their copol-
ymers poly(lactic acid-co-glycolic acid) 
(PLGA) along with poly-H-caprolactone are 
some of the well-defined biomaterials with 
regard to design and performance for drug-
delivery applications. 
2.2.1 PLGA 
PLGA, a copolymer of lactic acid and 
glycolic acid, has generated tremendous 
interest due to its excellent biocompatibil-
ity, biodegradability, and mechanical 
strength. PLGA is approved by the US 
FDA and European Medicine Agency 
(EMA) in various drug delivery systems in 
humans. In order to improve the formula-
tion of controlled drug delivery systems, an 
understanding of the physical, chemical, 
and biological properties of polymers is 
helpful. In fact, the polymer is commercial-
ly available with different molecular 
weights and copolymer compositions. The 
degradation time can vary from several 
months to several years, depending on the 
molecular weight and copolymer ratio 
(Danhier et al., 2012). For example, lactic 
acid is more hydrophobic than glycolic acid 
and, therefore, lactide-rich PLGA copoly-
mers are less hydrophilic, absorb less water, 
and subsequently, degrade more slowly 
(Dinarvand et al., 2011). PLGA particles 
are widely used to encapsulate active mole-
cules with a broad spectrum of pharmaceu-
tical applications (Danhier et al., 2012; 
Menei et al., 2005; Singh et al., 2004).  
 
2.2.2 PLA 
PLA is a biocompatible and biodegra-
dable synthetic polyester which undergoes 
scission in the body to monomeric units of 
lactic acid. The latter is a natural intermedi-
ate in carbohydrate metabolism. PLA pos-
sess good mechanical properties and it is 
largely used for the preparation of particles 
(Gupta and Kumar, 2007). 
 
2.2.3 PCL 
It was in 1930s that the ring-opening 
polymerization of PCL was studied. The 
biodegradable property of this synthetic 
polymer was first identified in 1973. PCL is 
suitable for controlled drug delivery due to 
its high permeability to many drugs and 
non-toxicity (Sinha et al., 2004). Molecular 
weight dependent surface hydrophobicity 
and crystallinity of PCL are the causes for 
its slower biodegradation in two distinct 
phases such as random non-enzymatic 
cleavage and enzymatic fragmentation. 
Lipophilic drugs are generally distributed 
uniformly in the matrix while hydrophilic 
drugs tend to move towards the interface 
and remain on the surface of PCL formula-
tion in adsorbed state. Diffusion was de-
scribed as the only possible mechanism by 
which the lipophilic drugs release from 
PCL particles as they were shown to be in-
tact for a much longer duration in vivo. 
However, two phenomena could be impli-
cated in hydrophilic drugs’ release. Highly 
lipophilic drugs that resist complete diffu-
sion are released upon surface erosion by 
enzymatic action while hydrophilic drugs 
that accumulate at the interface during the 
formulation processes are released by de-
sorption at the initial period of release study 
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or dosage intake. This results in a biphasic 
drug release pattern for PCL particles with 
much higher burst release for hydrophilic 
drugs than lipophilic ones (Dash and 
Konkimalla, 2012). 
 
2.3 Pegylated polymers 
Many of the above cited polymers could 
be conjugated to PEG chains, which allows 
the enhancement of their hydrophilicity and 
permits the obtaining of a stealth surface 
that could protect the prepared carriers from 
degradation by the cells belonging to the 
reticuloendothelial system. Conjugation to 
PEG confers also bioadhesive properties for 
the carriers (Yoncheva et al. 2005). 
 
3. Used methods for the encap-
sulation of active molecules 
3.1 Nanoprecipitation 
The nanoprecipitation technique was 
first developed by Fessi et al. in 1986 (De-
vissaguet et al., 1991). The technique al-
lows the obtaining of either nanospheres or 
nanocapsules. The organic phase could be 
added to the aqueous phase under magnetic 
stirring. This one-step process allows the 
instantaneous and reproducible formation 
of monodisperse nanoparticles. Nanopre-
cipitation is simple, is by far the fastest, 
most reproducible, and industrially feasible 
preparation procedure of nanospheres 
(Vauthier and Bouchemal, 2009). Practical-
ly, two miscible phases are required: an or-
ganic solvent in which the polymer is dis-
solved and an aqueous phase (non-solvent 
of the polymer). The most common used 
organic solvents are ethanol and acetone. 
Such solvents are miscible in water and 
easy to remove by evaporation. Some oils 
could be added to these solvents to allow 
the dissolving of the active (Rosset et al., 
2012). As Figure 1 shows, the method is 
based on the addition of one phase to the 
other under moderate magnetic stirring 
which causes the interfacial deposition of a 
polymer after displacement of the organic 
solvent from the organic solution. This 
leads to the formation of a suspension of 
nanoparticles. The organic phase could be a 
mixture of solvents such as, mixture of ace-
tone with water or ethanol etc. Similarly, 
the aqueous phase could consist of a mix-
ture of non-solvents and could contain sur-
factants. Commonly used polymers are bio-
degradable polyesters, especially PCL, PLA 
and PLGA (Rao and Geckeler, 2011). Par-
ticle formation process includes three basic 
steps which are, particle nucleation, molec-
ular growth and aggregation. The rate of 
every step has a crucial impact on the parti-
cle size distribution. Supersaturation is the 
driving force that manages all of these 
steps, namely, particles nucleation rate. Su-
persaturation, itself, is influenced by fluid 
dynamics and mixing. In fact, low stirring 
rate results in low nucleation rates while 
higher mixing rates give high nucleation 
rates (Lince et al., 2008). 
 
Figure 1: The nanoprecipitation technique (Pinto Reis et al., 2006) 
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Operational parameters that should be 
controlled include the organic phase to non 
organic phase ratio, the concentration of the 
polymer and the stabilizer and the amount 
of the drug. Every one of these parameters 
may exert an impact on the characteristics 
of the obtained nanoparticles (size, uni-
formity and charge). In fact, an increase of 
the polymer amount generally increases 
particles’ size (Chorny et al., 2002; Simúek 
et al., 2013; Dong and Feng, 2004; Asadi et 
al., 2011). The same effect was obtained 
after increasing the polymer molecular 
weight (Limayem Blouza et al., 2006; Hol-
gado et al., 2012). These findings were ex-
plained by an increase of the viscosity of 
the organic phase which rendered solvent 
diffusion more difficult and thus, led to 
larger nanoparticles’ size. The effect of in-
creasing organic phase volume seems con-
flicting: some studies showed that it causes 
a decrease of the particles size (Dong and 
Feng, 2004) while others showed the oppo-
site phenomenon (Asadi et al., 2011). In-
creasing the water phase amount leads to a 
decrease of the particles size as a result of 
the increased diffusion of the water-
miscible solvent in the aqueous phase and 
thus, the more rapid precipitation of the 
polymer and formation of nanoparticles 
(Budhian et al., 2007). An increase of the 
surfactant amount generally causes a de-
crease of the particles size and reduces size 
distribution (Contado et al., 2013; Siqueira-
Moura et al., 2013). Some studies did not, 
however, found significant change follo-
wing surfactant amount increase (Dong and 
Feng, 2004). The nature of the surfactant 
may also influence the particles’ size (Li-
mayem Blouza et al., 2006). Increasing 
mixing rate decreases the particles size as it 
causes faster diffusion rate (Asadi et al., 
2011). Theoretical drug loading may also 
influence particles size and drug loading 
(Govender et al., 1999). Nanoprecipitation 
is generally designed for the encapsulation 
of hydrophobic drug molecules (Seju et al., 
2011; Katara and Majumdar, 2013; 
Seremeta et al., 2013). Such actives may be 
dissolved within the organic phase. Bilalti 
et al. (2005) described a nanoprecipitation 
technique intended to the encapsulation of 
hydrophilic molecules but the size of the 
obtained particles was not sufficiently uni-
form (Bilati et al., 2005). To further im-
prove the reproducibility of the nanoprecip-
itation technique and make it more conven-
ient for industrial applications, membrane 
contactor and microfluidic technology were 
successfully used (Khayata et al., 2012; Xie 
and Smith, 2010). These techniques allow 
better size control within different batches 
of particles. Table 2 contains some exam-
ples of the applications of the nanoprecipi-
tation technique in drug delivery during the 
last years. It can be concluded that polyes-
ters are among the most used polymers for 
the preparation of the nanoparticles by this 
technique. 
 
3.2 Emulsion diffusion (ESD) 
ESD was first developed by Quintanar-
Guerrero and Fessi (Quintanar-Guerrero et 
al., 1996) to prepare PLA based nano-
spheres. Three liquid phases are needed in 
this technique: an organic phase, an aque-
ous phase and a dilution phase. The organic 
phase generally contains the polymer and 
the hydrophobic drug. The aqueous phase is 
a solution of a stabilizing agent while the 
dilution phase usually consists of a large 
volume of water. Mutual saturation of the 
aqueous and organic phase allows further 
obtaining of a thermodynamically equili-
brated emulsion upon high speed homoge-
nization. Subsequent addition of an excess 
of water enables the diffusion of the organic 
solvent from the dispersed phase resulting 
in precipitation of the polymer and the for-
mation of the particles (Figure 2). Com-
monly used polymers in this method in-
clude PCL, PLA and Eudragit® (Mora-
Huertas et al., 2010). Table 3 shows that the 
technique is mainly used for the encapsula-
tion of hydrophobic molecules. However, 
hydrophilic molecules may also be encap-
sulated by a modified solvent diffusion 
method using an aqueous inner phase (Ma 
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et al., 2001). Operating conditions affecting 
the size of the obtained particles include 
external/internal phase ratio, emulsification 
stirring rate, volume and temperature of wa-
ter for dilution, polymer amount and con-
centration of the stabilizer (Quintanar-
Guerrero et al., 1996; Mora-Huertas et al., 
2010). Influence of high shear homogeniza-
tion and sonication on the particles size was 
assessed and it was found that sonication 
was more efficient for particle size re-
duction. The nature of the surfactant influ-
enced also the particles size. In fact, when 
Pluronic F68 (PF68), didodecyldime-
thylammonium bromide (DMAB) and pol-
yvinylalcohol (PVA) were compared, 
DMAB gave the smallest particles but with 
the lowest encapsulation efficiency (Jain et 
al., 2011). Particles size was also described 
to increase with an increase of initial drug 
amount (Youm et al., 2012), polymer 
amount (Youm et al., 2012; Esmaeili et al., 
2011) and the oil phase volume (Esmaeili et 
al., 2011; Poletto et al., 2008). An increase 
of the surfactant amount resulted in a de-
crease of the size but it seems that above 
some level further significant size reduction 
is no longer possible (Jain et al., 2011; Su-
rassmo et al., 2010). An increase of the ho-
mogenization rate led to a decrease of the 
particles’ size (Jain et al., 2011; Kwon et 
al., 2001; Galindo-Rodríguez et al., 2005). 
Likely, the same effect was obtained fol-
lowing an increase of the temperature and 
the volume of added water (Kwon et al., 
2001; Song et al., 2006). The nature of the 
organic solvent also influenced particle size 
(Song et al., 2006). Table 3 shows some of 
the recent applications of the ESD tech-
nique. 
 
 
Table 2: Applications of the nanoprecipitation technique 
Encapsulated 
molecule 
Polymer  Size (nm) Zeta potential
(mV)
Reference 
Doxorubicin Gelatin-co-PLA-DPPE 131.5-161.1 - Han et al., 2013 
Aceclofenac Eudragit RL 100 75.5-184.4 22.5 - 32.6 Katara and Majumdar, 
2013 
Doxorubicin Dextran-b-
polycaprolactone 
95-123.3 - Li et al., 2013 
Chloroaluminum 
phthalocyanine 
PLGA 220.3-326.3 -17.7-(-40.9) Siqueira-Moura et al., 
2013 
Efavirenz PCL and Eudragit® RS 
100 
89.5 - 173.9 -17.9-53.8 Seremeta et al., 2013 
Paclitaxel PLGA 50 - 150 -15 - (-20) Wang et al., 2013 
Retinoic acid PLA 153.6-229.8 -27.4-(-20.9) Almouazen et al., 2012 
Brimonidine  
Tartrate 
Eudragit® RL 100 123.5 - 140.2 13.1- 20.8 Khan et al., 2012 
Vitamin E PCL 123-320 -24.5-(-1.46) Khayata et al., 2012 
Paclitaxel Hydrophobized pullulan 127.6-253  Lee et al., 2012 
Curcumin PCL, chitosan 104-125 (-0.099)-79.8 Mazzarino et al., 2012 
Diclofenac PCL 152 -50 Mora-Huertas et al., 2012 
Amphotericin B PLGA 86-153 -31.4-(-9.1) Van de Ven et al., 2012 
Epirubicin Poly(butyl cyanoacry-
late) 
217-235 -4.5-(-0.1) Yordanov 2012 
Camptothecin Beta-cyclodextrin 
PLGA 
PCL 
281 
187 
274 
-13 
-0.06 
-19 
CÕrpanlÕ et al., 2011 
Naringenin Eudragit® E 90 - Krishnakumar et al., 2011 
Olanzapine PLGA 91.2 -23.7 Seju et al., 2011 
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Figure 2: Emulsion diffusion technique (Pinto Reis et al., 2006) 
 
 
Table 3: Applications of the emulsion diffusion method 
Encapsulated 
molecule 
Polymer  Size (μm) Zeta potential
(mV) 
Reference 
Articaine PCL - - Campos et al., 2013 
Omeprazole Eudragit L 100-55 0.256.3- 0.337 8.92 - 16.53 Hao et al., 2013 
Curcumin  Polyurethane and 
polyurea 
0.216- 4.901 - Souguir et al., 2013 
Matricaria recutita 
L. extract 
PEG-PBA-PEG 0.186- 0.446  - Esmaeili et al., 2011 
Bovine serum 
albumin 
Chitosan  81-98  - Karnchanajindanun et 
al., 2011 
Alendronate PLGA 0.145  -4.7 Cohen-Sela et al., 
2009 
An oligonucleo-
tide 
PLA 0.390  - Delie et al., 2001 
 
 
3.3 Simple Emulsion evaporation 
(SEE)
The SEE technique is widely used in the 
field of particulate carriers’ development. 
This method was first developed by 
(Vanderhoff et al., 1979). It consists on the 
formation of a simple emulsion followed by 
the evaporation of the organic solvent. Sub-
sequent precipitation of the polymer allows 
the obtaining of the particles (Figure 3).
Practically, for oil in water emulsion meth-
od, the polymer is dissolved in a volatile 
and non miscible organic solvent such as 
chloroform, ethylacetate or dichloro-
methane. This organic phase, in which the 
drug and the polymer are dissolved, is then 
dispersed by high speed homogenization or 
by sonication in an aqueous phase contain-
ing a surfactant. Once an oil-in-water (o/w)
emulsion is obtained, the evaporation of the 
organic solvent permits the precipitation of 
the polymer and thus, the formation of the 
particles. As it can be seen in Table 4, SEE 
is generally used for the encapsulation of
hydrophobic drugs (O’Donnell and McGin-
ity, 1997). The evaporation of the organic 
solvent is obtained by moderately stirring 
the emulsion at room temperature or under 
high temperature and low pressure condi-
tions. The obtained particles can be then 
harvested by ultracentrifugation or filtra-
tion, then washed and lyophilized. Mem-
brane technology was also used to prepare 
particles by the simple emulsion technique 
(Doan et al., 2011). Another alternative of 
the technique is the use of water in oil 
emulsion method that is suitable for the en-
capsulation of hydrophilic active molecules. 
Particulate carriers are obtained after evap-
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oration of the water phase which causes the 
precipitation of the hydrophilic polymer 
(Banerjee et al., 2012). Parameters that 
have to be managed include organic phase 
to water phase ratio, nature of the surfactant 
and its concentration, stirring rate, polymer 
amount and evaporation rate. Decreasing 
the organic solvent volume resulted gener-
ally in a decrease of particle size (Budhian 
et al., 2007). Particle size could also be de-
creased by increasing surfactant amount 
(Valot et al., 2009; Manchanda et al., 2010; 
Khaled et al., 2010; Su et al., 2009), increa-
sing stirring rate (Su et al., 2009; Lee et al., 
2012; Avachat et al., 2011; Yadav and 
Sawant, 2010) or increasing aqueous phase 
volume (Adibkia et al., 2011). However, an 
increase of polymer amount generally in-
creases particles’ size (Doan et al., 2011; 
D’Aurizio et al., 2011; Adibkia et al., 2011; 
Agnihotri and Vavia, 2009). Table 4 shows 
the applications of the SEE technique in 
drug delivery. Polyesters were widely used 
for the encapsulation of hydrophobic drugs. 
 
 
Figure 3: Simple emulsion solvent evaporation (Pinto Reis et al., 2006) 
 
Table 4: Applications of simple emulsion solvent evaporation technique 
Encapsulated 
molecule 
Polymer  Size (μm) Zeta potential 
(mV)
Reference 
 
Curcumin PLGA and PLGA-
PEG 
0.161-0.152 - Khalil et al., 2013 
Efavirenz  PCL and Eu-
dragit® RS 100 
0.083-0.219 53 Seremeta et al., 
2013 
Human amylin PCL 0.202 - Guerreiro et al., 
2012 
Azithromycin PLGA 14.11-15.29  - Li et al., 2012 
Teniposide PLGA 0.113-0.135 -36.6-(-23.1) Mo et al., 2012 
Camptothecin PCL-PEG-PCL 4.2-5.4  - Dai et al., 2011 
Naproxen PLGA 352-824 - Javadzadeh et al., 
2010 
Doxorubicin PLGA 0.137-0.164  -12.3-(-9.9) Manchanda et al., 
2010 
Dexamethasone PLGA 5.18-7  - Rawat and Bur-
gess, 2010 
Ibuprofen Eudragit RSPO 14-51.1 - Valot et al., 2009 
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3.4 Double emulsion evaporation 
(DEE)
Double emulsion technique is suitable 
for the encapsulation of hydrophilic mole-
cules (see Table 5 and Figure 4). Generally, 
the method consists on the dispersion of an 
aqueous phase in a non miscible organic 
solvent to form the first emulsion (W1/O). 
This dispersion is performed under high 
shear homogenization or low power soni-
cation for a short time. This step is followed 
by the dispersion of the obtained emulsion 
in a second aqueous phase containing a hy-
drophilic emulsifier. Again, homogeniza-
tion could be carried under high shear ho-
mogenization or with a sonication probe. 
When sonication is used, it must be per-
formed at low power and within a short pe-
riod of time to not break the first emulsion 
(Giri et al., 2013). After the formation of 
the multiple emulsion, evaporation of the 
volatile organic solvent under low pressure 
(by a rotary evaporator) or at ambient tem-
perature allows the obtaining of the particu-
late carriers (Figure 4). There are other 
types of multiple emulsions like w/o/o or 
o/w/o (Giri et al., 2013). A lot of parame-
ters may influence the properties of the ob-
tained particles such as, relative phases’ 
ratio (Khoee et al., 2012), amount of the 
polymer, its nature and molecular weight 
(Zambaux et al., 1998; Péan et al., 1998; 
Van de Ven et al., 2011), nature of the sur-
factants and their amounts (Zhao et al., 
2007; Khoee and Yaghoobian, 2009; Dha-
naraju et al., 2004), homogenization speed 
(Eley and Mathew, 2007; Basarkar et al., 
2007), the composition of the external 
phase (Péan et al., 1998; Tse et al., 2009) 
and evaporation speed (Khoee et al., 2012). 
Operating conditions may also influence 
strongly encapsulation efficiency (Tse et 
al., 2009; Billon et al., 2005; Silva et al., 
2013; Zhou et al., 2013; Karataú et al., 
2009; Hachicha et al., 2006; Al-Kassas, 
2004; Cun et al., 2011; Gaignaux et al., 
2012; Cun et al., 2010). Membrane tech-
nique and microfluidic devices were also 
used to prepare particulate carriers by the 
DES method (Vladisavljeviü and Williams, 
2008; van der Graaf et al., 2005). 
 
3.5 Spray drying 
Spray drying is a simple process which 
gained too much interest due to its cost-
effectiveness and scalability (Sou et al., 
2011). Practically, a polymer containing 
drug solution is atomized and sprayed into a 
drying chamber where droplets are dried by 
heated air (See Figure 5). Reduction of 
droplets’ size that follows atomization al-
lows the obtaining of an enormous surface 
area between droplets and the drying gas. 
The subsequent precipitation of the polymer 
permits the encapsulation of the drug within 
the obtained particulate carriers. The evapo-
ration of the solvent occurs within a very 
short period of time. Consequently, the ma-
terials never reach the inlet temperature of 
drying gas. This is very attractive for en-
capsulating heat-sensitive drug molecules 
like proteins (Cal and Sollohub, 2010; Sol-
lohub and Cal, 2010; Prata et al., 2013). 
Many operating conditions could influence 
the properties of the obtained particles. Pa-
rameters to be controlled include the drying 
air temperature and humidity (Bruschi et 
al., 2003), the rate and fluid dynamics of 
the air flow, the atomization process (Drop-
let size, spray rate, spray mechanism) and 
the composition of ingredients and excipi-
ents in the feeding solution (Rattes and 
Oliveira, 2007). PLA (Baras et al., 2000; 
Gander et al., 1996; Sastre et al., 2007; 
Muttil et al., 2007), PLGA (Wang and 
Wang, 2002; Mu and Feng, 2001; Castelli 
et al., 1998; Bittner et al., 1999; Prior et al., 
2000; Conti et al., 1997), PCL, methacryla-
te polymers (Esposito et al., 2002; Año et 
al., 2011; Cruz et al., 2010; Hegazy et al., 
2002; Raffin et al., 2008) and chitosan (He 
et al., 1999; Giunchedi et al., 2002; Cevher 
et al., 2006) are among the most used po-
lymers in spray-drying method. As Table 6 
shows, the technique allowed the obtaining 
of mainly microparticles bearing better drug 
solubility and sustained release. 
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Table 5: Applications of the double emulsion technique 
Encapsulated molecule Polymer  Size (μm) Zeta potential
(mV) 
Reference 
Vancomycin PLGA 0.450-0.466 -7.2-(-3.5) Zakeri-Milani et al., 2013
Prostaglandin E1 PLGA 7-22.5  - Gupta and Ahsan, 2011 
Deoxyribonuclease I PLGA 0.190-0.349 - Osman et al., 2011 
S. equi antigens PCL 0.242-0.450 -53.1-38.7 Florindo et al., 2009 
Hepatitis B surface antigen PLGA 1-5  0.51-14 Thomas et al., 2009 
Plasmid DNA PLGA 1.9-4.6 -24.6-(-22.9) Tse et al., 2009 
 
 
 
Figure 4: Double emulsion solvent evaporation technique (Giri et al., 2013) 

 
Figure 5: The spray drying method (Pinto Reis et al., 2006) 
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Table 6: Applications of the spray drying technique 
Encapsulated 
molecule 
Polymer  Size (μm) Zeta potential
(mV)
Reference 
 
Nimodipine PLGA 1.9-2.37  - Bege et al., 2013 
Theophylline Eudragit RS30D < 60 - Garekani et al., 2013 
Ofloxacin PLA 2.6-4.9  - Palazzo et al., 2013 
Sodium diclofenac PGA-co-PDL 
PEG-PGA-co-PDL 
and mPEG-co-
(PGA-co-PDL) 
2.3  
3.9  
2.5  
-32.2 
-29.9 
-31.2 
Tawfeek, 2013 
Sodium fluoride Chitosan 3.4-5.3  - Keegan et al., 2012 
Plasmid  Chitosan 2.5-11.7  - Mohajel et al., 2012 
Heparin PLGA 2.5-3.8 -63.5 - (-28.2) Yildiz et al., 2012 
Alendronate  Eudragit® S100 13.8  - Cruz et al., 2010 
Zolmitriptan Chitosan glutamate 
and Chitosan base 
2.6-9.4  - Alhalaweh et al., 
2009 
Triamcinolone PLGA 0.5-1.5  - da Silva et al., 2009 
Acyclovir Chitosan  18.7-34.9  - Stulzer et al., 2009 
 
 
3.6 Supercritical fluid technology (SFT) 
In the recent years, novel particle for-
mation techniques using supercritical fluids 
(SCF) have been developed in order to 
overcome some of the disadvantages of 
conventional techniques that are: (1) poor 
control of particle size and morphology; (2) 
degradation and lost of biological activity 
of thermo sensitive compounds; (3) low en-
capsulation efficiency and (4) low precipi-
tation yield (Santos et al., 2013). Moreover, 
SFT presents the main advantage of not re-
quiring the use of toxic solvents. In fact, 
SCF based technologies have attracted 
enormous interest for the production of mi-
croparticles  and nanoparticles (Table 7), 
since their emergence in the early 1990s 
(Sanli et al., 2012). 
The supercritical state is achieved when 
a substance is exposed to conditions above 
its critical pressure and temperature. In such 
conditions, the fluid will have liquid-like 
density and, thus, solvating properties that 
are similar to those of liquids and, at the 
same time, gas-like mass transfer proper-
ties. Carbon dioxide (CO2) is the most 
commonly used critical fluid. In fact, CO2 
is nontoxic, nonflammable and easy recy-
clable. Moreover, CO2 has moderate critical 
parameters of CO2 (a critical pressure of 7.4 
MPa and a critical temperature of 304.1 K) 
and low price and is highly available which 
makes it very attractive from an economical 
point of view and also for the processing of 
labile compounds (Elizondo et al., 2012). 
Supercritical fluid technology methods can 
be divided in four methods which are rapid 
expansion of supercritical solution (RESS), 
Particles from gas saturated solutions 
(PGSS), gas antisolvent (GAS) and super-
critical antisolvent process (SAS). These 
methods depend on whether CO2 was used 
as a solvent, a solute or an antisolvent. Fig-
ure 6 shows the experimental set up of the 
RESS technique. In the RESS technique, 
the drug and the polymer are first dissolved 
in supercritical CO2 in high pressure cham-
ber. The subsequent passing of the solution 
through a nozzle results in a rapid decrease 
of the pressure and thus, a precipitation of 
the drug particles embedded in the polymer 
matrix and their recovery in the extraction 
unit (Byrappa et al., 2008). Many parame-
ters such as the density of the SCF (Pres-
sure and temperature of supercritical fluid) 
(Kalani and Yunus, 2012), flow rate of 
drug-polymer solution and/or CO2 and for-
mulation variables (Martin et al., 2002) 
could influence the size of the obtained par-
ticles. Table 7 shows that SFT was used for 
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the processing of nanoparticles and micro-
particles mainly based on polyesters. 
 
3.7 Ionic gelation (IG) 
IG method is used mainly with natural 
hydrophilic polymers to prepare particulate 
carriers. These polymers include gelatin, 
alginate, chitosan and agarose. IG has the 
advantage of not using organic solvents. 
The technique is based on the transition of 
the polymer from liquid state to a gel (Fig-
ure 7). For instance, gelatin based particles 
are obtained after the hardening of the drop-
lets of emulsified gelatin solution. The par-
ticles are obtained after cooling gelatin 
emulsion droplets below the gelation point 
in an ice bath. For alginate, however, parti-
cles are produced by drop-by-drop extru-
sion of the sodium alginate solution into the 
calcium chloride solution. Sodium alginate 
is, in fact, a water-soluble polymer that gels 
in the presence of multivalent cations such 
as calcium. Chitosan particles are prepared 
by spontaneous formation of complexes 
between the positively charged chitosan and 
polyanions (tripolyphosphate or gelatin) or 
by the gelation of a chitosan solution dis-
persed in an oil emulsion (Mahapatro and 
Singh, 2011). Figure 7 illustrates the gela-
tion mechanism of polysaccharides. At high 
temperatures, a random coil conformation 
is assumed. With decreasing temperature, 
the aggregation of double helices structure 
forms the physical junctions of gels (Rees 
and Welsh, 1977). Table 8 displays some 
recent applications of IG. This technique 
has been mainly used to prepare chitosan 
nanoparticles. 
Table 7: Applications of the SCF technology 
Encapsulated  
molecule 
Polymer  Size (μm) Zeta poten-
tial
(mV) 
Reference 
Hydrocortisone acetate PLGA 1-5  - Falco et al., 2013 
17D-methyltestosterone PLA 5.4-20.5  13.9 - 67.7 Sacchetin et al., 2013 
Paracetamol PLA 0.301-1.461  - Kalani and Yunus, 2012 
5-fluorouracil PLLA-
PEG/PEG 
0.175  - Zhang et al., 2012 
Human growth  
hormone 
PLGA 93  - Jordan et al., 2010 
Azacytidine  PLA 2  - Argemí et al., 2009 
Bovine serum albumin PLA 2.5  - Kang et al., 2009 
Retinyl palmitate PLA 0.040-0.110 - Sane and Limtrakul, 2009 
Indomethacin PLA 2.35 - Kang et al., 2008 
 
Figure 6: Schematic 
presentation of the 
experimental set up 
for the RESS process 
(Byrappa et al., 2008) 
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Table 8: Some applications of the ionic gelation technique 
Encapsulated 
molecule 
Polymer Size (μm) Zeta potential 
(mV) 
Reference 
Articaine  
hydrochloride 
Alginate/chitosan 0.340-0.550 -22 - (-19) de Melo et al., 2013 
TNF-D siRNA Trimethyl chitosan-
cysteine 
0.146  25.9 He et al., 2013 
Paclitaxel O-carboxymethyl 
chitosan 
0.130-0.180  -30 - (-12) Maya et al., 2013 
pDNA Chitosan 0.153-0.403 46.2-56.9 Cadete et al., 2012 
Gemcitabine Chitosan 0.095  - Derakhshandeh and 
Fathi, 2012 
Dexamthasone 
sodium  
phosphate 
Chitosan 0.256-0.350  - Doustgani et al., 2012 
Itraconazole Chitosan 0.190-0.240  11.5-18.9 Jafarinejad et al., 2012 
5-fluorouracil and 
leucovorin 
Chitosan 0.040-0.097  25.6-28.9 Li et al., 2011 
Insulin Chitosan and  
arabic gum 
0.172-0.245  35.7-43.4 Avadi et al., 2010 
CKS9 peptide 
sequence 
Chitosan 0.226  - Yoo et al., 2010 
3.8 Layer by layer
Polyelectrolyte self assembly is also 
called layer-by-layer (LbL) assembly pro-
cess. The earliest technology was based on 
the assembly of colloidal particles on a sol-
id core (Iler, 1966). From the 1990s, appli-
cations were expanded. LbL allowed, in 
fact, the assembly of polyelectrolyte films 
using biopolymers, proteins, peptides, poly-
saccharides and DNA (Powell et al., 2011). 
This approach was first developed by Su-
khorukov et al. (Sukhorukov et al., 1998). 
Polyelectrolytes are classified according to 
their origin. Standard synthetic polyelectro-
lytes include poly(styrene sulfonate) (PSS), 
poly (dimethyldiallylammonium chloride) 
(PDDA), poly(ethylenimine) (PEI), poly(N-
isopropyl acrylamide (PNIPAM), poly-
Figure 7: Gelation 
mechanism of poly-
saccharides in water 
(Guenet, 1992) 
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(acrylic acid) (PAA), poly (methacrylic ac-
id) (PMA), poly(vinyl sulfate) (PVS) and 
poly(allylamine) (PAH). Natural polyelec-
trolytes include nucleic acids, proteins and 
polysaccharides such as, alginic acid, chon-
droitin sulfate, DNA, heparin, chitosan, cel-
lulose sulfate, dextran sulfate and carbox-
ymethylcellulose (de Villiers et al., 2011). 
The obtained particles are vesicular and are 
called polyelectrolyte capsules. Assembly 
process is based on irreversible electrostatic 
attraction that leads to polyelectrolyte ad-
sorption at supersaturating polyelectrolyte 
concentrations. Other interactions such as, 
hydrogen bonds, hydrophobic interactions 
and Van der Waals forces were also de-
scribed (de Villiers et al., 2011). A colloidal 
template that serves to the adsorption of the 
polyelectrolyte is also needed. The com-
monly used cores for the formulated parti-
cles are derived from stabilized colloidal 
dispersions of charged silica, charged 
poly(styrene) spheres, metal oxides, poly-
oxometalates and conducting liquid crystal-
line polymers. Carrier systems can be func-
tionalized with stimuli-responsive compo-
nents that respond to temperature, pH and 
ionic strength. The polymers/colloids used 
in LbL technique can also be functionalized 
to alter their properties preceding layer by 
layer assembly. Experimental parameters 
that have to be managed include coating 
material concentration, ion concentration 
and the pH of the medium (Vergaro et al., 
2011). Polymer assembly occurs after incu-
bation of the template in the polymer solu-
tion or by decreasing polymer solubility by 
drop-wise addition of a miscible solvent 
(Radtchenko et al., 2002). This procedure 
could be repeated with a second polymer to 
allow sequential deposition of multiple pol-
ymer layers (Figure 8). LbL presents ad-
vantages over several conventional coating 
methods: (1) simplicity of the process and 
equipment; (2) its suitability for coating 
most surfaces; (3) availability and abun-
dance of natural and synthetic colloids; (4) 
flexible application to objects with irregular 
shapes and sizes; (5) formation of stabiliz-
ing coats and (6) control over the required 
multilayer thickness (de Villiers et al., 
2011). Table 9 contains some recent appli-
cations of LbL technique. 
 
 
 
Figure 8: The layer by layer technique based on electrostatic interaction (Ariga et al., 2011) 
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Table 9: Applications of the layer-by-layer technique 
Active Polyelectrolytes Size (μm) Zeta
potential 
(mV) 
References 
Kaempferol Sodium 
Alginate and protamine sulfate 
0.161 - 8.9 Kumar et al., 2012 
Designed pep-
tide DP-2015 
Poly-l-glutamic acid and poly-l-
lysine 
- - Powell et al., 2011 
5-fluorouracil Poly(L-glutamic acid) and  
chitosan 
1  25-40 Yan et al., 2011 
Plasmid DNA Plasmid DNA and reducible hy-
perbranched poly(amidoamine) 
or polyethylenimine 
- - Blacklock et al., 2009 
Artemisinin Alginate, gelatin and chitosan 0.806  -33 Chen et al., 2009 
Insulin Glucose oxidase and catalase  6  - Qi et al., 2009 
Heparin Poly(styrene sulfonate) and chi-
tosan 
1 -10.4 Shao et al., 2009 
Acyclovir Poly(vinyl galactose 
ester-co-methacryloxyethyl tri-
methylammonium chloride) and 
poly(sodium 4-styrenesulfonate) 
- - Zhang et al., 2008a 
Propranolol  
hydrochloride 
Poly(vinyl galactose ester- 
co-methacryloxyethyl trime-
thylammonium 
chloride) and Poly(sodium  
4-styrenesulfonate) 
5-15.6 - Zhang et al., 2008b 
 
 
CONCLUSION 
Encapsulation of active molecules is a 
crucial approach that has been widely used 
for many biomedical applications. It per-
mits enhancement of bioavailability of mol-
ecules, sustained delivery, passive or active 
targeting and decrease of toxicity and side 
effects. These formulations can render 
some active molecules more suitable for a 
specific route such as the delivery of pro-
teins by the oral route or the delivery of 
some drugs via the blood brain barrier. 
Thus, they enhance efficiency, patient com-
pliance and allow successful management 
of diseases. Many biodegradable and bio-
compatible polymers were investigated. 
The choice of the technique and the suitable 
polymer is a crucial step. It depends on the 
physicochemical properties of the drug to 
be encapsulated. The management of oper-
ating conditions is also a hard task to moni-
tor particles’ properties and to enhance drug 
loading. Recent research works are focus-
ing on active targeting by the coating the 
carriers by biomolecules that specifically 
recognize a well-defined cell receptor. One 
can also notice a shift for more ’intelligent’ 
drug delivery systems. Responsive materi-
als, for example, react to a specific physio-
logical stimulus such as a variation of pH to 
release the encapsulated drug. Other ther-
mo-sensitive materials deliver drugs at a 
specific temperature. It can be noted also 
that more attention is paid to safer methods 
that avoid the use of organic solvents 
(RESS) or to techniques that provide better 
reproducibility and easy scalability (micro-
fluidics and membrane emulsification tech-
nology), which could be attractive for in-
dustrial processing.  
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 II.2. Encapsulation via double emulsification process 
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 Summary 
Double emulsions also termed as multiple emulsion or “emulsions of emulsions” are systems in 
which the droplets of dispersed themselves comprises of one or more smaller dispersed droplets. 
In this system, two liquid phases are separated by a third non miscible liquid phase. They can be 
composed of aqueous droplets encapsulating oil drops, or vice versa. 
The entrapment of water-soluble drug in polymeric micro- and nanoparticles with high loading 
remains a challenge because of rapid diffusion of the compound into the external aqueous 
continuous phase. The double emulsion solvent evaporation technique can be used, in order to 
overcome the problem of inefficient encapsulation of hydrophilic drugs. The most commonly 
used type is W1/O/W2 double emulsion solvent evaporation method, in which emulsification is 
performed in two step. First, the primary emulsion (W1/O) is prepared by homogenization of 
inner aqueous phase (W1) with organic phase (polymer solution). Then, the primary emulsion is 
dispersed in a second aqueous phase containing suitable stabilizer (s) and homogenizes to form 
double emulsion. The formation of emulsion is followed by evaporation of volatile organic 
solvent from the dispersed phase leading to a point of insolubility and precipitation of the 
polymer encapsulating the active material. The outer aqueous phase acts as dispersion medium. 
The volatile solvent may be eliminated by stirring at ambient temperature or under reduced 
pressure by rotary evaporator depending upon the nature of organic solvent.  
The organic solvent used for the encapsulation of drugs via double emulsion method 
should be of low boiling point in order to facilitate the removal of residual solvent from final 
particulate dispersion. Commonly used solvents are: dichloromethane, chloroform, methylene 
chloride, propylene carbonate and ethyl acetate. Among them, methylene chloride and ethyl 
acetate are very frequently used. Compared to the more hydrophobic methylene chloride, ethyl 
acetate usually exerts a less deteriorative effect on bioactivity of the entrapped peptides and 
proteins. Though, most of the researchers still prefer  methylene chloride as the organic solvent 
due to its ability to dissolve huge amounts of biodegradable polymers, low solubility in water 
(2.0%, w/v) and low boiling point (39.8 °C), thus, facilitating its removal by evaporation. 
Conversely, the relatively high solubility in water (8.7%, w/v) and the high boiling point (76.7 
°C) of ethyl acetate limited its application in W1/O/W2 double emulsion technique. The 
comparatively high solubility of ethyl acetate in water contributes to a fast diffusion of ethyl 
acetate from oil droplets into the external aqueous phase during the second step of emulsification 
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 process, which leads to polymer precipitation rather than the formation of micro- and 
nanoparticles. 
The performance of the polymeric encapsulation via double emulsion method depends on 
several factors such as biodegradable polymer nature (polymer composition and molecular 
weight), physicochemical properties organic solvents, type and concentration of surfactant, etc. 
Biodegradable polymers have the ability to degrade into nontoxic components; therefore, they 
have been used vastly in drug delivery system for encapsulation of pharmaceuticals and 
pharmaceuticals. Commonly used biodegrade polymers in double emulsion process include, poly 
(lactic acid) (PLA), poly lactic-co-glycolic acid (PLGA) and polycaprolactone (PCL), which are 
being widely researched for encapsulation various active drugs, genes and macromolecules. PCL 
is a nontoxic, biodegradable and biocompatible polymer, and possess low glass transition 
temperature and melting point (60 °C) and its metabolites are eliminated from the body by innate 
metabolic process. It has been widely studied for encapsulation of drugs for control drug delivery 
system due to its compatibility with vast range of drugs and its slow degradation to release drug 
for long time. PLGA is another biocompatible and biodegradable polymers commonly used in 
encapsulation via double emulsion method. After its approval by FDA for use in humans, it has 
been a popular choice for drug delivery. It degrades slowly into the biocompatible products of 
lactic and glycolic acid via hydrolysis and thus releases the encapsulated agents slowly over a 
long period of time.  This polymer is available in different PLGA/PLA ratio. As lactic acid is 
more hydrophobic than glycolic acid and, thus, lactic acid-rich PLGA copolymers are less 
hydrophilic, and degrade very slowly. PLA polymers are also approved by FDA in humans and 
have been frequently used for encapsulation in drug delivery system. It belongs to the most 
promising category of biodegradable polymers having excellent mechanical properties, good 
biocompatibility, and low toxicity. It is semi-crystalline polymer with a melting point of about 
180 °C, glass transition temperature of about 55 °C and tensile strength of 50–70 MPa and 
commonly prepared by ring-opening polymerization (ROP). Beside many advantages of 
biodegradable PLA and PLGA polymers in controlled drug delivery systems, they have certain 
drawbacks such as a risk of toxicity and immunogenicity because of their acidic by-products 
when used for long duration. 
This method has been used widely for encapsulation of different pharmaceuticals and 
biopharmaceuticals. Various types of biomolecules such as nucleic acids proteins and peptides 
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 have the challenge of their effective and efficient delivery to the target site without its 
degradation. Due to their water solubility, they tend to diffuse into continuous aqueous phase 
during emulsification process, which leads to low entrapment efficiency of bioactive molecule. 
Moreover, the negative charged biomolecules are unable to pass through the cell membrane 
properly and can be denatured by different enzymes such as proteases and nucleases. Therefore, 
different approaches have been used for encapsulation of nucleic acid in order to protect it 
against degradation, facilitating its intracellular penetration enhancing its delivery to intended 
site and controlling the rate of release. These apaches include, emulsion solvent evaporation, 
coacervation, spray drying and double emulsion techniques. However double emulsion technique 
is considered one of the most appropriate method, especially for encapsulation of hydrophilic 
nucleic acid. This technique is reproducible and can be scale up for large batches. Beside several 
advantages, double emulsion process has a shortcoming of shear force used for homogenization 
of nucleic acid’s solution in the organic phase. Which can damage the integrity of biomolecules, 
thus leads to loss of its bioactivity. Moreover, the organic solvents can damage the structure of 
nucleic acid during emulsification process. This damage can be minimized by condensation of 
nucleic acid with cationic polymers, in order to reduce its size and maintain its supercoiling 
structure, and thus preserve its biological activity. 
Several categories of pharmaceuticals have been encapsulated by double emulsion 
method such as anticancer drugs, antibiotics and anti-inflammatory drugs. The anticancer are 
encapsulated into biodegradable polymer in order to provide prolonged release of drug in 
controlled manner and to target the drug to specific cancerous tissues. Moreover co-delivery of 
both hydrophilic and hydrophobic drug and diagnostic agent simultaneously (theranostic) can be 
possible by this technique. These processes are also useful for effective encapsulation of highly 
water soluble antibiotics and for sustained release of antibiotics. Similarly the anti-inflammatory 
medicaments can be encapsulated in order to diminish their systemic side effects and to reduce 
the chances of possible drug interaction with concurrent medications. During encapsulation of 
various drugs via double emulsion method, the ratio of aqueous phase to oil phase has a 
significant effect on double emulsion stability. It has been established that, an emulsion with 
ratio of 1:10 (water: oil) is more stable than ratio of 1:5 (water: oil). Similarly, the emulsion of 
smaller particle size can be prepared with water: oil ratio of 1:30 as compared to ratio of 1:10 
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 (water: oil), however beyond water: oil ratio of 1:20 a decrease in encapsulation efficiency has 
also been observed, thus water: oil ratio in between 1:10 and 1: 20 are widely used. 
Beside many applications in controlled drug delivery and encapsulation of hydrophilic drugs, 
double emulsion has also several applications in theranostics. Theranostic is an approach in 
which agents are developed for simultaneous diagnosis and treatment of various diseases. It has 
been the field of extensive investigations in recent years for biomedical applications. These 
multifunctional theranostic agents allow for feedback mechanism to establish the localization of 
drug, release of drug, disease phase and efficacy of the treatment. For example, Yang et al 
fabricated polymer wormlike vesicles loaded with loaded with superparamagnetic iron oxide 
(SPIO) nanoparticles and anticancer drug doxorubicin (DOX) for targeted cancer therapy and 
MR imaging. The calculated SPIO nanoparticles (NPs) loading content in the vesicles was about 
48.0 wt. %, while The DOX loading level for these vesicles was about 9.0 wt. %. This 
theranostic vesicle nanocarrier system was established to be very efficient, which can provide 
controlled and targeted drug delivery to the tumor as well as it can be used as an efficient MRI 
contrast agent, thus providing targeted cancer therapy and diagnosis simultaneously. 
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 Abstract
Double emulsions are complex systems, also called "emulsions of emulsions", in which the 
droplets of the dispersed phase contain one or more types of smaller dispersed droplets 
themselves. Double emulsions have the potential for encapsulation of both hydrophobic as well 
as hydrophilic drugs, cosmetics, foods and other high value products. Techniques based on 
double emulsions are commonly used for the encapsulation of hydrophilic molecules, which 
suffer from low encapsulation efficiency because of rapid drug partitioning into the external 
aqueous phase when using single emulsions. The main issue when using double emulsions is 
their production in a well-controlled manner, with homogeneous droplet size by optimizing 
different process variables. In this review special attention has been paid to the application of 
double emulsion techniques for the encapsulation of various hydrophilic and hydrophobic 
anticancer drugs, anti-inflammatory drugs, antibiotic drugs, proteins and amino acids and their 
applications in theranostics. Moreover, the optimized ratio of the different phases and other 
process parameters of double emulsions are discussed. Finally, the results published regarding 
various types of solvents, stabilizers and polymers used for the encapsulation of several active 
substances via double emulsion processes are reported. 
Keywords: Double emulsion, Solvent evaporation, Encapsulation, Theranostics, Control release,
Drug delivery. 
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 1. Introduction
Nowadays, scientific advanced technologies are being directed towards evolution of 
innovative pharmaceutical products. The conventional therapies are progressively supplemented 
by more adaptable and well refined drug deliveries by the exploration of these advanced 
diversified technologies. Special focus is paid on tackling the restrictions associated with 
traditional drug delivery. Some of the most common obstacles encountered are the low 
bioavailability, poor stability, bitter taste and unpleasant odor of certain active agents. Here, 
encapsulation plays a vital role in overcoming the aforementioned obstacles. Premature 
degradation of active agents especially of proteins and peptides can be prevented by their 
encapsulation. Furthermore, encapsulation technologies also aid in achieving controlled and 
targeted release formulations. Colloidal carriers find immense applications in biomedical and 
biotechnology field. Various kinds of colloids employed in medicine are dendrimers, block 
ionomer complexes, polymeric biodegradable nanoparticles (NPs), polymeric micelles, 
liposomes (Laouini et al., 2012; Naseer et al., 2014), nanotubes, nanorods  (Wang et al., 2012)
and quantum rods.
Recently, polymers are increasingly used to constitute biodegradable particles. Such 
particles serve as drug reservoirs which bring not only local therapeutic effect but also deliver 
drugs, genes and vaccines to target organs for site specific delivery (Mohsen Jahanshahi, 2008; 
Zafar et al., 2014). Polymers are also employed in regenerative medicines and tissue engineering. 
Polymer selection is primarily based on toxicity and final application of the polymer. 
Biodegradable polymer encapsulated drugs show superb attributes e.g. non-toxicity and stability 
in blood. Moreover, polymeric materials permit modification in a) physicochemical 
characteristics (e.g. hydrophobicity, zeta potential), b) drug release properties (e.g. delayed, 
prolonged, triggered) and c) biological behaviour (e.g. bioadhesion, improved cellular uptake) of 
the NPs (Galindo-Rodriguez et al., 2005; Kumari et al., 2010; des Rieux et al., 2006). Examples 
of commonly used biodegradable polymers for encapsulation include poly (lactic acid), 
poly(glycolic acid), and poly (lactic-co-glycolic acid) (PLGA). Biodegradable polymers have the 
advantage that the release of loaded drug depends mainly on the degradation kinetics of the 
polymers used e.g. the release rate from PLGA carriers can be controlled by altering the lactic 
acid and glycolic acid ratio and molecular weight (Ye et al., 2010). Successful encapsulation of 
drugs like paclitaxel, 9-nitrocamptothecin, cisplatin, insulin, dexamethasone, estradiol, 
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 progesterone, tamoxifen, tyrphostins and haloperidol (Kumari et al., 2010) has been done by 
using various natural and synthetic polymers. 
Several encapsulation processes have been used in order to protect and to transport active 
molecules. These techniques can be divided in two major classes: (i) chemistry based processes 
e.g. emulsion polymerization, miniemulsion polymerization and interfacial polymerization, (ii) 
physicochemical processes e.g. multiple emulsion techniques, spray drying, emulsion solvent 
diffusion and layer by layer process. Different pharmaceutical carriers such as microparticles, 
nanoparticles and liposomes can be obtained by these techniques (Miladi et al., 2013).
Microencapsulation by solvent evaporation is mostly used in pharmaceutical industries to get 
controlled release formulations. Different methods are available to use microencapsulation by 
solvent evaporation technique. The selection of a method that will give adequate drug 
encapsulation usually depends on the hydrophilicity or hydrophobicity of the active molecules 
(Li et al., 2008). Oil-in-water (o/w) method is generally adopted for the encapsulation of 
insoluble or poorly water soluble active agents. Few examples of hydrophobic active agents that 
have been encapsulated via this technique include Cisplatin (Verrijk et al., 1992), 5-Fluorouracil 
(Boisdron-Celle et al., 1995), Lidocaine (Chung et al., 2001) and Progesterone (Aso et al., 1994; 
Bums et al., 1993). However, this technique fails when it comes to encapsulation of highly 
hydrophilic agents. This is because the active agent may diffuse into the continuous phase during 
the formulation or it may not get dissolved in the organic solvent. Multiple emulsions play a 
pivotal role in such cases. The most common type of multiple emulsions is water-in-oil (w/o/w) 
emulsion. Most hydrophilic drugs have been encapsulated via (w/o/w) method (Crotts and Park, 
1998; Okochi and Nakano, 2000; Sinha and Trehan, 2003). The water soluble agent is 
solubilized within the inner W1 phase of the emulsion which then shows prolonged drug release, 
lesser toxic effects (Nakhare and Vyas, 1996) and high encapsulation efficiency of the active 
agent. For this reason, proteins have been widely encapsulated by w/o/w emulsion system. The 
stability and release properties of double emulsions can be greatly improved by a change in the 
type and concentration of stabilizer employed in the system. Combining targeted delivery and 
prolonged drug release by using double emulsion system presents tremendous benefits in cancer 
therapy. Many advantages are associated with the use of double emulsion systems. Such systems 
are biocompatible, biodegradable and versatile with respect to different oils and emulsifiers 
being employed. Moreover, both hydrophobic and hydrophilic kinds of drugs can be 
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 encapsulated (separately and simultaneously) and protected. However, some difficulties are also 
linked with multiple emulsions such as difficulty in formulation, bulky and susceptibility to 
different routes of physical and chemical degradation. Various attempts have been made by 
researchers to improve the stability of multiple emulsions. Some of these efforts include 
surfactant concentration modulation, interfacial complexation, polymerization gelling, additives 
in different phases, steric stabilization and pro-emulsion approach (Garti, 1997; Garti and Aserin, 
1996; Hino et al., 2000). The objective of this work is to present a comprehensive literature
review on double emulsion technique. The review begins with a brief description of double 
emulsion and a comprehensive history of this technique. It progresses on to discuss the 
mechanism involved in formulation of a double emulsion. This review also reports the different 
polymers, stabilizers, surfactants, drugs encapsulated and average particle size obtained in 
different studies via this technique.
2. What is a double emulsion?
The first paper on double emulsion dates back 89 years (Seifriz, 1924), but detailed 
investigation on double emulsions was started at the end of 1970s. We can find several reviews 
on multiple emulsions, which come primarily from three research groups namely: Florence and 
Whitehill, (Florence and Whitehill, 1981a, 1982), Matsumoto et al. (Matsumoto et al., 1980) and 
Frenkel et al. (Frenkel et al., 1983). Double emulsion also termed as emulsion of emulsion, are 
complex system, in which the droplets of dispersed phase themselves comprises even small of 
dispersed phase (Garti and Bisperink, 1998). Double emulsion (DE) droplets are mostly 
polydispersed in size. In some cases its droplets are big enough containing many small 
compartments with 50-100 droplets in each drop of double emulsion, while on the other hand 
small droplets of DE may consist of one or few droplets. There are two common types of DE; 
water-oil-water (w/o/w) and oil-water-oil (o/w/o). Two step processes are most commonly used 
for preparation of double emulsions, in which for w/o/w DE preparation, the inner aqueous phase 
(W1) is dispersed in oil phase containing lipophilic emulsifier in the first step, which is followed 
by dispersion of the primary emulsion into outer aqueous phase (W2) containing hydrophilic 
emulsifier (Garti and Bisperink, 1998; Schuch et al., 2013).
Florence et al (Florence and Whitehill, 1981b) identified that double emulsion droplets 
could be of three types (A, B, C), which did not exist exclusively in any one system but usually 
one of them is predominant. The type A, was found to be the simplest system consists of 
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 relatively small droplets with almost single droplet of the internal aqueous phase (Fig.1 A). The 
droplet size in the type B emulsion system is larger composed of several small droplets (less than 
50) of internal aqueous phase (Fig.1 B). The system became more complex (type C) when 
majority of droplets achieve relatively largest size, encapsulating numerous droplets of internal 
aqueous phase (W1) (Fig.1 C). The system C, showed slow release of entrapped moiety than A or 
B, so system C would expected to be more promising in drug delivery system.
Fig. 1. Types of double emulsion droplets. (Florence and Whitehill, 1981b)
Double emulsion has the ability to prepare polymeric particles, which allow the 
controlled release of active ingredients soluble in the internal aqueous phase or dispersed in the 
polymeric matrix. Its foremost function is regarded as internal reservoir to entrapped active 
ingredients whatever you chose into the inner confined space, which can protect the entrapped 
sensitive ingredient against light, enzymatic degradation, and oxidation.  It also allows the slow 
and sustained release of active ingredients from the internal reservoir to the external dispersion 
media and their key importance is due to their capability to encapsulate some water-soluble 
flavors and active ingredients(Benichou et al., 2004). In cosmetic field, it offers the possibility of 
combining incompatible ingredients in the same formulation to enhance the efficacy. Regarding 
disadvantages of double emulsion, it a complex process and thermodynamically unstable. The 
particles produced by this technique are comparatively heterogeneous and particle size is 
sensitive to various process parameter of double emulsion technique. Few prominent advantages 
and limitation of various techniques for encapsulation of drug are given in the table (Table 1). 
Single emulsion solvent evaporation, double emulsification, nanoprecipitation, emulsion 
diffusion and salting out techniques can be used to encapsulate lipophilic active agents. Double 
emulsion is a unique process encompassing the advantage of encapsulating both lipophilic and 
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 hydrophilic drug molecules. Both emulsion diffusion and coacervation techniques are used for 
incorporation of thermosensitive drugs whereas phase inversion temperature method cannot be 
utilized to encapsulate thermolabile actives like peptides and proteins. Techniques that generally 
require high shearing stress and high pressure homogenization include single and double 
emulsification. Moreover, double emulsion generally gives polydisperse particles as compared to 
other techniques. Lastly, the techniques that do not require the use of toxic solvents or organic 
solvents are; emulsion diffusion, microemulsion, nanoprecipitation, high pressure 
homogenization and phase inversion temperature technique. 
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 3. Formulated double emulsion based dispersion
The most often used double emulsion technique for preparation of miro- and 
nanoparticle, and encapsulation of active molecules is double emulsion solvent evaporation 
technique. Initially, this technique was used for microencapsulation (Alex and Bodmeier, 1990; 
Pisani et al., 2008). In this method, homogenization is performed in two steps; in the first step, 
water soluble drugs are incorporated in the inner aqueous phase (W1) and polymer/ lipophilic 
drugs are added into oil phase (O), then both phases are homogenize by proper agitation to form 
the primary emulsion (W1/O). Then, the primary emulsion is emulsified with the outer aqueous 
phase containing appropriate stabilizer to form double emulsion (W1/O/W2).  Formation of 
double emulsion (particulate dispersion) is followed by evaporation of the organic solvent (O) 
from the dispersed phase leading to a point of insolubility and consequently, hardening of the 
polymer encapsulating the active material. The solvent may be evaporated under reduced 
pressure via rotary evaporator or by simple stirring at ambient temperature depending upon the 
boiling point of organic solvent. The outer aqueous phase act as dispersion medium and the 
agitation can be provided either by mechanical stirring or sonication depending upon the nature 
of drug to be encapsulated and the intended particle size. 
3.1. Commonly used polymers in double emulsion solvent elimination preparations 
Biodegradable polymers have been used tremendously in drug delivery system for 
encapsulation of pharmaceuticals and pharmaceuticals as they can be degraded into nontoxic 
components. These polymers are consisting of ester, amide and ether functional groups. 
Different polymers such as PLA, PLGA and PCL are being intensively researched for 
encapsulation various active drugs, genes and macromolecules using double emulsion process 
(Badri et al., 2014; Pillai and Panchagnula, 2001; Rosset et al., 2012). PCL is a nontoxic, 
biodegradable and biocompatible polymer; with low glass transition temperature and melting 
point and its metabolites are eliminated from the body by innate metabolic process. It has been 
extensively study for encapsulation via double emulsion process for control drug delivery system 
in several formulations due to its compatibility with wide range of drugs and its slow degradation 
to release drug for extended period of time (Florindo et al., 2008a; Wang et al., 2008a) (Iqbal et 
al., 2014; Lowery et al., 2010). Poly(lactic-co-glycolic acid) is another biocompatible and 
biodegradable polymers commonly used in double emulsion techniques (Hattrem et al., 2014; 
Rizkalla et al., 2006; Takai et al., 2011). After its approval by FDA for use in humans, it has 
56
 been a popular choice for drug delivery. It degrades gradually into the biocompatible products of 
lactic and glycolic acid via hydrolysis and thus releases the encapsulated agents slowly over a 
long period of time (weeks-months).  This polymer is available in different PLGA/PLA ratio. As 
lactic acid is more hydrophobic than glycolic acid and, thus, lactic acid-rich PLGA copolymers 
are less hydrophilic, and degrade very slowly (Dinarvand et al., 2011). PLGA has been 
investigated for encapsulation of protein, peptides and nucleic acids, and for attachments of 
legends to targeting particle to specific tissues and imaging (McCall and Sirianni, 2013). 
Poly (L-lactic acid) (PLA) polymers are approved by FDA in humans (Zille et al., 2010) 
and have been frequently used for encapsulation in drug delivery system via double emulsion 
process (Hong et al., 2005; Montiel-Eulefi et al., 2014; Nihant et al., 1994). It belongs to the 
most promising category of biodegradable polymers having excellent mechanical properties, 
good biocompatibility, and low toxicity. It is semi-crystalline polymer with a melting point 
of about 180 °C, glass transition temperature of about 55 °C and tensile strength of 50–70 MPa 
and commonly prepared by ring-opening polymerization (ROP) (A. Auras et al., 2010; 
Södergård and Stolt, 2002) . The properties such as crystallinity, hydrophobicity and melting 
point of PLA can be tailor made by copolymerization (random, block, and graft) with other 
comonomers, modification in molecular architecture (hyperbranched, star shaped, or 
dendrimers), functionalization or blending with other polymers. For example, glycolide, ε-
caprolactone, δ-valerolactone, trimethylene and carbonate have been often used to modify its 
thermal properties (GRUVEGÅRD et al., 1998). These modifications also affect drug loaded 
PLA particles properties such as drug release rate, permeability and degradation rate of the 
matrix. Beside many advantages of biodegradable PLA polymers in controlled drug delivery 
systems, they have certain shortcomings such as a risk of toxicity and immunogenicity due to 
their acidic by-products when used for long period of time (Naraharisetti et al., 2005).
The selection of the appropriate polymer during encapsulation of drug is a critical step, 
which depends upon the chemical nature of the drug and polymer and their intended application. 
Table 2 is listing some of the most commonly used biodegradable polymers in encapsulation via 
double emulsion process.  
3.2. Stabilizers
Stabilizers make it possible to maintain the physicochemical state of a dispersion of two 
or more immiscible phases and prevent the separation of phases, thus making emulsion system 
57
 more stable. The commonly used stabilizers in double emulsion process include PVA, Tween 80 
and Span 80. However, poly vinyl alcohol (PVA) is one of the most frequently used stabilizers in
double emulsion process for encapsulation of different active moieties (Liu et al., 2005a; 
Rizkalla et al., 2006; Yang et al., 2001). It is a well-known hydrophilic, biocompatible polymer 
and possesses good mechanical strength, low fouling potential, and lasting temperature stability 
and pH stability. These properties of PVA make it suitable candidate to be used in encapsulation 
of various pharmaceuticals and biopharmaceuticals (Xia and Xiao, 2012).
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 4. Encapsulation of active ingredients
The selection of a specific technique for an efficient drug encapsulation is generally 
determined by the hydrophilicity or hydrophobicity of the drug molecules (Jelvehgari and 
Montazam, 2012). Despite the fact that various techniques have been described in the literature 
as well as successfully employed by researchers to encapsulate hydrophobic agents into 
biodegradable nanoparticles (Ibrahim et al., 2013; Palamoor and Jablonski, 2013, 2014), the 
encapsulation of hydrophilic drugs into such carriers is not facile. This is because the hydrophilic 
compound is pushed out from hydrophobic matrix into the dispersing water phase during 
formulation of the particles (Ibrahim et al., 2013). W/O or O/O emulsion prepared via solvent 
evaporation methods are quite suitable for biologically active substances encapsulation into 
microspheres but certain problems are involved in these techniques e.g. it is difficult to remove 
the large volumes of solvents from the dispersions (Jelvehgari and Montazam, 2012). The 
mineral or vegetable oil used as external phase in both w/o or o/o emulsion makes 
washing/collecting of resultant particles difficult. However, more innovative method to 
encapsulate hydrophilic drugs via emulsion solvent evaporation technique includes double 
emulsions (multiple emulsions) e.g. in w/o/o emulsion type, the problems associated with w/o or 
o/o methods are eliminated. Jelvehgari and Montazam (Jelvehgari and Montazam, 2012) 
prepared theophylline loaded microparticles via emulsion-solvent extraction or evaporation 
techniques to compare the results (Fig. 2). In any case, the formulation should be adapted to the 
chemical nature of used polymer and the chemical stability of the active molecule in the used 
solvent and encapsulation conditions. 
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 Fig. 2. Ethyl cellulose loaded microparticles prepared via double emulsification (W/O1/O2)
technique (Jelvehgari and Montazam, 2012).
4.1. Encapsulation of common pharmaceutical molecules by double emulsion solvent 
evaporation process  
Some common pharmaceutical drugs encapsulated into particles by double emulsion 
process such as anticancer drugs, anti-inflammatory and antibiotics are reviewed here. The most 
encapsulated active molecules are anticancer drugs. 
4.1. 1. Anticancer drugs 
Among anticancer drugs, doxorubicin, cisplatin, fluorouracil and epirubicin have been 
encapsulated by this technique (Ji et al., 2012a; Matsumoto et al., 1997; Wang et al., 2010; Zhou 
et al., 2006). Doxorubicin is an antitumor drug and has been frequently incorporated into 
different polymeric particles prepared by double emulsion process (Amjadi et al., 2013; Jiang et 
al., 2011). It is an antibiotic commercially available as a water soluble hydrochloride salt, which 
used in cancer chemotherapy. Tewes et al (Tewes et al., 2007) prepared PLGA particles loaded 
with doxorubicin. The hydrodynamic size of DOX loaded particles was found to be 316 nm and 
its encapsulation efficiency was 67%. The release rate was slow and over a period of 24 hours 
only 1.5% of drug was released, which indicates the controlled release of formulation. Release 
rate depends upon several factors such as water-solubility, dissolution, particles size  and 
   Stirring
EC in solvent system
(acetonitrile and DCM)
Syringe pump
(W/O emulsion)
W/O emulsion Span 80 in liquid 
paraffin (O2)
TH in D.W (W1)
Solvent extraction 
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 thickness of polymeric coating (Pearnchob et al., 2003; Siepmann et al., 2004).In another study, 
Wang et al (Wang et al., 2011) demonstrated that the anti-tumor efficacy of doxorubicin (DOX) 
and paclitaxel (TAX) can be enhanced by its co-delivery strategy. They prepared drug-loaded 
Methoxy poly(ethylene glycol)-poly(lactide-co-glycolide) (mPEG-PLGA) nanoparticles by 
double emulsion process.  The hydrophilic doxorubicin was incorporated in inner aqueous phase 
and the hydrophobic paclitaxel in methylene chloride (oil phase) and emulsified by sanitation. 
Average size of drug loaded particles (NPs-DOX-TAX) was measured by DLS and found to be 
243 nm. The in vitro drug release profile was determined in phosphate-buffered saline (PBS) at 
pH 7.4 and pH 4.4 and the release rate of both DOX and TAX were pH dependent (Fig. 3). At 
neutral pH, the release rates of both drugs were slower than acidic pH, and about 90% of drugs 
were released within 300 hours at pH 7.4. 
Fig. 3. Release profiles of DOX and TAX from mPEG-PLGA nanoparticles in PBS at 37 °C at 
pH 4.4 (black, red) and pH 7.4 (blue, purple) (Wang et al., 2011). 
4.1. 2. Anti-inflammatory drugs 
Anti-inflammatory drugs encapsulated by double emulsion process included 
acetaminophen, aceclofenac , diclofenac sodium, aspirin and ketoprofen etc (Bhatnagar et al., 
1995; Lai and Tsiang, 2005; Nagda et al., 2009; Pavanetto et al., 1996). Aspirin is widely utilized 
nonsteroidal anti-inflammatory drug (NSAID). It may be used to reduce pain and swelling in 
conditions such as arthritis, to reduce fever and relieve mild to moderate pain from conditions 
such as muscle aches, toothaches, common cold. Fargnoli et al (Fargnoli et al., 2014)
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 encapsulated aspirin and prednisolone drugs in  poly-lactic glycolic acid polymer (PLGA) 
nanoparticles by double emulsion process for cardiac gene therapy. And it was found that aspirin 
particles have large size (323 nm) than prednisolone nanoparticles (234 nm), this difference in 
size was attributable to higher aspirin mass content. Loading Efficiency results were uniform for 
all nanoparticle types, i.e. PLGA 50:50 Prednisolone [88.9 %], PLGA 65:35 Prednisolone [88.2 
%], PLGA 50:50 Aspirin [89 %] and PLGA 65:35 Aspirin [88.8 %]. The control release of drug 
for over a time period of 5 days are shown in Fig. 4. The release rate of aspirin was faster as 
compared to prednisolone as shown in the Fig. 4. 
Fig. 4. PLGA Nanoparticle formulations release analysis. Controlled release study results 
demonstrate that aspirin particles overall release faster than prednisolone types (Fargnoli et al., 
2014). 
4.1. 3. Antibiotic drugs  
Antibiotics such as, erythromycin, gentamicin, norfloxacin, cephalexin, capreomycin 
(Chaisri et al., 2009; Fan et al., 2009; Huang and Chung, 2001) Cefazolin, ciprofloxacin, 
clindamycin, colistin, doxycycline,and vancomycin (Shah et al., 2014) have been encapsulated 
by double emulsion technique. Encapsulation of highly hydrophilic drugs such as gentamicin has 
been performed by many researches via double emulsion method (Virto et al., 2007; Yang et al., 
2001). Gentamicin is the most important aminoglycoside that has been used widely for the 
treatment of osteomyelitis and against a wide range of Gram-positive and Gram-negative 
bacteria (Lecároz et al., 2006). However, a prolonged dosage regimen of antibiotics (4–6 weeks) 
for the treatment of osteomyelitis is needed, which may cause systemic toxicity.  Thus, localized
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 drug delivery of gentamicin has been proposed, in order to minimize the side effects by reducing 
administered dose and to reduce probability of drug resistance (Huang and Chung, 2001). The in 
vitro drug release is dependent on the distribution of drug within microsphere, polymer blend 
ratio, polymer degradation pattern, stabilizer and size of microsphere (Faisant et al., 2002; 
Lecomte et al., 2005; Luan et al., 2006, 2006). The high initial burst release of drug is often 
attributed to the associated drug on the particles surfaces (Kassab et al., 1997). On the other 
hand, larger size particle release drug more slowly and for extended period of time compared to 
smaller particles (Berkland et al., 2003).  
In a study conducted by Shah et al (Shah et al., 2014) cefazolin, ciprofloxacin, 
clindamycin, colistin, doxycycline and vancomycin were loaded at 10 wt% and 20 wt% into 
PLGA microparticles using double emulsion solvent evaporation technique. All the antibiotics 
were first solubilized in the inner aqueous phase at 37 C° and then added to the oil phase (PLGA 
dissolved in methylene chloride) at a ratio of 1:5.6 v/v.  The internal phase/oil phase emulsion 
was then homogenized with outer aqueous phase (0.3 wt% PVA solution) at 700 rpm. Finally, 
the solvent was evaporated and the particles were washed. Table 3 shows their loading 
efficiencies. 
Table 3 
Loading Efficiencies of Microparticle Formulations (Shah et al., 2014) 
Loading efficiency of 10 wt% 
antibiotic-loaded PLGA MPs 
(%)
Loading efficiency of 20 wt% 
antibiotic-loaded PLGA MPs 
(%)
Cefazolin 36.4±3.3 51.3±6.1
Ciprofloxacin 86.8±10.9* 38.9±17.8*
Clindamycin 84.9±6.9 89.5±4.0
Colistin 102.0±5.0 105.3±4.4
Doxycycline 71.4±2.3 89.4±0.9
Vancomycin 83.3±4.8 76.9±6.2
Data is presented as mean ± standard deviation, n = 3 per group 
* Indicates significant difference between 10 and 20 wt% loaded for a given antibiotic 
The release kinetics of all of the antibiotics loaded PLGA particles Were determined in 
phosphate buffered saline at pH 7.4. The in vitro release curves are shown in Fig. 5. From the 
release analysis, it was found that during phase-1 (0-1 day), 20 wt % loaded ciprofloxacin 
formulation has greater burst release as compared to 20 wt % clindamycin, cefazolin and 
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 doxycycline loaded formulations, while no significant difference was found between 20 wt% 
cefazolin, clindamycin and doxycycline formulations. Most of the loaded drugs were released 
during phase-2 (1-21 days). In this phase, drug release rates were almost same for cefazolin, 
ciprofloxacin, clindamycin, and doxycycline for both 10 wt % and 20 wt % loaded particles. In 
case of colistin and vancomycin loaded particles, the drugs were mainly released during  phase 3 
(24-38 days) and there was no significant difference in release rates between colistin and 
vancomycin loaded particles (Shah et al., 2014). 
Fig. 5. Release curves for (a) cefazolin, (b) ciprofloxacin, (c) clindamycin, (d) colistin, (e) 
doxycycline, and (f) vancomycin loaded PLGA microparticles at 10 and 20 wt%. Significant 
differences between release rates during each phase for the same antibiotic are indicated by 
letters A and B. For colistin loaded PLGA MPs, Phase 2 and Phase 3 are significantly different 
between 10 and 20 wt% loaded MPs (p<0.05). Ciprofloxacin and doxycycline 10 wt% loaded 
MPs demonstrate increased release of antibiotic during Phase 3 compared to 20 wt% loaded 
MPs, and vancomycin loaded MPs demonstrate increased release from 20 wt% MPs compared to 
10 wt% MPs in phase 4 (p<0.05). Cumulative percent release is the same between 10 and 20 
wt% for any antibiotic (p>0.05). The three release phases of cefazolin, ciprofloxacin, 
clindamycin and doxycycline are: phase 1 (0-1d), phase 2 (1-21d), phase 3 (21-49d), and four 
phases of colistin and vancomycin are: phase 1 (0-10d), phase 2 (10-24d), phase 3 (24-38d) and 
phase 4 (38-49d) (Shah et al., 2014).
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 4.2. Encapsulation of biopharmaceuticals via double emulsion method 
4.2. 1. Encapsulation of proteins 
Advancement in the field of biotechnology/genetic engineering (Hutchinson and Furr, 
1990) and better understanding of the role of peptides and proteins in the physiology and 
pathology has enhanced the importance of peptides and proteins as therapeutic agents.  However, 
certain hurdles are associated with the therapeutic usage of the available peptides and proteins 
such as their short half-life. Moreover, these can be easily degraded and most peptides possess 
poor passage through biological barriers due to their poor diffusivity and low partition 
coefficient (Lee, 1988). Due to these reasons, during the past two decades, the researchers have 
focused their interest in encapsulation of these agents within colloidal particles by employing 
different biodegradable polymers (Arshady, 1991; Heller, 1993; Jalil and Nixon, 1990; Langer, 
1990; Zhou and Wan Po, 1991). Encapsulation protects these agents from degradation, controls 
their release from site of administration and in some cases, it can also improve the passage 
through biological barriers. Although the double emulsion encapsulation technique is taken as a 
complex process, it is still widely employed to encapsulate hydrophilic agents, particularly 
protein and peptide drugs, into polymeric microspheres resulting in higher encapsulation 
efficiencies (Alonso et al., 1994; Bley et al., 2009; Kreitz et al., 1997; Leach and Mathiowitz, 
1998). Engel et al. (Engel et al., 1968) successfully encapsulated insulin via this technique to 
enhance the efficiency of insulin upon oral administration as well as to facilitate its 
gastrointestinal absorption. 
Protein encapsulation via double emulsion is performed in two steps (Nihant et al., 1994; Tan
and Danquah, 2012): In the primary emulsion formation stage, the aqueous solution of protein is 
added to the polymeric organic solution in the presence of high shearing forces 
(ultrasonication/homogenization). In the second stage, double emulsion (w/o/w) is formed by 
dispersing the primary emulsion in an external aqueous phase containing suitably selected 
stabilizer. Finally, organic solvent removal either by evaporation or extraction results in the 
formation of protein loaded particles (Fig. 6).
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 Fig. 6. Double emulsion solvent evaporation method for microencapsulation of proteins (Yeo et 
al., 2001). 
Many proteins have been encapsulated via this technique such as bovine serum albumin 
(Benoit et al., 1999; Lu et al., 1999; Sah et al., 1995; S. R. Jameela, 1996; Yang et al., 2001; 
Youan et al., 1999). Lamprecht et al. (Lamprecht et al., 2000) also prepared BSA based 
nanoparticles via double emulsion pressure homogenization technique with the goal to 
investigate the influence of miscellaneous process control parameters on the obtained 
nanoparticles. Some novels method for the encapsulation of proteins and peptides were also 
introduced such as Viswanathan et al. (Viswanathan et al., 1999) introduced a (water in oil) in oil 
emulsion. They used oil as processing medium to prevent the hydrophilic proteins from diffusing 
out of the microspheres before they harden. Whereas, in another case, BSA loaded PCL 
microparticles were prepared by Lin and Huang, (Lin and Huang, 2001a) via w/o/o/o emulsion 
solvent evaporation method. They utilized two types of homogenizers and investigated the 
influence of solvent evaporation rate on the crystallinity and performance of particles. Another 
study was also performed on similarly prepared particles i.e. via w/o/o/o emulsion technique (Lin 
and Huang, 2001b) to study the effect of pluronics on the BSA loaded microparticles.
A luteinizing hormone-releasing hormone (LHRH) agonist i.e. Leuprolide acetate was 
encapsulated via w/o/w emulsification by Ogawa et al. (Ogawa et al., 1988a) and Okada et al. 
(Ogawa et al., 1988b). Currently this product is available in the market. There are many other 
examples of proteins encapsulated by double emulsion technique and few of these examples are 
listed in the following table (Table. 4).
Protein 
solution 
in water
 
Hardened 
microsphere
Secondary emulsion 
(W/O/W)
Oil
Primary 
emulsion W/O
Water
Solvent removal 
& drying
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 Table 4 
Various proteins encapsulated via double emulsion technique using different polymers  
Protein Polymer Encapsulation
efficiency
Initial release
in 1 day
Reference
Carbonic 
anhydrase
PLGA 45-48% < 10% (Lu and Park, 
1995)
BSA PLGA 56-85% 30-50% (Igartua et al., 
1997)
Recombinant 
human growth 
hormone (rhGH)
PLGA 40-66% 20% (Cleland et al., 
1997)
Urease PLGA 17-55% 17-45% (Sturesson and 
Carlfors, 2000)
Leuprolide PLGA 13.4% 10% (Woo et al., 
2001)
Brain derived 
neurotr-ophic factor 
(BDNF)
PLGA,PLL,
PEG
- BDNF delivered 
for longer than 
60 days
(Bertram et al., 
2010)
Vascular 
endothelial growth 
factor (VEGF)
PLGA 46-60% -4ng/mL
-27ng/mL
(Karal-Yılmaz et 
al., 2011)
Alpha-1 antitrypsin 
(α1AT)
PLGA Varies with
copolymer ratio 
of PLGA
- (Pirooznia et al., 
2012)
Lysozyme PEG/PBT
block
89% < 5% (J M Bezemer, 
2000)
Although, this technique is widely used for protein encapsulation, still there are certain 
limitations associated with this method. The drug encapsulation efficiency is not very good and 
the production cost of protein drugs is high. Moreover, the use of toxic organic solvents such as 
dichloromethane and ethyl acetate is also not very favorable. Furthermore, protein drugs tend to 
denature and form aggregates due to various factors like high shearing forces and exposure to 
large interface between aqueous and organic phases. 
4.2. 2. Encapsulation of Nucleic acids 
Nucleic acid is an important biomolecule in our body having many applications in gene 
therapy and diagnostics (Chen et al., 2009). However the major challenge is its effective and 
efficient delivery to the site of interest without its degradation. Different strategies have been 
adopted for this purpose such as, complexation of DNA with polycations (Möbus et al., 2012; 
Putnam, 2006) encapsulation within liposomes (Edwards and Baeumner, 2007; Tsumoto et al., 
71
 2001), encapsulation via double emulsion (Ibraheem et al., 2013a) and polyelectrolyte capsules 
(Kreft et al., 2006; Shchukin et al., 2004). In modern drug delivery system, it is a challenge to 
administered hydrophilic biomolecules such as nucleic acids. Because of their water solubility, 
they tend to diffuse into continuous aqueous phase during emulsification process (Iqbal and 
Akhtar, 2013; Luo et al., 1999; Perez et al., 2001; Woodrow et al., 2009) which leads to low 
encapsulation efficiency of active moiety (Cun et al., 2011). Additionally, the negative charged 
biomolecules are unable to penetrate the cell membrane appropriately and also labile to 
degradation by different enzymes such as proteases and nucleases (Amidon et al., 1995; Li et al., 
2006; Verdine and Walensky, 2007).In order to overcome these problems, researchers have 
focused on encapsulation of nucleic acid drugs inside biodegradable polymer, because it 
protecting the nucleic acid against degradation, facilitating its intracellular penetration,
minimizing fluctuation in plasma concentration, enhancing the drug delivery to intended site and 
controlling the rate of drug release by diffusion  (Lecomte et al., 2004; Singh et al., 2010; 
Streubel et al., 2006) 
Various approaches have been used for encapsulation of nucleic acids including emulsion 
solvent evaporation, coacervation, spray drying and double emulsion techniques (Oster and 
Kissel, 2005; Tan and Danquah, 2012; Zhao et al., 2014). However double emulsion is technique 
is considered one of the most appropriate method, especially for encapsulation of hydrophilic 
nucleic acid drug inside biodegradable polymer (Jeffery et al., 1991, 1993; Mehta et al., 1996),
this technique is reproducible and can be scale up for large batches (Jorgensen and Nielson, 
2009). Typically in this method, the aqueous solution of nucleic acid is mixed with a solution of 
polymer dissolved in organic solvent by using sonication or homogenization techniques 
(Ducheyne et al., 2011). Beside several advantages, double emulsion process has a drawback of 
shear force used for homogenization of nucleic acid’s solution in the organic phase. Which can 
damage the integrity of biomolecules, thus leads to loss of its biological activity. Moreover, the 
organic solvent can adversely affect the structure of nucleic acid during homogenization. This 
damage can be minimized by condensation of nucleic acid with cationic polymers, in order to 
reduce its size and maintain its supercoiling structure, and thus preserve its biological activity 
(Ducheyne et al., 2011). It has been established that during second step of double emulsion 
emulsification, the applied shearing force disrupts the primary emulsion droplets, thus the inner 
aqueous phase containing nucleic acid mixed with outer aqueous phase, allowing diffusion of 
72
 nucleic acid into outer aqueous phase. Which may leads to poor loading efficiency, in systems with low 
stability of primary emulsions (Jorgensen and Nielson, 2009). The ratio of aqueous phase to oil phase has 
a significant effect on double emulsion stability. It has been reported that, an emulsion with ratio of 1:10 
(water: oil) is more stable than ratio of 1:5 (water: oil) (Mohamed and van der Walle, 2006). Similarly, 
the emulsion of smaller particle size can be prepared with water: oil ratio of 1:30 as compared to ratio of 
1:10 (water: oil), however beyond water: oil ratio of 1:20 a decrease in encapsulation efficiency has also 
been observed, thus water: oil ratio in between 1:10 and 1: 20 are frequently used (Hsu et al., 1999).
For encapsulation of nucleic acid, both homogenization and sonication process can be used, 
which results in almost same % encapsulation efficiency. Though, homogenization is the most commonly 
used technique. In case of sonication technique, there are concerns regarding scale up of process to 
produce large batches and stability of larger biomolecules (Hsu et al., 1999). The particle size decreases 
with an increase in homogenization speed (Díez and Tros de Ilarduya, 2006). However, this is not ideal 
choice to decrease the particle size, because vigorous homogenization in second step of emulsification 
can disrupt the primary emulsion droplet and consequently, leakage of nucleic acid into the outer aqueous 
phase may occur (Jorgensen and Nielson, 2009). Encapsulation efficiency of nucleic acid can be further 
enhanced by addition calcium phosphate to inner aqueous phase of double emulsion. Dördelmann et al 
(Dördelmann et al., 2014) reported that, by addition of calcium phosphate to inner aqueous phase of 
double emulsion, the encapsulation efficiency of siRNA and DNA was increase by 37% and 52% 
respectively, compared to nanoparticle without calcium phosphate (Fig. 7). They obtained nucleic acid 
loaded PLGA nanoparticles with a diameter of 200 nm and zeta potential of -26 mV, prepared by a 
double emulsion solvent evaporation technique and stabilized with PVA. The addition of 
polyethyleneimine has changed the zeta potential to +30 mV, thus facilitating the cellular uptake of these 
particles. 
 
 
 
 
 
 
 
Fig. 7.  Schematic illustration of the improved loading efficiency of nucleic acids by the addition 
of calcium phosphate nanoparticles. (A) PLGA nanoparticles, (B) Calcium phosphate-PLGA 
nanoparticles (Dördelmann et al., 2014)
    
A. B. Enhanced loading of biomolecules by 
the addition of calcium phosphate
Low encapsulation efficiencies 
of hydrophilic biomolecules
Polymeric shell
Loaded bio-
molecules
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 4.2. 3. Encapsulation of miscellaneous biopharmaceuticals 
Nanoparticles encapsulating enzymes prepared via w/o or w/o/w emulsifications are quite 
susceptible to denaturation, aggregation, oxidation, cleavage, especially at the aqueous phase 
solvent interface. This obstacle has been overcome by the addition of stabilizers like carriers 
proteins (e.g. albumin), surfactants during primary emulsification or by adding molecules like 
mannitol, trehalose to the protein phase. Three model enzymes i.e. L-asparaginase, catalase and 
glucose oxidase were encapsulated in poly(3-hydroxybutyrate-co-3-hydroxyvalerate via w/o/w 
emulsification (Baran et al., 2002) The enzyme activity was increased upon usage of low 
molecular weight PHBV and adjusting second aqueous phase to isoelectric point of proteins 
enhanced the encapsulation yields of catalase and L-asparaginase. L-asparaginase was also 
encapsulated in PLG nanospheres via w/o/w emulsification by (Gasper et al., 1998). They 
investigated the influence of molecular weight of copolymer and presence of carboxyl-end 
groups in copolymer chains on the physicochemical and in vitro release characteristics of the 
nanoparticles. Particles having higher molecular weight PLG displayed larger sizes, higher 
loading and slower release rates than particles made from low molecular weight PLG. Moreover, 
nanoparticles made of PLG with free carboxyl-end groups showed high protein loading (4.86%) 
and continuous delivery of active for about 20 days. α-Chymotrypsin (proteolytic enzyme) was 
encapsulated into PLGA microparticles by w/o/w double emulsion technique (Pérez-Rodriguez 
et al., 2003). It was observed that interface induced protein aggregation and inactivation could be 
reduced by co-dissolving it with maltose and poly ethylene glycol in the primary aqueous phase. 
(Liu et al., 2005c) loaded lysozyme into PLA microparticles by combining Shirasu porous glass 
membrane (SPG) emulsification and w/o/w double emulsification techniques. They observed 
that SPG gave higher encapsulation efficiency than stirring method. In another work, lysozyme 
were loaded into PLGA microparticles via the same w/o/w double emulsion technique to find out 
the effect of emulsification of lysozyme solutions with methylene chloride on the structural 
integrity and recovery of active (van de Weert et al., 2000). Another enzyme Staphylokinase 
variant K35R (DGR) was loaded into PLGA microparticles via double emulsion technique (He 
et al., 2006). Results showed that encapsulation efficiency was enhanced from 7% to 78% upon 
coencapsulation of 2% PVA and introduction of 2.5% NaCl into the external aqueous phase of 
the w/o/w emulsion.
74
 Double emulsion technique has also been applied to encapsulation of antibodies. Poor 
stability and low efficiency are major hurdles in the formulation of engineered monoclonal 
antibodies (mAbs) for different therapeutic uses, which may be severer for application to 
encapsulation into nanoparticles. Son et al.( 2009) investigated the formulation and stabilizing 
conditions for encapsulation of mAb (3D8 scFv) into PLGA nanoparticles via double emulsion. 
It was concluded that mannitol was the most suitable stabilizer to retain stability and activity of 
3D8 scFv. Immunoglobulin G is an antibody contributing to 75% of serum immunoglobulin in 
humans and it provides protection to fetus in uterus This antibody was encapsulated into PLGA 
microparticles via s/o/w double emulsion technique (Wang et al., 2004). They investigated the 
stabilizing effects of different excipients during the period of protein atomization by spray freeze 
drying and subsequent encapsulation into the particles. They observed that double emulsion 
solvent evaporation process inactivated approximately 80% of the total IgG. More recently 
another monoclonal antibody Anti-Annexin A2 (AnxA2) was encapsulated via w/o/w emulsion 
into microparticles (Gdowski et al., 2015). Nanoparticles were monodispersed, 250 nm in size 
and had encapsulation efficiency of 18.7%. Particles exhibited sustained release and maintained 
their functionality upon release. In one study, malarial antigen SPf66 was encapsulated into 
PLGA microparticles via w/o/w emulsification (Igartua et al., 2008b). They observed the effect 
of gamma-irradiation on the biopharmaceutical properties of the particles and found out that the 
irradiation exposure did not affect the integrity of SPf66. Moreover, in vivo activity of malarial 
antigen was retained for week 27. (Wei et al., 2008) used w/o/w emulsification and premix 
membrane emulsification to encapsulate hepatitis B surface antigen. They observed that usage of 
diblock copolymer PLA-mPEG provided higher encapsulation efficiency as compared to using 
triblock copolymer PLA-PEG-PLA. Double emulsion solvent evaporation technique has been 
applied to encapsulation of other miscellaneous biopharmaceuticals as summarized in Table 5.
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 5. Theranostic applications
The development of agents for simultaneous diagnosis and treatment of various diseases 
has gone through extensive investigations in recent years for biomedical applications. These 
multifunctional theranostic agents allow for feedback mechanism to establish the localization of 
drug, release of drug, disease phase and efficacy of the treatment (Ahsan et al., 2013; Eissa, 
2014; McCarthy, 2010). At present most of the researches in theranostic have been focused 
primarily on oncology, since, cancer is one of the most fatal diseases and currently the main 
cause of morbidity and mortality. It is assumed that a by this approach cancer can be managed 
timely with reduced cost (Ahmed et al., 2012a). Though, double emulsion technique has been 
frequently used for encapsulation of proteins, peptides hydrophilic and hydrophobic drugs, 
however limited work has been done in encapsulation of diagnostic agent and therapeutic agent 
simultaneously via double emulsification process, to the best of our knowledge. Some of the 
published studies are summarized here. 
Theranostic particles fabricated from different polymers have been used for better 
diagnosis and improved drug delivery, by several groups of researchers such as Yang et al (Yang 
et al., 2010) fabricated polymer wormlike vesicles loaded with loaded with superparamagnetic 
iron oxide (SPIO) nanoparticles (as MRI contrast agent) and anticancer drug doxorubicin (DOX) 
for targeted cancer therapy and MR imaging. The calculated SPIO nanoparticles (NPs) loading 
content in the vesicles was about 48.0 wt%, while The DOX loading level for these vesicles was 
about 9.0 wt%. This type of nanocarriers has the advantage that the SPIO and DOX loading 
amount can be easily changed by adjusting various process parameter during preparation and by 
changing the chemical structure of the triblock copolymers. This theranostic vesicle nanocarrier 
system was established to be very efficient, which can provide controlled and targeted drug 
delivery to the tumor as well as it can be used as an efficient MRI contrast agent, thus providing 
targeted cancer therapy and diagnosis simultaneously. Similarly,  Park et al (Park et al., 2012) 
incorporated dexamethasone in PLGA  nanoparticles and drug-loaded particles were then 
complexed with (PEI)/siRNA. Co-delivery approach of siRNA and dexamethasone was used in 
the treatment of rheumatoid arthritis. Almost over 50% of dexamethasone was loaded onto 
PLGA NPs. And, Ngaboni et al (Ngaboni Okassa et al., 2005) prepared biodegradable sub-
micron PLGA  particles by double emulsion technique,  loaded with magnetite/maghemite 
nanoparticles (Mag NPs) for intravenous drug targeting. Mag NPs were incorporated in the inner 
77
 aqueous phase and the final particle size was found to be 268-327 nm with the magnetite 
entrapment efficiency up to 60%. Several biomolecules have been also encapsulated via double 
emulsification for theranostic applications such as Ibraheem et al (Ibraheem et al., 2014b) 
entrapped human albumin protein into biodegrable polymer (PCL) along with fluorescence 
active molecule i.e. FITC-BSA (albumin-fluorescein isothiocyanate labeled bovine serum 
albumin). They incorporated human albumin into inner aqueous phase and emulsified in DCM 
solution containing polycaprolactone polymer using ultra-turrax hominization. The encapsulation 
efficiency of albumin was sufficiently high (up to 95%) and albumin-loaded particle was about 
340 nm. And the confocal microscopy revelled that all the loaded molecules were evenly 
distributed in the polycaprolactone matrix. 
Another study performed by Ahmed et al (Ahmed et al., 2012b) demonstrates the 
effective loading of iron oxide and a hydrophilic model drug (stilbene) into polymeric submicron 
particles for in vivo theranostics. They incorporated the hydrophilic model drug i.e stilbene in the 
inner aqueous phase (W1) of double emulsion and homogenized with polycaprolactone dissolved 
in DCM (oil phase). Subsequently the primary emulsion was dispersed in 0.5 % PVA solution 
(outer aqueous phase). Additionally, organic iron oxide nanoparticles were incorporated in oil 
phase to be used as MRI contrast agent for imaging. The results showed that iron oxide particles 
were proper encapsulated by biodegradable polymeric shell of polycaprolactone and the average 
size of loaded particles were about 300-400 nm.  Such hybrid particles owning the dual 
properties of diagnosis and therapy can be used for co-delivery of multimodal diagnostic agents 
and a variety of drugs in treatment of fatal disease such as cancer. Some examples of theranostic 
particle encapsulated via double emulsion process are listed in Table 6.  
The double emulsion technique has also been used for particle preparation with dual 
targeting ability (magnetic and molecular targeting) and co-delivery of hydrophilic and 
hydrophobic drugs simultaneously. Chiang et al (Chiang et al., 2014b) encapsulated hydrophilic 
doxorubicin (DOX) and hydrophobic paclitaxel (PTX) in nanoparticles along with 
superparamagnetic iron oxide (SPIO), and these particles were further conjugated with 
trastuzumab (monoclonal antibody) in order to specifically target the HER-2 positive cancer 
cells. DOX was added into the inner hydrophilic phase I (2 wt% PVA solution) while PTX was 
added to the hydrophobic phase II (chloroform containing 5 mg SPIO) and sonicated to form the 
primary emulsion (W/O). The primary emulsion homogenized using sonication with 
78
 hydrophobic phase III to form a double emulsion (W/O/W). Afterward, organic solvent was 
removed and particles were collected by centrifugation at 9000 rpm and redispersed in DI-water. 
The average particles were found to be 174 nm, while the encapsulation efficiency of PTX and 
DOX in PTX-DOX-nanoparticles were 91% and 72% respectively. They reported that HER-2 
positive antigens showed excellent binding ability toward the trastuzumab-conjugated 
nanoparticles, thus, demonstrating the targeting ability of these nanoparticles. When the 
magnetic field was applied on the tumor site, there was an increase in amount of particles 
accumulation. By using magnetic targeting, about 25.8% of PTX and 20% of DOX from the 
initial dose were accumulated in the tumor for trastuzumab-PTX-DOX-nanoparticles, which was 
2.47-fold higher compared to the particle without trastuzumab conjugation. Drug delivery using 
dual targeting may provide a more specific accumulation of drug-loaded particles at the desired 
tumor site, which can contribute to lower drug doses and thus reduce the side effects of cancer 
therapy. Shen et al  (Shen et al., 2013) prepared PLGA nanoparticles by using double emulsion 
technique. Two hydrophilic drugs, doxorubicin and verapamil (VER) were initially combined 
with chitosan shell coated on magnetic nanoparticles (MNPs), which were then incorporated into 
PLGA nanoparticles to be used for cancer therapy through dual-drug delivery system (DDDS). 
Additionally, a tumor-targeting ligand was also conjugated onto the end carboxyl groups on the 
PLGA-NPs. From morphological observations, drug loaded NPs were found to be spherical and 
with a narrow range of distribution of the particle sizes (about 130-140 nm). While, the 
entrapment efficiencies of DOX and VER were about 74.8 and 53.2 wt % respectively. In vitro 
drug release behaviors were evaluated under dialysis condition at 37 °C in a simulative normal 
body fluid (50 mM PBS, pH 7.4) and an acidic environment (50 mM PBS, pH 5.3). The 
cumulative release of DOX and VER at 37 °C was 29.0 and 41.3% respectively at pH 5.3; and 
25.0 and 34.5% respectively at pH 7.4. It was demonstrated that the intelligent DDDS could 
significantly inhibit both, the growth of tumor as well as DOX-induced cardiotoxicity in mice, 
and potentially offer an approach for safe cancer therapy. 
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 6. Conclusion
Double emulsions have many potential applications. In biomedical field, it can be used in 
drug delivery systems for encapsulation of both hydrophobic as well as hydrophilic active 
medicaments, cosmetics, foods, imaging agents and other high value products. In modern drug 
delivery system, it is a challenge to administered hydrophilic biomolecules such as nucleic acids 
and proteins. Because of their water solubility, they tend to diffuse into continuous aqueous 
phase during emulsification process. However, the double emulsion technique has been 
extensively used for the encapsulation highly water soluble compounds including protein and 
peptides. Encapsulation of these compounds prevents its degradation, control the rate and extent 
of release and enhances the loading efficiency. Nanoparticles made by double emulsion solvent 
evaporation method are excellent carriers for delivery of hydrophilic molecules such as proteins, 
peptides and variety of pharmaceutical and biopharmaceutical compounds. It offers stability and 
controlled release of encapsulated molecules. Beside several advantages, double emulsion 
process has a drawback of shear force used for homogenization of inner aqueous phase 
containing biomolecules in the organic phase. Which can damage the integrity of biomolecules, 
thus leads to loss of its biological activity. Moreover, the organic solvent can adversely affect the 
structure of biomolecules during homogenization. This damage can be minimized by 
condensation of biomolecules with cationic polymers, in order to reduce its size and preserve its 
biological activity. Consequently, the research works reported in this review give information 
about different polymers, stabilizers and solvents that can be used in this technique, the effects of 
process parameters and the application of this technique in encapsulation of various 
pharmaceutical and biopharmaceuticals. 
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General summary 
Different Polymer-based encapsulation techniques have been widely studied by different 
research groups, including: nanoprecipitation method, emulsion diffusion method, double 
emulsion evaporation method, emulsion coacervation method and layer by layer assembly 
method. In this work, we studied the effects of various parameters on the particle’s properties 
including, particle size, zeta potential and morphology, prepared by emulsion solvent evaporation 
techniques (DESE). Particles were prepared by DESE process in two steps: in first step, inner 
aqueous phase (W1) was homogenized with organic phase (O) containing polymer, to form first 
emulsion.  This  was  followed  by  second  step,  in  which,  first  emulsion  was homogenized 
with outer aqueous phase using high shear ultra-turrax homogenizer for specific time and speed 
to achieve double emulsion (W1/O/W2). Subsequent evaporation of organic solvent from 
dispersed phase has led to particulate suspension at the end. Polycaprolactone (polymer)  
dissolved  in  dichloromethane  (solvent)  was  used  as  organic  phase  (O),  while polyvinyl 
alcohol solution was used as outer aqueous phase (W2). 
As a general tendency, zeta potential of all prepared particles was found to be constant at 
different pH (3, 5, 7, 9 and 11) for all samples, which means that changing of PCL particles 
preparation conditions have no significant effect on the zeta potential. No change in zeta potential 
can be attributed to non-charged character of polycaprolactone particle as already reported in 
literature. The effects of different parameters on particle size was studied and found that: stirring 
speed of homogenizer has significant effect on the particle size in the second step of 
emulsification process and almost small size particles were obtained at high stirring speed; while 
in the first step, there was insignificant effect of stirring speed. 
Similarly, the effect of stirring duration (time) on particle’s size was investigated, and 
results showed that with an increase in stirring time there is significant decrease in particle size 
during  the  second  step;  however  its  effect  was  insignificant  during  the  first  step  of 
emulsification. It was found that the increase in polymer amount leads to large size particles, and 
with increase in outer aqueous phase volume a slight decrease in particles size was reported. The 
decrease in PVA concentration below 0.2% leads to large particle formation, while above 0.2% 
PVA concentration it showed no significant   effect on particle’s size. From SEM images 
observation, it was found that the surface of obtained microparticles can be assumed to be 
spherical with smooth surface, having narrow size distribution. Compare to the results from 
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Laser Diffraction  Particle  Size  Analyses (LS-13  320), the  particles  measured  with  SEM 
were slightly smaller in size this may be due to contraction  induced by drying during evaporation  
of solvent. 
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a b  s  t  r  a c t
Preparation  of  polycaprolactone  (PCL) based microparticles  by  double emulsion  solvent  diffusion like
process  was  studied  in  this  work.  The double  emulsion  was  prepared  in  two  steps. In ﬁrst step, the  inner
aqueous  phase  (W1) was  added to dichloromethane  (DCM)  solution  containing  PCL  and  homogenized  to
form  primary  emulsion  (W1/O). In the  second  step, the primary  emulsion  (W1/O)  was  emulsiﬁed  with  the
outer  aqueous  phase  (W2) containing  polyvinyl  alcohol  (PVA)  as  stabilizer using  ultra-turrax  at a speciﬁc
speed  and  time in  order  to  achieve the  double emulsion  (W1/O/W2).  Effects  of  various parameters  such
as  stirring  time and speed,  polymer  amount  and the volume  fraction  of  each  phase  on  hydrodynamic
particle  size,  size  distribution  and  zeta potential were  investigated.
As a general  tendency,  zeta potential  of  all prepared  particles was  found  to be constant irrespective  of
investigated  parameter.  Whereas, the  increase  in  polymer  amount leads  to large particles  size  and  lowest
sizes  were  obtained when high  stirring  speed was  used  during  the second emulsiﬁcation  step.
© 2014 Published by Elsevier B.V.
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1.  Introduction
The key point for pharmaceutical researches is to fabricate phar-
maceutical drug delivery system that enhance drug efﬁciency and
diminish the undesirable effects [1,2]. Encapsulation technique is
one  of  the techniques, which are used effectively for achieving
this aim. It can be identiﬁed as the technique by  which the active
material is walled or  coated by a  supported material, that shiel-
ding it  from the external environment [3–5]. It has found many
0927-7757/$ – see front matter ©  2014 Published by Elsevier B.V.
http://dx.doi.org/10.1016/j.colsurfa.2014.01.012
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applications in different ﬁelds like pharmaceuticals [6,7], cosmet-
ics [8,9], foods [10], diagnoses [11] and printing industries [12]. For
instance, in pharmaceutical ﬁeld, drug encapsulation can  protect
the active ingredient against harsh biological environment; mask
the unpleasant taste and smell of the drug. Additionally, it can be
used in drug delivery system for targeting the drug to speciﬁc site
and to control the drug release [13,14].
Encapsulation technique, based on the method of preparation,
may lead to the formation of spheres or capsules [15]. Generally,
spheres are more stable than capsules. As a result, the drug
liberation from the spheres is slower; therefore, spheres can be
employed when a prolonged drug release is needed [16]. Encap-
sulation can be achieved by using various strategies [17]. Among
these strategies, biopolymer-based encapsulation techniques are
the  most appropriate in pharmaceutical domain [18–20], due to
the  biodegradability and biocompatibility of polymers which is
suitable for in vivo applications [21]. Polymer-based encapsulation
techniques have been well studied and reviewed by various
researcher teams [22–24], including: nanoprecipitation method,
emulsion diffusion method, double emulsiﬁcation method,
emulsion–coacervation method, polymer-coating method, and
layer-by-layer (LBL) assembly method.
Here we studied particles preparation by double emulsiﬁca-
tion method (multiple emulsion method); as this technique can
be used to encapsulate both hydrophilic and lipophilic substances
[25]. In addition, it is suitable for water-soluble fragile drug mate-
rials which are very sensitive to the high temperatures, such as
nucleic acids and protein [26–28].
Multiple emulsions were described for the ﬁrst time in 1925
by Seifriz [29], it can be identiﬁed as complex [30] polydispersed
systems, in which the dispersed phase is itself an emulsion, that
has inner phase of the same nature of the double emulsion [32].
In double emulsion two types of emulsion (water in oil and oil
in water) are found simultaneously [33] using two types of sur-
factants (lipophilic and hydrophilic) for stabilizing them. Garti has
identiﬁed these systems as “emulsions of emulsions” [34]. The pres-
ence of two types of emulsion simultaneously in one system, gives
it  the properties of the two  emulsions. The multiple emulsions may
be  classiﬁed into two types: water in oil in water (W/O/W) and oil
in  water in oil (O/W/O) [35], the ﬁrst type (W/O/W) is frequently
employed for pharmaceutical purposes [36]. The  composition of
double emulsions and their properties make them promising sys-
tems that have potential applications in various ﬁelds for example,
in pharmaceutical [37], in food industry and in cosmetics [38]. In
spite of all these important properties, the applications of multiple
emulsions are still limited because of their inherent thermody-
namic instability. In recent years, great efforts have been made to
improve the multiple emulsions properties, especially, increasing
the emulsion stability, decreasing and homogenizing the emulsion
droplets size. Many factors can affect the double emulsion sta-
bility such as, method of preparation, type of oil phase, type and
concentration of emulsiﬁers and so on [39].
The aim of the present work is to study for the ﬁrst time the
inﬂuence of various parameters on colloidal properties (i.e. parti-
cles size, zeta potential, size distribution and  morphology) of the
ﬁnal particles prepared by double emulsion solvent diffusion like
process like. The parameters investigated were; polymer content,
concentration of stabilizer (PVA), inner and outer aqueous phase
volumes,  time and speed of stirring in 1st and 2nd steps of emulsi-
ﬁcation process.
2.  Materials and methods
2.1.  Materials
Polycaprolactone (PCL) (Mw  = 14,000 g/mol), polyvinyl alcohol
(PVA) (Mowiol® 4-88, Mw = 31,000 g/mol), and dichloromethane
(DCM) were obtained from Sigma–Aldrich, Germany, distilled
water. Ultra-turrax (T-25 basic IKA-WERK), Laser Diffraction Parti-
cle Size Analyzer LS 13 320 (Beckman Coulter, USA). Field Emission
Scanning Electron Microscope (S-800 Hitachi, Japan). Zetasizer
(Nano-ZS, Malvern, UK). Analytical balance (Acculab ALC-110.4)
was supplied by Sartorius Group, Germany.
2.2. Preparation of PVA solution
To be used as outer aqueous phase, 0.5% PVA solution was pre-
pared by adding 2.5 g of PVA in 500 ml  ﬂask and distilled water was
added to make up the volume, and then PVA was dissolved using
magnetic stirrer under heating at 60 ◦C for 40  min  to obtain a clear
PVA solution.
2.3. Preparation of particle by  double emulsion like process
The  microparticles were fabricated by double emulsion solvent
diffusion method. Two-step emulsiﬁcation process was used; the
primary emulsion (W1/O) was dispersed as small droplets in the
outer aqueous phase (W2) with the help of ultra-turrax stirrer. PVA
was used as emulsion stabilizer in the outer aqueous phase.
2.3.1.  Preparation of primary emulsion (1st step)
In  the ﬁrst step, in order to make the primary emulsion (W1/O);
3 g of  polycaprolactone (polymer) was dissolved in 12 ml of DCM
and shacked on rolling shaker until form a  clear solution. And then
1.5 ml of distilled water was added in PCL solution, this mixture was
homogenized properly using ultra-turrax (T-25 basic IKA-WERK)
at a  speciﬁc speed and for a speciﬁc time (Table 2) to have the ﬁrst
emulsion (W1/O).
2.3.2.  Preparation of double emulsion (2nd step)
In  the second step, the primary emulsion (W1/O) was added in
the outer aqueous phase (W2) containing 0.5% PVA as stabilizer.
This mixture was  homogenized by  using ultra-turrax (T-25 basic
IKA-WERK) at speciﬁc speed for speciﬁc time (Table 2), to achieve
the double emulsion (W1/O/W2).  Finally, the diffusion of organic
solvent from dispersed primary emulsion droplets to outer aque-
ous phase (W2),  resulted into the formation of solidiﬁed suspended
polycaprolactone (PCL) particles. In 2nd step we used excess of
outer aqueous phase (W2) in order to facilitate the diffusion of
organic solvent from PCL particle to outer aqueous phase. Fig. 1
represents the two  steps process for microparticles preparation by
double emulsion solvent diffusion like process.
2.4. Reference emulsion composition
The value of parameters indicated in Table 1 was  used to pre-
pared reference emulsion. A set of experiments were performed,
Table 1
Composition of reference parameters of double emulsion.
Primary emulsion’s parameters (1st step) Double emulsion’s parameters (2nd step)
Amount of PCL
(g)
Volume of inner
phase  w1 (ml)
Stirrer speed
(rpm)
Stirrer time
(min)
PVA (%, w/v) Stirrer speed
(rpm)
Stirrer  time
(min)
Volume of outer
phase  w2 (ml)
3 1.5 17,500 5  0.5% 21,500 5 150
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Table 2
Parameters (changed and ﬁxed) in different set of experiments. The “bold” values show the  parameters, which were changed in their respective recipes.
Studied parameters Primary emulsion’s parameters
(1st step)
Double  emulsion’s parameters
(2nd  step)
Average  particle
size  (m)
PCL (g) Inner phase
W1 (ml)
Stirring  time
(min)
Stirring  speed
(rpm)
PVA  (%) Outer phase
W2 (ml)
Stirring  time
(min)
Stirring
speed (rpm)
Stirring speed for 1st
emulsion
3  1.5 5 6500 0.5 150 5 21,500 6.5
3  1.5 5 9500 0.5 150 5 21,500 6.5
3  1.5 5 13,500 0.5 150 5 21,500 6.8
3  1.5 5 17,500 0.5 150 5 21,500 6.7
Stirring  speed for 2nd
emulsion
3  1.5 5 17,500 0.5 150 5 6500 37.9
3  1.5 5 17,500 0.5 150 5 9500 21.8
3  1.5 5 17,500 0.5 150 5 13,500 13.7
3  1.5 5 17,500 0.5 150 5 21,500 7
Stirring  time for 1st
emulsion
3  1.5 2  17,500 0.5 150 5 21,500 7.7
3  1.5 4  17,500 0.5 150 5 21,500 7
3  1.5 6  17,500 0.5 150 5 21,500 7.8
3  1.5 8  17,500 0.5 150 5 21,500 7.3
Stirring  time used for 2nd
emulsion
3  1.5 5 17,500 0.5 150 2 21,500 9.9
3  1.5 5 17,500 0.5 150 4 21,500 8.3
3  1.5 5 17,500 0.5 150 6 21,500 7.7
3  1.5 5 17,500 0.5 150 8 21,500 6.6
Concentration of stabilizer
(PVA)
3  1.5 5 17,500 0.05 150 5 21,500 12.7
3  1.5 5 17,500 0.1 150 5 21,500 8.65
3  1.5 5 17,500 0.2 150 5 21,500 8.5
3  1.5 5 17,500 0.5 150 5 21,500 10.6
3  1.5 5 17,500 1 150 5 21,500 9.1
3  1.5 5 17,500 2 150 5 21,500 10.6
Amount  of polymer used
(PCL)
1  1.5 5 17,500 0.5 150 5 21,500 4.2
2  1.5 5 17,500 0.5 150 5 21,500 6
3  1.5 5 17,500 0.5 150 5 21,500 8.5
4  1.5 5 17,500 0.5 150 5 21,500 11.6
Volume  of inner aqueous
phase  (W1)
3 1  5 17,500 0.5 150 5 21,500 8.7
3  1.2  5 17,500 0.5 150 5 21,500 9.6
3  1.5  5 17,500 0.5 150 5 21,500 9.2
3  2  5 17,500 0.5 150 5 21,500 8.6
Volume  of outer aqueous
phase  (W2)
3 1.5 5 17,500 0.5 50 5 21,500 10.8
3  1.5 5 17,500 0.5 100 5 21,500 7.9
3  1.5 5 17,500 0.5 150 5 21,500 9.8
3  1.5 5 17,500 0.5 200 5 21,500 8.9
to study the effect of different parameters on the characteristics of
the  particles prepared via double emulsiﬁcation by changing only
one parameter at  a  time and keeping all other parameters ﬁxed.
For example, to study the parameter “polymer amount” four sam-
ples were prepared with different amount of PCL i.e. 1  g,  2 g, 3 g
and 4 g while keeping all other conditions (stirring time, stirring
speed, phase volume, etc.) constant (Table 1);  and particles size
were measured for all samples.
2.5. Particles size measurement
The  particles size and size distribution were studied using Beck-
man  Coulter LS 13 320 Laser Diffraction Particles Size Analyses. The
samples were added drop by drop into the sample cell comprising
continuous phase (deionized water), the pump speed was  adjusted
to 20% for appropriate mixing of sample. When the obscuration
reached 8–9% then sample analysis was started.
2.6. Zeta potential
Zeta  potential was measured at different pH values at 25 ◦C, for
this purpose solution of 1 mM (milli Molar) concentration of NaCl
was prepared and its pH was adjusted to different values like 3, 5,
7,  9 and 11. After that each sample’s zeta potential was measure at
these pH values with help of Zetasizer (Nano-ZS, Malvern).
2.7. SEM observation
Scanning  Electron Microscopy, SEM, was performed with a
Hitachi S800 FEG microscope at the “Centre Technologique des
Microstructures” (CT) at the University of Lyon (Villeurbanne,
France). A drop of diluted aqueous suspension of microparticles
was deposited on a ﬂat steel holder and dried at  room temperature.
The sample was  ﬁnally coated under vacuum by cathodic sputter-
ing with platinum. The samples were observed by SEM under an
accelerating voltage of 15 kV.
3. Results and discussion
The  purpose of this work was  to study the effects of different
parameters such as polymer amount, stabilizer concentration, stir-
ring time and stirring speed used, on the size of  particles prepared
by double emulsion like process. Double emulsion W1/O/W2 was
prepared by a  two-step emulsiﬁcation process using PVA as stabi-
lizer in the second step.
3.1.  Effects of different parameters on particle size and size
distribution
3.1.1.  Effect of  stirring speed
Since  the emulsion is  a  mixture of two or more immiscible liq-
uids so, in order to make it uniformly dispersed, it is necessary
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Fig. 1.  Schematic illustration of a two-step process in formation microparticles via  double emulsion solvent diffusion like process.
to provide this system with the adequate energy [40], either by
high stirring or by ultrasound system [34]. However, the agitation
used to provide the needed energy should not be very severe, espe-
cially during the second step of emulsion preparation, because it
may  rupture the droplets obtained from the ﬁrst step [34,36]. Yang
et  al. have found that the stirring speed is a  governing factor in
size determining of the particles prepared via double emulsiﬁca-
tion technique [40]. The work of Yang’s team demonstrates that,
high stirring speed produces very small size particles because of
the  dismantling of second emulsion into smaller droplets. How-
ever, the ﬁnal particles yield is  low, due to the breaking down of
the resultant microspheres [40]. In this work the necessary energy
was supplied to the system via high stirring using ultra-turrax and
the  inﬂuence of stirring speed on the ﬁnal particles size was stud-
ied in both steps of emulsiﬁcation. In ﬁrst step, the stirring speed
used to prepare the ﬁrst emulsion was changed only, while stirring
speed of second emulsion and other conditions were kept constant
(Table 2). In the second step, contrary to ﬁrst step was done, it
means that stirring speed of ﬁrst emulsion with all other parame-
ters were kept constant and only the stirring speed for preparation
Fig. 2. Effect of stirring speed in 1st step and 2nd step  of emulsiﬁcation on the mean
particle size prepared by double emulsion.
of second emulsion was  changed. The particles size obtained were
measured by using Laser Diffraction Particle Size Analyzer, the ﬁnal
particles size was in micro range as shown in Fig. 2.
It  is  obvious from Fig. 2 that the change in stirring speed
from 6500 rpm to 9500 rpm during ﬁrst emulsion preparation has
no inﬂuence on the size of ﬁnal particles. And the particles size
changed slightly when the stirring speed was  further increased
i.e. from 9500 rpm to 13,500 rpm, at  this stirring speed the resul-
tant particles size was 6.8 m.  By increasing starring speed further
to 17,500 rpm, the particle size decreased to 6.7 m. Fig. 2 shows
that, the stirring speed used to prepare the ﬁrst emulsion has no
signiﬁcant effect on the size of the resulting particles.
In  second step of double emulsion, by increasing the stirring
speed of ultra-turrax and keeping all other parameters constant,
has led to a proportional reduction in the obtained particles size as
shown in Fig. 2. Here, the size of particles was 37.6 m  at stirring
speed of 6500, and particle size gradually decreased to 21.8 m,
13.7 m  and 7.0 m  at stirring speed of 9500 rpm, 13,500 rpm and
21,500 rpm respectively. The ﬁndings of this study proved that the
stirring speed in the second step of double emulsions preparation
is a signiﬁcant factor in particle size determination, i.e. by increas-
ing the stirring speed in 2nd step of emulsion preparation, the size
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Fig. 4. (a) Effect of polymer amount on the mean particle size. (b). Average hydro-
dynamic  size versus (polymer amount)1/3.
of obtained particles decreased proportionally, Which is in accor-
dance with the results reported by Yang [40].
3.1.2. Effect of stirring time
The  time duration of providing energy is  quite important
because short time of stirring grants insufﬁcient energy to the sys-
tem, while long time of stirring may  lead to break down of the
emulsion, which in turn will lead to low entrapment efﬁciency. In
this  experiment, the stirring time of  the ﬁrst emulsion was changed
only, while keeping all other parameters of the recipe constant
(Table 2). Four recipes were prepared with different stirring time
(2  min, 4 min, 6 min  and 8  min) and size of particles achieved were
7.7 m,  7 m,  7.8 m,  7.3 m respectively (Fig. 3).  These results
demonstrated that the time duration of stirring for the ﬁrst emul-
sion (W1/O) has no signiﬁcant effect on the particle size prepared
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via multiple emulsions solvent diffusion like process as shown in
Fig. 3.
The stirring time of the second emulsion was  investigated too,
by changing the stirring time for the second emulsion and keeping
all other conditions unchanged. It was  found that the stirring time
is  an  important and inﬂuential factor in determining the ﬁnal parti-
cles size in double emulsion. Adequate agitation time is  required to
obtain small, mono-dispersed particles and to avoid aggregation of
the  formed particles. However, the stirring time must not exceed
a certain limit in order to avoid emulsion spoilage. Here, differ-
ent stirring time i.e. 2  min, 4  min, 6  min  and 8  min were used in 2nd
step emulsiﬁcation, which resulted into particulate dispersion with
mean size 9.88 m,  8.33 m,  7.7 m and 6.6 m,  respectively. Fig. 3
shows that there is a  gradual decrease in particles size as stirring
time increase, this reduction in particle size may  be due to supply
of input power for longer period of time.
3.1.3. Effect of  polymer amount
The  polymer amount may  be an important factor inﬂuencing
the particle’s characteristics like encapsulation efﬁcacy and parti-
cle size. In this work, polycaprolactone was  used as polymer and its
effects were investigated at  different amount of polymer (1, 2,  3  and
4  g) by keeping all other conditions constant. The results obtained
(Fig. 4a) implies that at  small amount (1 g) of polymer small par-
ticles were obtained (4.2 m) but as the amount of polymer was
increased further to 2 g, 3 g and 4 g, the particle size increased sig-
niﬁcantly which were 5.9 m,  8.5 m and 11.6 m,  respectively.
These results revealed that by increasing the amount of polymer,
the particle size also increases and similar results were reported by
Lamprecht et al. [41].
In  order to point out the real effect of  polymer, we deduced the
mathematic relationship between the average particle size (R) and
the polymer amount (M), which is; R = (3/4dNp)1/3 × (M)1/3 where
(d) is the density of polymer, Np is the number of particles.
0
2
4
6
8
10
12
14
16
18
20
250200150100500
Si
ze
 (μ
m
)
Outer aq ueous  phase vo lume (ml)
Fig. 7. Effect of outer aqueous phase volume (W1).
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Fig. 8. (a) Particle size distribution of sample prepared using 1  g of PCL. (b) Particle size distribution of sample prepared using 3 g of PCL. (c) Particle size distribution of
sample prepared using 4  g of PCL. (d) Particle size distribution of sample prepared using 0.5% g PVA. (e)  Particle size distribution of sample prepared using 0.05% g  PVA.
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Table 3
Zeta  potential values (in mV)  of different recipes at  different pH.
Parameters Zeta potential (mV) as a function of pH
Name pH = 3  pH = 5 pH = 7  pH = 8  pH = 10
Stirring time in 1st step of
emulsion
2 min −0.70 −2.42  −2.41  −3.21 −1.58
4 min −1.04 −2.41  −2.71  −3.38 −2.01
6 min −1.16 −2.33  −2.64  −2.83 −1.70
8 min −0.993 −2.14 −1.69  −3.01 −1.44
Stirring  time in 2nd step of
emulsion
2 min 1.72 −2.11  −0.65 −2.91 −1.81
4 min −1.22 −2.46  −2.32  −3.28 −2.02
6 min 1.96 −1.38  −0.63 −3.22 −1.33
8 min −1.18 −1.87  −2.13  −3.22 −1.62
PCL  content 1  g −1.88 −2.55 −1.65 −3.55 −1.72
2 g −0.89 −1.82 −2.44 −2.72 −2.10
3 g −1.12  −2.51  −2.37  −3.12 −2.01
4 g −0.62 −3.92  −1.83  −3.25 −1.76
PVA  (wt./v) 0.2%  0.37 −3.59  −2.85  −3.45 −2.03
0.5% −0.98 −2.12  −1.66  −2.23 −2.15
1% −0.88 −3.40 −2.33  −3.26 −1.92
2% −1.05 −2.53  −1.42  −2.83 −1.70
Stirring  speed in 1st step of
emulsion
6500 rpm −0.90 −1.85  −1.52  −1.83 −1.49
9500 rpm −0.89 −2.12  −1.28  −2.40 −0.94
13,500 rpm −1.14 −1.32 −1.59 −2.48 −1.46
17,500 rpm −0.59 −1.79  −1.19  −2.39 −1.86
Stirring  speed in 2nd step
of  emulsion
6500  rpm −1.56 −1.20 −3.14  −2.11 −1.93
9500 rpm −0.82 −1.51  −1.65  −1.35 −0.92
13,500 rpm −0.91 −1.73  −2.25  −2.00 −1.44
21,500 rpm −0.721 −2.79  −1.87  −3.19 −1.30
Inner  (W1)  aqueous phase
volume
1  ml −0.96 −3.38  −1.23  −3.95 −1.77
1.2 ml −1.66  −2.75  −2.66  −2.73 −2.25
1.5 ml −0.97 −2.52  −2.29  −3.59 −2.00
2 ml −1.11 −3.21  −1.59  −3.48 −1.73
Outer  (W2) aqueous phase
volume
50  ml −1.24 −4.67  −3.74  −4.78 −3.32
100 ml  −1.67 −4.12  −3.16  −3.90 −2.43
150 ml −1.02 −3.52  −1.56  −3.57 −2.09
200 ml 1.00  −3.88  −2.98  −3.97 −2.30
In this relationship, if  the number of particles is constant inde-
pendent of the used polymer amount, the slope that represents the
relationship between the particle size and (M)1/3 will be straight.
But in our case it  seems that the slope increases with the increas-
ing of polymer amount in the formulation, as illustrated in Fig. 4b.
Such increase in the slope exhibits that using more polymer amount
leads to increase the number of obtained particles in the forma-
tion. Such increase in the number and in the size of particles can
be attributed to the aggregation of unstable particles that can be
enhanced by increasing the solid content (polymer amount) and
also by low stabilizing efﬁciency of PVA.
3.1.4. Effects of stabilizer concentration
The addition of suitable stabilizer plays a key role in
liquid–liquid dispersion [42]. The concentration and type of stabi-
lizer affect the stability and formulation of emulsion. The stability
of emulsion is very important because during the evaporation of
solvent, the volume of emulsion can be decreases, which in turn
increase its viscosity. This may  affect the ﬁnal size of the droplet
and may  results in the coalescence and aggregation of the droplets
during solvent evaporation [43].
The stabilizer stays at  oil/water interface during solvent evap-
oration. In recent times polyvinyl alcohol (PVA) is frequently used
as an emulsion stabilizer [44] and  its concentration in the exter-
nal water phase is considered to be vital factor to inﬂuence the
size of microparticles [40]. Since PVA is a  high molecular weight
polymer, the presence of PVA in the outermost water phase (W2)
may  increase the viscosity of the dispersion phase, resulting in an
increased difﬁculty to reduce the emulsion particles to smaller size
[40,45].
In this study, six samples were prepared with different concen-
tration of PVA in the outer aqueous phase (W2),  it was found that
by increasing PVA concentration (0.05%, 0.1%, and 0.2%) has led to
marked decrease in particle size and minimum size was achieved
at 0.2% PVA which was  8.4 m (Fig. 5). By  increasing further the
PVA concentration to 0.5%, 1% and 2% the particle size were slightly
increased with some variations, which was  10.6 m, 9.1 m and
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Fig. 10. (a) SEM image of PCL particles prepared by double emulsion like method. The scale bar represents 50 m. (b) Particle size distribution diameter from Laser Diffraction
analysis.
10.6 m,  respectively. Additionally one sample was prepared with-
out PVA in outer aqueous phase (W2) but in this case no particles
were formed and the emulsion was absolutely unstable. The results
obtained (Fig. 5) showed that 0.2% PVA was more appropriate in
achieving smaller size microparticles in this method.
3.1.5.  Effect of inner aqueous phase volume
In this work, we used different volumes of internal aqueous
phase (W1) including 1 ml,  1.2 ml,  1.5 ml and 2  ml of distilled water
to determine its effects on the ﬁnal PCL particle prepared by double
emulsion. These volumes were emulsiﬁed in 25% solution of poly-
caprolactone in DCM. It was found that the volume of the internal
aqueous phase has no signiﬁcant effect on the size of the ﬁnal par-
ticle in double emulsion. By increasing the volume of inner phase
there was insigniﬁcant decrease in size of microparticles with some
variations (Fig. 6). Smallest particle size was achieved at  2 ml of
inner  aqueous phase. The smaller particle size at high volume of
inner aqueous phase may  be due to the factor that; the high poly-
mer  amount solution coagulates faster during the second emulsion
and results in tighter structure due to chain entanglement [40]. So
at  high volume ratio of inner aqueous phase (W1),  polymer may
form thin layer over water droplet and  thus a  low probability to
coagulation into large particle.
3.1.6. Effect of outer aqueous phase volume
Four samples were prepared with different volumes of outer
aqueous phase (Table 2) and its effect was  evaluated on the ﬁnal
PCL particles prepared by double emulsion. It was found that by
increasing the volume of  outer aqueous phase (W2) the size of
the microparticles decreased slightly with some variations (Fig. 7).
Larger  particles were obtained at 50 ml and smallest particles were
achieved at 100 ml volume of the outer aqueous phase in this study.
Fig. 11. (a) SEM image of PCL particles prepared by double emulsion like method. The scale bar represents 5  m.  (b) SEM image of PCL particles prepared by double emulsion
like method. The scale bar represents 10 m.
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Fig. 12. (a) SEM image of PCL microparticles prepared using 3 g of PCL. (b) SEM image of PCL microparticles prepared using 1 g of PCL.
This may  be due to decrease in the viscosity of the emulsion at  high
volume of outer phase, so  there is  efﬁcient shearing force to reduce
the particle size.
3.1.7.  Effect on particle size distribution
Particle size distribution for different recipes was investigated
using laser diffraction. Size distribution was found to be large and
ranging from 0.4 to 40 m revelling incontestably the polydisper-
sity of the prepared dispersions. But for low polymer amount (i.e.
1  g) one single size distribution peak (0.4–20 m)  was  observed
(Fig. 8a). Whereas, above 1 g of PCL tow peaks were obtained as
shown in Fig. 8b and c.
In case of PVA concentration, particle size distribution ranges
from (0.4 to 40 m) irrespective of PVA amount with the presence
of two distributions as shown in (Fig. 8d and e).
3.2. Zeta potential
Actually, the value of zeta potential reﬂects the charge of parti-
cles surfaces and this value depends on three factors, the chemical
nature of the polymer, the surfactant, and medium pH values [22].
In this study, zeta potential was  measured for all samples at
different pH i.e. pH 3, 5, 7, 9  and 11 (Table 3),  and it was  found that
there was  no signiﬁcant change in the values of  zeta potential of  all
samples (Fig. 9), which means that changing of PCL microparticles
preparation conditions such as changes in polymer concentration,
stabilizer amount, stirring time and  speed, phase volume for 1st and
2nd  emulsion have no  signiﬁcant effect on the zeta potential. In fact,
the zeta potential was found in between +1 and −4  mV which can
be considered in zero range reﬂecting the non charge character of
the particles as already reported in the literature [46]. This low zeta
potential can bi attributed to non-charge character of PCL.
Fig. 13. (a) SEM image of PCL microparticles prepared in 0.5% PVA concentration. (b) SEM image of PCL microparticles prepared in  2% PVA concentration.
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Fig. 14. (a) SEM image of PCL microparticles prepared under 4 min stirring. The scale bar represents 5 m.  (b) SEM image of PCL microparticles prepared under 6  min  stirring.
3.3. Effects of different parameters on the morphology of  the
particles
The  morphology of the PCL microparticles prepared by dou-
ble emulsion technique was observed with help of Field Emission
Scanning Electron Microscope (S-800 SEM Hitachi, Japan). Fig. 10a
shows that the shape of the obtained microparticles can be assume
to be spherical with smooth surface and unimodel size distri-
bution Fig. 11(b). Compare to the results obtained from Laser
Diffraction Particle Size Analyzer, the particles measure with SEM
were slightly smaller this may  be due to contraction induced
by drying during evaporation of solvent. SEM images (Fig. 11a)
show that some particle are observed to connected with each
other, which may  be due to surface tension of water acting on
microparticles during drying which is  in accordance to the results
observed by Wu  et  al. [47]. These images show that all the par-
ticles are rounded shape. Some particles have pores on their
surface, which may  be due to evaporation of solvent during dying
(Fig. 11b).
3.3.1. Polymer amount
The  polymer amount is  signiﬁcant factor that affects the char-
acteristic of microparticles prepared by double emulsion method
[40].
In this work, we observed two samples prepared with polymer
amount of 1  g and 3 g.  From SEM images observations it was  found
that, the particles obtained with 3 g  polymer (Fig. 12a) having
Fig. 15. (a) SEM image of PCL microparticles prepared under a stirring speed of 9500 rpm for the second emulsion. (b) SEM image of PCL microparticles prepared under a
stirring speed of 21,500 rpm for the  second emulsion. The scale bar represents 5  m.
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Fig. 16. (a) SEM image of PCL microparticles prepared with 50 ml  of outer aqueous phase. The scale bar represents 2  m. (b) SEM image of PCL microparticles prepared with
150 ml  of outer aqueous phase. The scale bar represents 10 m.
narrow size distribution and more regular shape as compare to
particles obtained from 1 g polymer amount as shown in Fig. 12b.
3.3.2. The inﬂuence of PVA concentration in the external water
phase
The  signiﬁcant inﬂuence of the concentration of PVA in the
external water phase on  the size of resultant particles is  reported
in many studies [48–50]. In this study, two samples were prepared
with PVA concentration of 0.5% and 2%  in the external water phase
and its inﬂuence on the particle morphology was  studied using
SEM. From the SEM images it  is  evident that the particles prepared
with 0.5% PVA has shown good morphology with regular rounded
shape (Fig. 13a) as compare to particles prepared with 2% PVA,
which were clumped together as show in Fig. 13b. This clumping
may  be due excessive PVA, which results in sticking of particles
during drying.
3.3.3.  The inﬂuence of time of  agitation
The inﬂuence of agitation time for both ﬁrst and second emul-
sion was studied. For 1st emulsion, particles were papered with
agitation time of 4 min  and 6 min. From the SEM images, it was
found that agitation time of ﬁrst emulsion has negligible effect on
the  size and morphology of particles.
In second emulsion the particles was prepared with the same
agitation time i.e. 4 min  and 6  min. When the samples of second
emulsion were observed with SEM, it was found that the parti-
cles papered with 6 min  agitation time has regular morphology
(Fig. 14b) on the other hand the particles with 4 min  agitation
time have not well encapsulated the inner water phase and some
Fig. 17. (a) SEM image of PCL microparticles prepared using 1000 l inner aqueous phase volume. The scale bar represents 10 m. (b) SEM image of PCL microparticles
prepared using 1500 l  inner aqueous phase volume. The scale bar represents 50 m.
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particles have cup shape morphology as shown in Fig. 14a. The
homogeneity of particles size increased when the second emulsion
was agitated for long period of time, these results in accordance
with the results reported by Ayoub et al. [2].
3.3.4. The inﬂuence of  stirring speed
The stirring speed is  the vital parameter affecting the particle
size because it supplies the necessary energy to disperse the dis-
persed phase into continuous phase, some researchers reported
that, the second emulsion is preferred to prepare by avoiding sever
mixing because it may  destroy the ﬁrst emulsion W1/O prepared in
the  ﬁrst step [34]. From SEM images, it was found that stirring speed
of  ﬁrst emulsion has no signiﬁcant inﬂuence on the particle shape
and size. In case of second emulsion, SEM study established that the
microparticles prepared with 21,500 rpm have narrow size distri-
bution (Fig. 15b) as compare to particles prepared with 9500 rpm
(Fig. 15a).
3.3.5. Effect of outer water-phase volume
The volume of external water phase is  an important factor that
plays vital role in determining the size, shape and size distribution
of resultant particles.
From  SEM observation, it was found that the particles prepared
by using external water phase 50 ml,  some particles obtained have
cup shape morphology as shown in Fig. 16a. On the other hand the
particles obtained with 150 ml external aqueous phase has regular
rounded shape and narrow size distribution (Fig. 16b).
3.3.6.  Inﬂuence of inner water phase (W1)  volume
The  effect of this parameter was studied by comparing the SEM
photographs of two samples, in ﬁrst one the internal aqueous phase
was1000 l and in the second it was 1500 l.
From the SEM images observation, it was found that the particle
obtained with 1000 l  internal aqueous phase have cracks on their
surfaces with spherical shape Fig. 17a, while the other particles
which are prepared by using 1500 l as internal aqueous phase
have rounded shape and good morphology.
4. Conclusion
Multiple emulsions are important systems; consisting of two
immiscible phases, this system is  thermodynamically unstable so
suitable emulsifying agent is  added in order to stabilize it.
In  this study the conditions and parameters which inﬂuenc-
ing properties especially particle size and morphology of double
emulsion were well studied. Microparticles were prepared by using
two-step emulsiﬁcation solvent diffusion process. The effect of
different parameters such as Stirring time (of 1st and 2nd step),
stirring speed (of 1st and 2nd step), polymer amount, stabilizer
concentration, phase volume of aqueous passes (inner and outer)
on the partial size was investigated.
The  main ﬁnding of this study was that:
There  was no signiﬁcant effect of stirring speed in double emul-
sion  preparation during step ﬁrst, but during step 2nd with an
increase  in stirring speed the particle size of emulsion decreased
proportionally.
The  time duration of stirring in ﬁrst step of double emulsion has
no  signiﬁcant impact on particle size while during 2nd step longer
stirring  time has led to smaller size particles.
The concentration of polycaprolactone (selected polymer for
encapsulating)  has a  signiﬁcant inﬂuence on the particles size i.e.
particles size proportionately increased when the amount of PCL
were increased. In case of stabilizer concentration it was  concluded
that at  low concentration of PVA (stabilizer) smaller size particle
can  be achieved than at higher concentration.
The relative volumes of  aqueous phases are also an important fac-
tor in double emulsion particle size evaluation; from this study it
is established, that the phase volume of inner aqueous phase (W1)
has  no signiﬁcant effect on the particle size of double emulsion
while  on the other hand volume of outer aqueous phase (W2)  has
a  prominent effect on the ﬁnal particle size.
From SEM images observation, it was found that the surface of
obtained  microparticles can be assumed to be spherical with
smooth  surface, having narrow size distribution. Compare to the
results from Laser Diffraction Particles Size Analyses, the particles
measure  with SEM were slightly smaller in size this may be due to
contraction induced by drying during evaporation of solvent.
In this work we study the effects of different parameters affect-
ing the particle size of double emulsion, further evaluation study
have to be performed in order to determine suitable amount of
active ingredient such as proteins to be loaded in the inner aque-
ous phase (W1) and also  to study the release of active medicaments
from these microparticles.
References
[1] E.V.R. Campos, N.F.S. de  Melo, E. de Paula, A.H. Rosa, L.F. Fraceto, Screening of
conditions for the preparation of poly(-caprolactone) nanocapsules contain-
ing the local anesthetic articaine, J. Colloids Sci. Biotechnol. 2  (June (2)) (2013)
106–111.
[2] M.  Ayoub, N. Ahmed, N. Kalaji, C. Charcosset, A. Magdy, H.  Fessi, A. Elaissari,
Study of the effect of formulation parameters/variables to control the  nanoen-
capsulation of hydrophilic drug via double emulsion technique, J.  Biomed.
Nanotechnol. 7 (April (2)) (2011) 255–262.
[3]  V. Nedovic, A. Kalusevic, V. Manojlovic, S. Levic, B. Bugarski, An overview
of encapsulation technologies for food applications, Proc. Food Sci. 1 (2011)
1806–1815.
[4]  Z. Fang, B. Bhandari, Encapsulation of polyphenols – a review, Trends Food Sci.
Technol. 21 (October (10)) (2010) 510–523.
[5]  R.M. Nitika Agnihotri, Microencapsulation – a novel approach in drug delivery:
a review, Indo Glob. J. Pharm. Sci. 2 (2012) 1–20.
[6]  R.  Langer, Drug delivery and targeting, Nature 392 (April (6679 Suppl.)) (1998)
5–10.
[7]  M.L. Hans, M.A. Lowman, Biodegradable nanoparticles for drug delivery and
targeting, Curr. Opin. Solid State Mater. Sci. 6 (August (4)) (2002) 319–327.
[8] M.J. Cocero, Á. Martín, F.  Mattea, S. Varona, Encapsulation and co-precipitation
processes with supercritical ﬂuids: fundamentals and applications, J. Supercrit.
Fluids 47 (January (3)) (2009) 546–555.
[9]  F.S. Poletto, R.C.R. Beck, S.S. Guterres, A.R. Pohlmann, Polymeric nanocapsules:
concepts and applications, in: R. Beck, S. Guterres, A. Pohlmann (Eds.), Nanocos-
metics and Nanomedicines, Springer, Berlin, Heidelberg, 2011, pp. 49–68.
[10] Y.P. Neo, S. Ray, J. Jin, M.  Gizdavic-Nikolaidis, M.K. Nieuwoudt, D. Liu,  S.Y. Quek,
Encapsulation of food grade antioxidant in natural biopolymer by electro-
spinning technique: a physicochemical study based on zein–gallic acid system,
Food Chem. 136 (January (2)) (2013) 1013–1021.
[11]  M.  Ahmd, K. Rashid, M. Nadeem, K. Masood, S. Ali, M. Nafees, N.  Gull, Mumtaz-
ul-Haq, N.  Ibrahim, A. Saeed, A. Qureshy, F. Aleem, H.  Naseer, S. Mehmood, S.W.
Hyder, A  simple method to  prepare aqueous dispersion of iron oxide nanopar-
ticles and their biodistribution study, J.  Colloids Sci. Biotechnol. 1 (December
(2)) (2012) 201–209.
[12] D. Palomino, C. Yamunake, P.L. Coustumer, S. Stoll, Stability of TiO2 nanoparti-
cles in  presence of fulvic acids. Importance of pH, J.  Colloids Sci. Biotechnol. 2
(March (1)) (2013) 62–69.
[13] A. Doustgani, E.V. Farahani, M.  Imani, A.H. Doulabi, Dexamethasone sodium
phosphate release from chitosan nanoparticles prepared by ionic gelation
method, J. Colloids Sci. Biotechnol. 1 (June (1)) (2012) 42–50.
[14] N.V.N. Jyothi, P.M. Prasanna, S.N.  Sakarkar, K.S. Prabha, P.S. Ramaiah, G.Y.
Srawan, Microencapsulation techniques, factors inﬂuencing encapsulation efﬁ-
ciency, J.  Microencapsul. 27 (May (3)) (2010) 187–197.
[15] R.  Arshady, Albumin microspheres and microcapsules: methodology of manu-
facturing techniques, J.  Control. Release 14 (October (2)) (1990) 111–131.
[16] R.  Herrero-Vanrell, M.F. Refojo, Biodegradable microspheres for vitreoretinal
drug delivery, Adv. Drug Deliv. Rev. 52 (October (1)) (2001) 5–16.
[17] J.  Sara, Risch, Encapsulation: overview of uses and techniques Encapsulation
and Controlled Release of Food Ingredients, vol. 590, American Chemical Soci-
ety, 1995, pp. 2–7.
[18] G.M. Barratt, Therapeutic applications of colloidal drug carriers, Pharm. Sci.
Technol. Today 3 (May (5)) (2000) 163–171.
[19]  M.V. Chaubal, Application of formulation technologies in lead candidate selec-
tion and optimization, Drug Discov. Today 9 (July (14)) (2004) 603–609.
118
D. Ibraheem et al. /  Colloids and Surfaces A: Physicochem. Eng. Aspects 445 (2014) 79– 91 91
[20] P. Legrand, G. Barratt, V.  Mosqueira, H. Fessi, J.P.  Devissaguet, Polymeric
nanocapsules as drug delivery systems, S.T.P. Pharm. Sci. 9 (1999) 411–418.
[21] M.  Li, O. Rouaud, D. Poncelet, Microencapsulation by solvent evaporation: state
of the art for process engineering approaches, Int. J.  Pharm. 363 (November
(1–2)) (2008) 26–39.
[22] C.E. Mora-Huertas, H. Fessi, A. Elaissari, Polymer-based nanocapsules for drug
delivery, Int. J.  Pharm. 385 (January (1–2)) (2010) 113–142.
[23] X. Rong, Y. Xie, X. Hao, T. Chen, Y.  Wang, Y. Liu, Applications of polymeric
nanocapsules in ﬁeld of drug delivery systems, Curr. Drug Discov. Technol. 8
(September (3)) (2011) 173–187.
[24] K.S. Soppimath, T.M. Aminabhavi, A.R. Kulkarni, W.E. Rudzinski, Biodegradable
polymeric nanoparticles as drug delivery devices, J.  Control. Release 70 (January
(1–2)) (2001) 1–20.
[25] A. Yaqoob Khan, S. Talegaonkar, Z. Iqbal, F. Jalees Ahmed, R.  Krishan Khar,
Multiple emulsions: an overview, Curr. Drug Deliv. 3  (October (4)) (2006)
429–443.
[26]  H.K. Makadia, S.J. Siegel, Poly lactic-co-glycolic acid (PLGA) as biodegrad-
able controlled drug delivery carrier, Polymers 3  (August (4))  (2011)
1377–1397.
[27]  P. Couvreur, M.J. Blanco-Prieto, F. Puisieux, B. Roques, E. Fattal, Multiple
emulsion technology for the  design of microspheres containing peptides and
oligopeptides, Adv. Drug Deliv. Rev. 28 (October (1)) (1997) 85–96.
[28] R. Alex, R. Bodmeier, Encapsulation of water-soluble drugs by a modiﬁed sol-
vent evaporation method. I. Effect of process and formulation variables on drug
entrapment, J.  Microencapsul. 7 (September (3)) (1990) 347–355.
[29] W.  Seifriz, Studies in Emulsions. III–V, 2002.
[30]  T. Schmidts, D. Dobler, A.C. Guldan, N. Paulus, F. Runkel, Multiple W/O/W
emulsions—using the  required HLB for emulsiﬁer evaluation, Colloids Surf.
Physicochem. Eng. Asp. 372  (December (1–3)) (2010) 48–54.
[32] J. Jiao, D.G. Rhodes, D.J. Burgess, Multiple emulsion stability: pressure balance
and interfacial ﬁlm  strength, J.  Colloids Interface Sci. 250  (June (2)) (2002)
444–450.
[33]  N. Akhtar, Y. Yazan, Formulation and characterization of a cosmetic multi-
ple emulsion system containing macadamia nut oil  and two  antiaging agents,
Turkish J. Pharm. Sci. (2005) 173–185.
[34] N. Garti, Double emulsions –  scope, limitations and new achievements, Colloids
Surf. Physicochem. Eng. Asp. 123–124 (May) (1997) 233–246.
[35] D.D. Vasiljevic, J.V. Parojcic, M.M.  Primorac, Rheological and droplet size anal-
ysis of W/O/W multiple emulsions containing low concentrations of polymeric
emulsiﬁers, J. Serb. Chem. Soc. March (2009) 801–816.
[36] R. Kumar, M.  Senthil Kumar, N.  Mahadevan, Multiple emulsions: a review, Int.
J. Recent Adv. Pharm. Res. (2012) 9–19.
[37]  L. Sapei, M.A. Naqvi, D. Rousseau, Stability and release properties of dou-
ble emulsions for food applications, Food Hydrocolliods 27 (June (2)) (2012)
316–323.
[38] I. Kobayashi, M.  Nakajima, S. Mukataka, Preparation characteristics of oil-
in-water emulsions using differently charged surfactants in straight-through
microchannel emulsiﬁcation, Colloids Surf. Physicochem. Eng. Asp. 229
(November (1–3)) (2003) 33–41.
[39] D. Vasiljevic, J.  Parojcic, M.  Primorac, G. Vuleta, An investigation into the char-
acteristics and drug release properties of multiple W/O/W emulsion systems
containing low concentration of lipophilic polymeric emulsiﬁer, Int. J. Pharm.
309 (February (1–2)) (2006) 171–177.
[40] Y.Y. Yang, T.S. Chung, N.P.  Ng, Morphology, drug distribution, and in vitro
release proﬁles of biodegradable polymeric microspheres containing protein
fabricated by double-emulsion solvent extraction/evaporation method, Bio-
materials 22 (February (3)) (2001) 231–241.
[41]  A. Lamprecht, N.  Ubrich, M.  Hombreiro Pérez, C. Lehr, M.  Hoffman, P.
Maincent, Biodegradable monodispersed nanoparticles prepared by pressure
homogenization–emulsiﬁcation, Int.  J. Pharm. 184 (July (1)) (1999) 97–105.
[42] L. Sánchez-Silva, J.F. Rodríguez, P. Sánchez, Inﬂuence of different suspension
stabilizers on the preparation of Rubitherm RT31 microcapsules, Colloids Surf.
Physicochem. Eng. Asp. 390 (October (1–3)) (2011) 62–66.
[43] R. Jalil, J.R.  Nixon, Biodegradable poly(lactic acid) and poly(lactide-co-glycolide)
microcapsules:  problems associated with preparative techniques and release
properties, J.  Microencapsul. 7 (September (3))  (1990) 297–325.
[44] S.C. Lee, J.T. Oh, M.H. Jang, S.I. Chung, Quantitative analysis of polyvinyl alco-
hol on the  surface of poly(d,l-lactide-co-glycolide) microparticles prepared by
solvent evaporation method: effect of particle size and PVA concentration, J.
Control. Release Off. J. Control. Release Soc. 59 (May (2))  (1999) 123–132.
[45] A.U. Khan, N.M. Ahmad, N.  Mahmood, Rheological studies on stabilised zirco-
nia aqueous suspensions, J.  Colloids Sci. Biotechnol. 1 (December (2)) (2012)
175–184.
[46]  C.E. Mora-Huertas, H. Fessi, A. Elaissari, Inﬂuence of process and formulation
parameters on the formation of submicron particles by solvent displacement
and emulsiﬁcation–diffusion methods: critical comparison, Adv. Colloids Inter-
face Sci. 163 (April (2)) (2011) 90–122.
[47] Y. Wu,  R.L. Clark, Controllable porous polymer particles generated by electro-
spraying, J.  Colloids Interface Sci. 310 (June (2)) (2007) 529–535.
[48] N. Celebi, N. Erden, A.  Türkyilmaz, The preparation and evaluation of salbuta-
mol sulphate containing poly(lactic acid-co-glycolic acid) microspheres with
factorial design-based studies, Int.  J.  Pharm. 136 (June (1–2)) (1996) 89–100.
[49] H. Jeffery, S.S. Davis, D.T. O’Hagan, The preparation and characterization of
poly(lactide-co-glycolide) microparticles. II. The entrapment of a model pro-
tein using a (water-in-oil)-in-water emulsion solvent evaporation technique,
Pharm. Res. 10 (March (3)) (1993) 362–368.
[50]  M.K. Yeh, A.G.A. Coombes, P.G. Jenkins, S.S. Davis, A  novel emulsiﬁcation-
solvent extraction technique for production of protein loaded biodegradable
microparticles for vaccine and drug delivery, J. Control. Release 33 (March (3))
(1995) 437–445.
119
III.2. Preliminary study of particles preparation via  
double emulsion using power ultrasound 
120
General summary 
Recently, polymer-based biodegradable particles got much attention in biomedical field 
due to their special properties and wide application in the drug delivery systems. Biodegradable 
particulate drug delivery has been widely studied mainly for parenteral, aerosol, oral and ocular 
applications. For the preparation of these particles, several methods have been developed but the 
most popular is emulsion solvent evaporation method and its modified version, the double 
emulsion solvent evaporation method. The main challenge of this method is the optimization of 
different process parameters that could be used for preparation of particles with appropriate size 
and size distribution. This study was performed with the aim, to investigate the effects of 
preparation conditions on the particles properties (particle size, zeta potential, morphology etc), 
prepared by double emulsion evaporation method using power ultrasound and to reduce the 
particle size compared to the previous systematic study. Two steps double emulsification method 
(W1/O/W2) was used, in the first step, distilled water was emulsified with organic phase 
(polycaprolactone dissolved in dichloromethane) via sonication to form first emulsion (W1/O), 
followed by addition of first emulsion in the outer aqueous phase (Polyvinyl alcohol solution) to 
form double emulsion. And subsequent evaporation of organic solvent via rotary evaporator from 
dispersed phase resulted in particulate suspension. Polycaprolactone was used as polymer and 
dichloromethane as organic solvent in the first step while, polyvinyl alcohol was used as 
stabilizer in the second step. 
The effects of parameters studied were included; ultrasound exposure time in the first and 
the second step of emulsification, ultrasonic amplitude, stabilizer concentration, polymer amount 
and outer aqueous phase volume. It has been demonstrated that ultrasound emulsification is an 
efficient method to obtained nanoparticles via double emulsion solvent evaporation technique. 
Sonication amplitude has a significant effect on particles size and morphology. In second step, 
smaller size particles were obtained at higher amplitude of ultrasound. It was reported that, 
modification in ultrasound exposure time has no significant impact on mean particle size in the 
first step of emulsification, while during the 2nd step an increased ultrasound exposure time has 
led to smaller size particles. In case of polymer amount, small size (235 nm) nanoparticles were 
obtained when 1 g of polycaprolactone was used as compared to 5g of PCL (748 nm). It was 
concluded that presence of PVA (stabilizer) is compulsory for NPs preparation by this process (in 
absence of stabilizer rapid phase separation were observed), and the particle size decreases by 
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increasing  PVA  concentration  from  0.05%  to 0.2%  and  beyond  this  value  there  was  no 
significant effect on mean particle size. 
Moreover, it was shown that, the particle size decreases significantly with an increase of 
outer aqueous phase volume from 50 ml to 150 ml, and beyond this value, no marked effect were 
observed. From SEM images observation, it was found that the surface of obtained nanoparticles 
can be assumed to be spherical with smooth surface, having broad size distribution but results are 
comparable with other high speed homogenizers. The change in preparation conditions have no 
effect on the zeta potential of polycaprolactone nanoparticle prepared by this technique. This may 
be due to non-charged nature of polycaprolactone. 
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Abstract Polymeric nanoparticles have attracted growing
attention because of their unique properties and extensive
application. In this study, polycaprolactone (PCL) nanopar-
ticles were prepared via double emulsion solvent
evaporation-like process using power ultrasound, and the
effects of various process parameters on particle size, zeta
potential, and morphology were investigated and opti-
mized. Nanoparticles (NPs) were prepared by two-step
emulsification process. In the first step, the inner aqueous
phase (W1) was homogenized with organic phase (PCL in
dichloromethane) to obtain primary emulsion. In the sec-
ond step, the primary emulsion was emulsified with outer
aqueous phase (W2) containing polyvinyl alcohol (PVA) as
stabilizer using power ultrasound, followed by evaporation
of solvent which resulted in a particulate suspension at the
end. Effects of various parameters like ultrasound exposure
time and amplitude, outer aqueous phase volume, PVA
concentration, and PCL content were investigated. It has
been shown that, by increasing ultrasound exposure time,
amplitude, and outer aqueous phase volume, the particle
size decreases. Additionally, particle size was also related
to amount of PCL and PVA concentration. Spherical NPs
with smooth surfaces were observed by scanning electron
microscopy (SEM).
Keywords Double emulsion process . Nanoparticles .
Colloidal properties . Parameters . Size . Ultrasound
Introduction
Recently, nanoparticulate carriers are getting more attraction
due to their potential application in targeted drug delivery
systems, [1] food technologies, and cosmetics [2–4]. There
has been extensive research in processes like double emulsion,
self-assembly, and phase separation for fabrication of colloidal
polymeric nanoparticles with unique shapes and properties
[5]. The preparation method mostly depends on the nature of
drug (hydrophilic or hydrophobic) to be encapsulated [6].
Double emulsion technique is an appropriate method often
used for encapsulation of hydrophilic molecules, in which
first, aqueous phase is dispersed in nonmiscible organic sol-
vent containing polymer to form primary emulsion (W1/O),
followed by the homogenization of primary emulsion into
outer aqueous phase containing emulsifier to get the double
emulsion using high-shear homogenizer or sonotrode. Subse-
quently, the evaporation of organic solvent from emulsion
leads to particulate suspension at the end [7]. Pharmaceutical
researchers are highly interested in fabricating a drug delivery
system that enhances the drug efficiency, bioavailability of
poorly soluble drugs and to minimize the undesirable effects
[8, 9]. Encapsulation of active moiety is one of the vital
techniques to protect the drug from the harsh environment of
the stomach and degradation. Especially for labile moiety like
proteins and DNA, it is essential to avoid their denaturation
during their transport to the site of action. In drug delivery
systems, colloidal carriers like nanoparticles are becoming
more important due to their smaller size, which enables them
to permeate through biological membranes [10–12]. The first
paper on double emulsion dates back 89 years [13]. It can be
identified as complex polydispersed systems and can be clas-
sified into two types: water-oil-water emulsion and oil-water-
oil emulsion. They are usually prepared by two-step emulsi-
fication process [14, 15]. Generally, for emulsion preparation,
we need oily phase, aqueous phase, surfactant, and
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appropriate energy. The type of the resulting emulsion is
determined primarily by type of surfactant used. In emulsions,
smaller size droplets are more stable against creaming, coa-
lescence, and flocculation [16]. Thus, droplet size plays a vital
role in emulsion stability [17, 18].
Double emulsion process is very versatile which can
be used for fabrication of various kinds of polymeric
particles including nanoparticles with hollow structures
[19]. The emulsion droplets can be used as templates for
further processing to form core-shell nanostructures, by
emulsifying the polymer-containing dispersed phase into
outer aqueous phase and then removing the organic sol-
vent via evaporation or diffusion, leaving polymeric dis-
persion [20, 21]. Several authors have prepared nanopar-
ticles by double emulsion solvent evaporation techniques
from different polymers like poly(lactic acid) [22],
polycaprolatone (PCL), and poly(D,L-lactic-co-glycolic
acid) [23, 24]. PCL is a biodegradable polymer with
low glass transition temperature and melting point, and
the polymer metabolites are eliminated from the body by
innate metabolic process [25]. Due to biodegradable,
biocompatible, and nontoxic nature of PCL, it is exten-
sively studied for control drug delivery system in several
formulations including nanoparticles, implants, nanofi-
bers, microspheres, etc. Its compatibility with wide range
of drug and its slow degradation to release drug for
extended period of time (month-years) makes it an ap-
propriate candidate for controlled drug delivery systems.
Moreover, it allows the modification of its physicochem-
ical and mechanical properties by copolymerization,
which in turn affect all other properties of PCL such
as solubility, ionic property, and degradation pattern
[26]. Poly vinyl alcohol (PVA) is one of the most
commonly used and commercially available polymer
stabilizers [27]. It is a well-known hydrophilic, biocom-
patible polymer and has good mechanical strength, low
fouling potential, and long-term temperature and pH
stability. These properties of PVA make it appropriate
stabilizer for nanoparticle preparation for medical and
pharmaceutical applications [28].
Ultrasound emulsification is an efficient method to obtain a
finely dispersed emulsion; typical results are comparable with
those of the best high-pressure homogenizers [29]. The ad-
vantages of ultrasound include lower energy consumption,
production of more homogeneous emulsion, with smaller
droplet size and more stable emulsion compared to a mechan-
ical homogenization with use of less surfactant [30, 31].
However, the mechanism of emulsification using ultrasound-
based technique is not fully known, but it is thought that
emulsification might occur by “transient” acoustic cavitation
produced by ultrasound’s horn. It was proposed that there are
two steps in acoustic emulsification: First, interfacial instabil-
ity at oil-water interface is caused by low-frequency acoustic
waves which are followed by formation of transient cavitation
bubbles in the second step [32]. Cavitation is the formation
and collapse of vapor cavities in the liquid, generated by the
mechanical vibration of sonicator probe. It is an important
phenomenon that occurs during transmission of acoustic pow-
er into liquid system. When liquid is exposed to very low
ultrasonic power and the power is gradually increased, a point
is reached at which the transmitted acoustic energy is suffi-
cient to cause cavitation in the fluid, this minimum energy
needed to form cavitation is termed as cavitation threshold.
Majority of sonochemical effects including emulsification
occurs only at power above the cavitation threshold [18, 33].
Several parameters affect the emulsification process by ultra-
sound including hydrostatic pressure, viscosity of continuous
phase [34], oil/ water ratio, surfactant concentration, position
of ultrasonic horn at oil-water interface, and ultrasonic power
and exposure time [30, 35–37].
With the progress in new emulsification techniques used
for encapsulation and their application in drug delivery sys-
tem, it is essential to understand the mechanism of emulsifi-
cation and process parameters affecting the emulsification
process. Most of the published work in emulsion field is
dealing with pure emulsions consisting of water, oil, and
emulsifier, while there has been very limited work to produce
emulsion with subsequent encapsulation of submicron parti-
cles, in which another component is involved called wall
material (biopolymer). The objective of the present work
was to investigate the most influential process parameters in
preparation of optimal NPs by double emulsion solvent evap-
oration using power ultrasound. These parameters were the
polymer content, concentration of stabilizer (PVA), outer
aqueous phase volume (W2), sonication time, and amplitude.
The influence of these parameters on the particle’s average
hydrodynamic size, zeta potential, and morphology was
studied.
Experimental section
Materials
Polycaprolactone (PCL) (Mw=14000 g/mol), polyvinyl alco-
hol (PVA) (Mowiol® 4–88, Mw=31000 g/mol), and dichlo-
romethane (CH2Cl2, Mw=84.94 g/mol) were obtained from
Sigma-Aldrich, Germany, and used as such. Water was deion-
ized using Aquadem® (Veolia Water, France). Ultrasonic
homogenizer system is “CY-500” ivymen® (500 W,
20 kHz) from SELECTA GROUP, Switzerland. Analyti-
cal balance (Acculab ALC-110.4) was supplied by Sar-
torius group, Germany. S-800 FEG Scanning Electron
Microscope was obtained from Hitachi, Japan. Zetasizer
3000 HSa and Zetasizer Nano-ZS were supplied by
Malvern, UK.
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Methods
Double emulsion solvent evaporation technique
The double emulsion solvent evaporation is a widely used
technique for preparation of nanoparticles [38]. This method
was previously used for the preparation of microparticles [39].
In this technique, the primary emulsion (W1/O) is prepared by
homogenization of inner aqueous phase (W1) with organic
phase (polymer solution). Then, the primary emulsion is
added to external aqueous phase and homogenizes to form
nanoemulsion. Nanoemulsion formation is followed by evap-
oration of organic solvent from the dispersed phase leading to
a point of insolubility and precipitation of the polymer encap-
sulating the active material. The outer aqueous phase acts
as dispersion medium. The solvent may be evaporated by
simple stirring at ambient temperature or under reduced
pressure by rotary evaporator depending upon the nature
of organic solvent.
Preparation of PVA solution in water
PVA solution (0.5%)was prepared in order to be used as outer
aqueous phase (W2), by taking 5 g of PVA in 1000-ml flask,
and sufficient amount of deionized water was added to make
up the volume. PVAwas dissolved under magnetic stirring at
60 °C for 40 min, which resulted in a clear PVA solution.
Preparation of nanoparticles
Nanoparticles were prepared by double emulsion solvent
evaporation-like process using power ultrasound. Double
emulsion was prepared by two-step emulsification process.
In the first step, in order tomake the primary emulsion (W1/
O), 3 g of PCL was dissolved in 12 ml of dichloromethane
(DCM) properly to form a clear solution (oil phase), and
then, 1.5 ml of deionized water (W1) was dispersed in
PCL solution. This mixture was homogenized properly
using ultrasonic homogenizer “CY-500” ivymen® at a
70 % amplitude for 5 min.
In the second step, the primary emulsion (W1/O) was
dispersed in the outer aqueous phase (W2) containing 0.5 %
PVA as stabilizer in 250-ml glass beaker. This mixture was
homogenized via ultrasonic homogenizers at specific ampli-
tude for specific time (Table 1), which produced double emul-
sion (W1/O/W2). The ultrasonic horn was positioned 2 mm
above the oil-water interface in the system and was kept
constant for all experiments. Afterword, the organic solvent
evaporation from dispersed droplets via rotary evaporator has
led to solidified PCL nanoparticles. These dispersed particles
were then recovered by centrifugation at 10,000 rpm for
10 min and washed three times with deionized water properly.
The ultrasonic transducer (homogenizer) used was of 500 W
power and 20-kHz frequency, consisting of titanium alloy
probe (5.6-mm diameter and 60-mm height). The above-
mentioned conditions were to prepare reference recipe, and
in all other experiments, only one parameter was changed
each time, while the rest of the parameters were kept fixed.
The double emulsion solvent evaporation process used to
prepare particles is schematically described (Fig. 1).
Reference emulsion composition
Specific values of different parameters were used to formulate
the reference emulsion as shown (Table 1). Afterward, several
sets of experiments were performed to investigate the effects
of different preparation conditions on the characteristics of the
nanoparticles prepared via double emulsification solvent
evaporation process by changing only one parameter and
keeping all other conditions constant. For example, to
study the parameter “polymer amount effect,” five sam-
ples were prepared with different amount of PCL, i.e., 1,
2, 3, 4, and 5 g while keeping all other conditions
constant as given in table (Table 1).
Hydrodynamic size measurement
After preparation, the average hydrodynamic particles
size was determined by Zetasizer HSa 3000, Malvern.
The mean particle size was the average of three indepen-
dent measurments. Each sample was prepared by adding
one drop of particulate dispersion in about 1.5 ml of
deionized water in quartz cell, and then, the cell was
placed in zetasizer for analysis. Mean particle size was
determined for each preparation.
Zeta potential
The zeta potential of different nanoparticle preparation was
determined by using Nano-ZS Malvern. Measurements were
performed at different pH values (pH 3±0.2, pH 5±0.2, pH 7
±0.2, pH 9±0.2, pH 11±0.2) using Malvern Auto-titrator
MPT-2 in aqueous dispersant (10−3 M NaCl) at 25 °C.
Particle morphology
Scanning electron microscopy (SEM) was performed with
Hitachi S800 FEG microscope at the “Centre Technologique
des Microstructures” (CTμ) at the University of Lyon (Vil-
leurbanne, France). A drop of diluted aqueous suspension of
nanoparticles was deposited on a flat steel holder and dried at
room temperature. The sample was finally coated under vac-
uum by cathodic sputtering with platinum (5 nm). The sam-
ples were observed by SEM under an accelerating voltage of
15 kV. Before deposition on steel holder, all samples of
particle were centrifuged at 1000 rpm for 10 min and washed
Colloid Polym Sci (2015) 293:861–873 863
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three times with deionized water in order to remove the excess
of PVA.
Results and discussion
Effect of different parameters on the mean particle size
obtained
The effects of different process parameters (for given conditions)
were first investigated in order to point out the relationship
between the used conditions, the colloidal stability, and the
colloidal properties of the formed dispersion, and also the rela-
tionship between different parameters (energy, time, volume,
polymer, stabilizer) and the final hydrodynamic particle size.
Effect of ultrasound exposure time
Ultrasound exposure time is vital parameter affecting ultra-
sonic emulsification process [36]. Exposure time effects were
investigated for both steps of emulsification process in prep-
aration of particles. During investigation of the ultrasonic
exposure time for the first step of emulsion, the ultrasonic
exposure time for the second was 8 min and constant, where-
as, during investigation of the ultrasonic exposure time for the
second emulsion, the exposure time for the first was constant
and equal to 5 min.
In the first step, the inner aqueous phase (W1) was emulsi-
fied with organic phase (PCL and DCM). Five samples of
particle dispersions were prepared with different ultrasonic
exposure time, i.e., 2, 4, 6, 8, and 10 min. The variation in
mean particle size as a function of exposure time (min) is
presented (Fig. 2), which showed that there was no significant
variation in mean hydrodynamic size when exposure time was
increased from 2 to 10 min during the first step of emulsifi-
cation process.
In the second step, several experiments were performed
under sonication of 2, 4, 6, 8, and 10 min using 70 % duty
cycle. It was found that, with increase in ultrasound exposure
time, the hydrodynamic particle size was decreased gradually
as shown in Fig. 2. This may be due to increasing energy
(energy input) with elongated ultrasound exposure time,
which causes more droplet fragmentation and consequently
decreases in final particle size. These results are in agreement
with the reported tendency by Jafari et al. [36]. It was observed
that for efficient homogenization, the tip of ultrasonic horn
Table 1 Reference emulsion composition used for preparation of nanoparticle via double emulsion evaporation process
Primary emulsion’s parameters (first step) Double emulsion’s parameters (second step)
Amount of
PCL (g)
Inner aqueous phase
W1 (ml)
Ultrasound’s
amplitude (%)
Sonication
time (min)
Concentration
of PVA (%)
Ultrasound’s
amplitude (%)
Sonication
time (min)
Outer aqueous phase
W2 (ml)
3 1.5 70 5 0.5 70 8 150
W1/O/W2 
emulsion
SEM image of PCL particles
PVA in 2
nd
aqueous 
phase (W2)
W1/O 
emulsion
PCL in DCM
Particles 
dispersion
2nd Step1st Step
Solvent    , 
evaporation
Aqueous 
phase(W1)
Fig. 1 Schematic illustration of
two-step double emulsion process
for preparation of nanoparticles
using ultrasonic homogenizer. a
The first step: homogenization of
water (W1) with PCL solution in
DCM. b The second step:
dispersion of first emulsion (W1/
O) in to outer aqueous phase
(W2). Subsequently, evaporation
of solvent from W1/O/W2 results
in particulate dispersion. SEM
image scale bare represents
500 nm
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should be at oil-water interface or few millimeters above it,
which supports Cucheval et al. findings [35]. With an increase
in ultrasound exposure time, a corresponding decrease in the
average particle size during the second step and no significant
influence on particle size during the first step was observed.
This could be due to fact that, in the first step, there is only
formation of unstable aqueous droplets, but no polymer par-
ticle solidification occurs; thus, the final particle size may not
be influenced by the first step sonication time. However, in the
second step, the diffusion of organic solvent from dispersed
primary emulsion droplets results in solidification of polymer
particle. As the solidified particle formation occurs during the
second step only, that is why, the second step may be consid-
ered as the size determining step.
Effect of ultrasonic amplitude (second step)
During ultrasonic emulsification, cavitations occur when am-
plitude of applied sound source reaches a certain minimum
value, called cavitation threshold [40]. If the amplitude is
below threshold value, then cavitation and emulsification
would not take place [41]. In the second step of emulsification,
several particle preparations were made using different ampli-
tude of ultrasound. Initially, 50 % amplitude was used for
emulsification of primary emulsion with outer aqueous phase,
but no emulsification occurred at this value. This may be due
to insufficient energy transmission to the system, required to
induce cavitation. Afterword, the amplitude was increased to
60, 70, 80, and 90 % in the next four recipes, which led to
emulsification process and colloidal particulate dispersion.
The average size of final particles with 60, 70, 80, and 90 %
amplitude was found to be 507, 427, 328, and 291 nm, re-
spectively, as shown (Fig. 3).
This trend showed that by increasing amplitude of ultra-
sound homogenizer, there was reduction in mean size of the
dispersion. This is probably due to high-energy dissipation in
the system at high amplitude which results in deformation and
break up of big droplets into small ones [35, 40].
Fig. 2 Hydrodynamic particle size as a function of the ultrasonic
exposure time. During the investigation of the ultrasonic exposure time
for the first emulsion, the ultrasonic exposure time for the second was
8 min and constant, whereas in investigation of the ultrasonic exposure
time for the second emulsion, the exposure time for the first was constant
and equal to 5 min
Fig. 3 Variations of mean particle size as a function of the ultrasound
amplitude (%). All parameters were kept constant except ultrasound
amplitude. Ultrasound amplitude was changed to 60, 70, 80, and 90 %
in different colloidal preparations
b
a
Fig. 4 a Effect of polymer content on the average hydrodynamic particle
size. Only polymer amount was changed in different preparations, which
was 1, 2, 3, 4, and 5 g of PCL, while all other parameters like ultrasound
exposure time, amplitude, phase volume etc., were fixed. b Average
hydrodynamic diameter of particle (nm) versus (PLC content in grams)1/3
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Effect of polymer amount
The polymer amount may be a vital factor influencing the
particle’s characteristics like drug encapsulation efficacy, par-
ticle size, size distribution, and morphology. In this study,
PCL was used as polymer in different amounts (1, 2, 3, 4,
and 5 g). Minimum size was observed (Fig. 4a) when small
amounts (1 g) of PCL were used, whereas, when polymer
amount was increased in different samples, consequently large
particle sizes were obtained. This is in agreement with results
reported by Lamprecht et al. [24]. They stated that an increase
in polymer amount leads to an increase viscosity of primary
emulsion, thus results in less efficient reduction of particle size
during the second step of emulsification process.
In order to know the real effect of polymer amount on the
final particle size and number of particles (Np), theoretical
relationship between the particle size (d) and polymer amount
(M) and the dispersion density (ρ) is expressed as follows:
d=2 ¼ 3=4πρNp
 1=3 Mð Þ1=3 ð1Þ
According to this basic relationship, if the number of
particle (Np) is constant in the investigated polymer amount
range, then the slope of hydrodynamic diameter particles
versus and (M)1/3 will be linear. But, in our case, it seems that
the slope increases with the increasing amount of polymer in
the formulation, as illustrated (Fig. 4b). This increase in the
slope shows that by increasing polymer amount, the number
of obtained particles also increases. Such increase in the
number and in the size of particles can be attributed to the
possible aggregation of unstable particles enhanced by in-
creasing the solid content (polymer amount) and also by low
stabilizing efficiency of PVA.
Table 2 Different parameters studied with their modified values used
in various experiments, and the obtained average particles sizes are
tabulated
Parameters studied Changed
value
Average particles
size (nm)
Ultrasound exposure time in the 1st
step (min)
2 388
4 371
6 379
8 381
10 344
Ultrasound exposure time in the 2nd
step (min)
2 677
4 521
6 441
8 403
10 351
Ultrasound Amplitude (%) 60 507
70 427
80 328
90 291
PCL amount (gr) 1 235
2 300
3 392
4 591
5 748
Outer aqueous phase volume (W2) 50 521
75 452
100 441
150 378
200 375
250 381
PVA concentration (%) 0.05 1456
0.1 660
0.2 392
0.5 385
1 376
2 354
3 364
Each time, only one parameter was changed, e.g., 1, 2, 3, 4, and 5 g of
PCL were used during study of “PCL amount” effects while other
parameters were kept fixed as given in Table 1
Fig. 5 Hydrodynamic particle size versus outer aqueous phase volume
(W2). Only outer aqueous phase volume was changed in different
samples (i.e., 50, 75, 100, 150, 200, and 250 ml), and all other
conditions were fixed
Fig. 6 Variations of mean particle size as a function of poly vinyl alcohol
concentration (%). The concentrations of PVA used were 0.05, 0.1, 0.2,
0.5, 1, 2, and 3 % in different preparations
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Effect of outer aqueous phase volume
Outer aqueous phase volume is an important parameter affect-
ing the particles and the dispersion properties. Six samples
with different volume of outer phase volume, i.e., 50, 75, 100,
150, 200, and 250 ml (Table 2), were prepared, and its effect
on particle’s mean size and morphology was studied. It was
observed that, when the volume of outer aqueous phase (W2)
increased from 50 to 150 ml, there was a significant decrease
in mean particle size. But, beyond 150ml (i.e., 150 to 250ml),
there was no significant variation in particle size as shown in
figure (Fig. 5). At constant PCL concentration, this increase in
particle size at lower volume of outer aqueous phase can
be attributed to increase in viscosity. The higher the
viscosity, the higher is the attractive forces between the
molecules, and so, higher threshold intensity of ultra-
sound is required for onset of cavitation [29]. In addi-
tion, by decreasing dispersant phase volume, the proba-
bility of collision among particles increases consequent-
ly; coalescence, at a constant amount of PCL amount, is
more probable.
Effects of stabilizer concentration
The addition of suitable stabilizer plays a key role in liquid-
liquid dispersion. The concentration and type of stabilizer
affect the colloidal stability of the prepared dispersion. The
colloidal stability of a given dispersion is very important
because during the evaporation of solvent, the volume of
emulsion can decrease which in turn increases its viscosity.
This may affect the final size of the droplet and may result in
the coalescence and aggregation of the droplets during solvent
evaporation (i.e., before reaching rigid-like polymer particles)
[42, 43].
In this study, seven samples were prepared with different
concentration of PVA in the outer aqueous phase (Table 2),
and average hydrodynamic particle size was measured for
each sample. It was found that initially, an increase in PVA
concentration (0.05, 0.1, and 0.2 %) has led to rapid decrease
in particle size as illustrated (Fig. 6). This result was found to
be in agreement with the results reported by Zambaux et al.
[22], although further increase in the concentration of PVA
beyond 0.2 % has no significant effect on particle size. The
Table 3 Zeta potential of
polycaprolactone particle
dispersions at different pH values
Parameters studied Zeta potential (mV) at different pH
pH=3 pH=5 pH=7 pH=9 pH=11
Ultrasound exposure time in the 1st step (8 min) −0.34 −0.57 −0.71 −1.00 −1.56
Ultrasound exposure time in the 2nd step (10 min) −0.47 −0.73 −0.75 −0.91 −0.84
Ultrasound amplitude (80 %) −0.67 −0.96 −0.97 −1.4 −1.34
PCL amount (3 gr) −0.68 −0.66 −0.84 −1.56 −1.12
Outer aqueous phase (200 W2) −0.32 −0.71 −0.74 −0.86 −0.84
PVA (1 %) −0.12 −0.59 −1.00 −1.40 −0.68
Fig. 7 Zeta potential (mV) of
prepared particles (after DCM
removal) versus pH and in 1 mM
NaCl. Zeta potential was
measured at pH 3, pH 5, pH 7,
pH 9, and pH 11
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increase in PVA concentration enhances the surface coating of
the formed dispersion and also enhances the depletion colloi-
dal stability of the formed droplets before solvent evaporation,
which leads to smaller emulsion droplets and consequently
smaller rigid particles after solvent evaporation [24]. More-
over, one sample was prepared without stabilizer (PVA) in
outer aqueous phase (W2), but in this case, no homogeneous
oil-water dispersion occurred, and rapid phase separation was
observed.
Zeta potential
The zeta potential reflects the charge on the particle surfaces,
and it depends on factors like the chemical nature of the
b
a
Fig. 8 a SEM image of PCL nanoparticles using 1 g of polycaprolactone.
b SEM image of PCL nanoparticles using 3 g of polycaprolactone
b
a
Fig. 9 a Nanoparticles prepared under 60 % ultrasound amplitude in the
second step of emulsification process. b Nanoparticles prepared under
70 % ultrasound amplitude in the second step of emulsification process
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polymer, the used stabilizer, and the pH values of the
dispersant medium (22). The zeta potential of six sam-
ples was measured at different pH values (i.e., 3, 5, 7, 9,
and 11). It was investigated in order to point out the
relationship between the used conditions and the colloi-
dal stability of the formed dispersion. In this study, the
zeta potential was measured as a function of pH (Ta-
ble 3), and it was observed that the pH has no significant
effect on zeta potential of PCL particle prepared at dif-
ferent conditions (Fig. 7). These results reveal that mod-
ification in process parameter like ultrasound exposure
time and amplitude, PVA concentration, PCL amount,
b
a
Fig. 10 a SEM image of nanoparticle prepared with 0.05% PVA in outer
aqueous phase. b SEM image of nanoparticle prepared with 0.5% PVA in
outer aqueous phase
b
a
Fig. 11 a SEM image of PCL nanoparticles with 6-min exposure time
during the first step of emulsification. b SEM image of PCL nanoparticles
with 10-min exposure time during the first step of emulsification
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and phase volume ratio has no significant effect on zeta
potential of PCL particles. The zeta potential was found
in between 0 and −2 mV, which can be considered in
zero range and consequently reflects noncharged particles
due to noncharged nature of PCL. Similar tendency has
been already reported in literature [44].
Morphology of nanoparticles
The morphology of the prepared particles was investigated via
SEM. From these images, the obtained particles were found to
be spherical in shape with smooth and homogeneous surfaces.
SEM images also showed the slight polydisperse property of
b
a
Fig. 12 a SEM image of nanoparticle prepared 4 min of sonication in the
second step of emulsification. b SEM image of nanoparticle prepared
8 min of sonication in the second step of emulsification
b
a
Fig. 13 a SEM image of nanoparticle prepared with 100-ml outer
aqueous phase (W2). b SEM image of nanoparticle prepared with 150-
ml outer aqueous phase (W2)
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the prepared particles as clearly evidenced in Fig. 9a. It is
interesting to notice the contact among particles from the SEM
images; these contacts among particles can be attributed to
PVA, which has sticky nature and is difficult to remove
completely [45].
The effects of modification in different preparation condi-
tions on particle morphology are discussed below:
Effect of PCL amount on nanoparticle morphology
The amount of PCL has a very vital influence on the nano-
particle size, number, and morphology. In this study, when 1 g
of PCL was used for preparation of particle dispersions,
consequently more homogenous and smaller particles were
observed from SEM images with comparatively narrow size
distribution (Fig. 8a); on the other hand, when the PCL
amount was increased to 3 g, then large size particles were
observed (Fig. 8b).
Effect of ultrasound amplitude
Several samples of particles were prepared with different
amplitude of ultrasound in the second step of emulsification
process. From SEM images, it was observed that the recipe
prepared with 60 % amplitude has several populations of
particles as shown in figure (Fig. 9a) with broad size distribu-
tion. On the other hand, the particles prepared with 70 %
amplitude were more uniform as illustrated (Fig. 9b) and of
smaller average particle size (Table 2). This can be attributed
to increase of shearing energy which induced high dispersion
and fragmentation and then decreases the average particle’s
size, as reported by Gaikwad et al. that when the amplitude is
high, smaller sizes were obtained [40].
Effect of PVA concentration
Initially, low PVA amount (i.e., 0.05 %) was used, and the
SEM image shows clearly distinct particles as illustrated
(Fig. 10a). While in subsequent sample, using 0.5 % PVA,
the formed particles appear to be attached to each other
(agglomeration) due to excessive PVA (0.5 %). The observed
phenomenon is due to residual PVAwhich acts as plasticizer.
PVA residues are on surface of the nanoparticles and are very
difficult to remove completely even after washing [45]
(Fig. 11).
Ultrasound exposure time (first step)
Several set of experiments were performed with different
ultrasound exposure time in the first step of nanoparticle
preparation by emulsification. From SEM images of
nanoparticles prepared at 6-min ultrasound exposure time
in the first step of emulsification (Fig. 11a) and nanoparticles
prepared at 10 min (Fig. 11b), it can be concluded that both
samples have almost same morphology and size. The particle
size was also confirmed by light scattering analysis. The
particle average size prepared at 10-min sonication was found
to be 344 nm while particles prepared with 6-min sonication
time was 379 nm.
Ultrasound exposure time (second step)
Similarly, effect of ultrasound exposure time in the second
step of emulsification process on the particle morphology was
also observed. The SEM images showed that the nanoparticles
of both samples are spherical with smooth surfaces, and the
sizes of particle prepared at 4-min sonication exposure are
obviously larger than the particles prepared at 8-min sonica-
tion time (Fig. 12a).
Outer aqueous phase (W2) volume fraction
The outer aqueous phase plays an important role in determi-
nation of size, morphology, and size distribution of nanopar-
ticles. In this part, different volume fractions of outer aqueous
phase were used during preparation of particles. It was shown
from SEM images that, in sample with 100-ml outer aqueous
phase, the particles were somewhat attached to each other and
were oval in shape (Fig. 13a). On the other hand, when 150ml
of outer aqueous phase was used, spherical particles were
observed (Fig. 13b). The high-degree particle attachment in
sample with 100-ml aqueous phase (Fig. 13a) may be due to
addition of low volume of dispersion phase (W2) in this
recipe, which may lead to high chance of collision among
particles due to high viscosity, subsequently resulting in
flocculation.
Conclusions
PCL nanoparticles were successfully prepared at different
conditions by double emulsion solvent evaporation-like pro-
cess using power ultrasound. The influence of different pro-
cess parameters on the nanoparticle characteristics like mor-
phology, zeta potential, and particle size was investigated.
From this systematic study, it has been demonstrated that
ultrasound emulsification is an efficient method to obtain
nanoparticles via double emulsion solvent evaporation tech-
nique. Typical results are comparable with those of high-speed
homogenizers like ultra-turrax. During emulsification process
by power ultrasound, sonication amplitude has a significant
effect on resultant nanoparticle size and morphology. Final
particles have been found to be related to sonication amplitude
in the second step of emulsification process. In the second
step, smaller size particles were obtained at higher amplitude
of ultrasound. It was reported that modification in ultrasound
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exposure time has no significant impact on mean particle size
in the first step of double emulsion process, while during the
second step, an increased ultrasound exposure time has led to
smaller size particles. In case of polymer amount, small size
(235 nm) nanoparticles were obtained when 1 g of PCL was
used as compared to 5 g of PCL (748 nm). It was concluded
that presence of PVA (stabilizer) is compulsory for NP prep-
aration by this process, and the particle size decreases by
increasing PVA concentration from 0.05 to 0.2 %, and beyond
this value, there was no significant effect on mean particle
size. The relative volumes of aqueous phases are also an
important factor in nanoparticle preparation process; from this
study, it was established that the particle size decreases signif-
icantly with an increase of outer aqueous phase volume phase
volume from 50 to 150 ml, and beyond this value, no marked
effect was observed. From SEM image observation, it was
found that the surface of obtained nanoparticles can be as-
sumed to be spherical with smooth surface, having broad size
distribution, but results are comparable with other pressure
homogenizers. Moreover, the change in preparation condition
has no effect on the zeta potential of PCL nanoparticle pre-
pared by this process.
After this systematic studies via power ultrasound, further
evaluation study has to be performed in order to determine
suitable amount of active ingredient such as proteins and
anticancerous molecules to be loaded in the inner aqueous
phase (W1), and also to study the release rate of active medi-
caments from these nanoparticles and its loading efficiency.
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III.3. Encapsulation of fluorescent nanoparticles in poly-
caprolactone particles to be used as contrast agent 
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General summary 
Bioimaging has become a powerful technique in biomedical research recently due to its 
unique abilities to visualize the morphological details of specific cells or tissues. Several imaging 
techniques have been used such as computed tomography, magnetic resonance imaging, positron 
emission tomography, single photon emission CT, ultrasound and optical imaging. These 
techniques   are,   generally,   complementary   rather   than   competitive.    Fluorescence-based 
techniques have been extensively used in biological imaging due to their features of high 
sensitivity, selectivity, convenience, and non-invasive approach. Fluorescence microscopy 
depends upon the inherent property of the fluorophore. When the fluorophore is excited by light 
of specific wavelength (visible light spectrum), it excites electrons from the ground state to a 
higher energy singlet state. The excited state exists for a very short time and return to ground 
state by emitting light of large wavelength. This difference in wavelength is called the Stokes 
shift. The Stokes shift is fundamental to the sensitivity of fluorescence techniques. Most of 
imaging techniques depend on contrast agent to visualize the different tissues, which augment the 
efficiency of imaging techniques by highlighting the differences between tissues. However, most 
of the currently used organic fluorescent dyes (contrast agents) have some limitations, such as: (i) 
They cannot fluoresce continuously for long periods of time for bioimaging observations because 
of their rapid photobleaching (instability). (ii) Majority of organic fluorophores have a relatively 
broad emission spectrum i.e they can overlap with the emission spectra of other fluorophores. 
(iii) They reach in low concentration at target site, which consequently affect image quality.  (iv) 
Faces problem of poor target specificity during diagnosis of diseases. 
Thus, encapsulation of fluorescent contrast agents have overcome many of the limitations 
of conventional contrast agents (organic dyes), it can offer a better fluorescent contrast agent, 
with desired chemical and optical properties, such as, in vitro and in vivo stability, surface 
modification, high photostability, high quantum yield, large stokes shift, resistance to metabolic 
disintegration and non-toxicity, and flexible processability in order to be further conjugated with 
various biomolecules and fluorophores. Moreover encapsulation of fluorescent agent with 
polycaprolactone could provide protective layer of a nontoxic and biocompatible material around 
dye molecules, reducing the penetration of oxygen molecules thus improve it photostability. The 
surface of polycaprolactone polymer can be easily modified to attaché different ligands and 
biomolecules. 
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In this study, the fluorescent polymer nanoparticles (as a model) were encapsulated by the 
modified double emulsion   (W1/O/W2)   solvent   evaporation   technique,   using   two-step   
emulsification   via sonication. A set of formulations were prepared by incorporating different 
concentrations of fluorescent nanoparticles (FluoSpheres®) in the inner aqueous phase (W1). In 
the first step, W1 was then added to polycaprolactone solution in dichloromethane (3 g in 12 ml) 
and homogenized to form primary emulsion. In the second step, the primary emulsion was 
homogenized with 0.5% polyvinyl alcohol solution (as outer aqueous phase). Subsequently, the 
organic solvent evaporation from the dispersion with the help of rotary evaporator has led to the 
formation of solidified fluorescent-loaded polycaprolactone particles. These dispersed particles 
were then recovered by centrifugation at 10000 rpm for 10 minutes and washed three times with 
deionized water properly. The prepared particles were then characterized in term of particle size, 
SEM and TEM morphology, confocal microscopy and % encapsulation efficiency. It was shown, 
that the biodegradable polymer polycaprolactone is a useful nano- and micro carrier for imaging 
agents that can be used in diagnosis of various daisies. It was observed that the presence of 
fluorescent contrast agent in formulation has no significant effect on the colloidal properties of 
the final particles.  Both, fluorescent-loaded particle and blank particles were analyzed for 
average particle size and it was found that the presence of fluorescent agent in particles did not 
affect the particle size when used in different concentrations. As the fluorescent nanoparticles 
were used in very small amount because they are highly sensitive and are effective in very minute 
concentration. Also, zeta potential of various formulations was determined at 25°C, using 
Malvern autotitrator MPT-2, and it was found to be stable at different pH values (pH 3, pH 5, pH 
7, pH 9, and pH 11), which reveals the non-charged nature of the polycaprolactone.  The particle 
morphology was observed under TEM, and the fluorescent-loaded submicron particle was seen to 
be spherical and fairly detached from each other and no impurities were observed in TEM 
images. The SEM images showed that the nanoparticles produced were in submicron size (< 400 
nm) and had spherical shape with smooth texture. The relatively smooth surface of the particle 
supported the assumption that the release of the encapsulated moiety may be caused by matrix 
erosion. The incorporation of fluorescent nanoparticles in different concentrations did not affect 
the morphology of submicron particles. The percentage loading efficiencies of the contrast agent 
were found in-between 84.4 % to 91.4 % in various formulations. The encapsulation efficiency 
was almost same for all the formulations containing various concentrations of contrast. Also, with 
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an increase in concentration of contrast agent, there was insignificant increase in   EE from 
84.4% to 91.4%. Furthermore, CLSM images showed that all particles are labeled and contrast 
agents are dispersed in polymer matrix. Although several fluorescent contrast agents have been 
encapsulated and applied biologically, still further research should be done before they can be 
widely employed as fluorescent probes in clinical trials. With further progresses in design and 
synthesis of high class multifunctional fluorescent particles, their extensive application may be 
expected in theranostics, which could include encapsulation of hydrophilic/hydrophobic or both 
drugs along with one or more fluorescent nanoparticles simultaneously. And, with the help of 
imaging technique, tracking of loaded drug, and drug distribution in target tissues would be 
possible. 
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a b s  t  r  a  c t
Fluorescent  materials  have  recently  attracted considerable  attention  due  to  their  unique properties and
high  performance  as  imaging  agent  in  biomedical  ﬁelds.  Different  imaging  agents  have  been  encapsulated
in  order  to  restrict  its delivery to a  speciﬁc area. In  this  study,  a ﬂuorescent  contrast  agent  was  encap-
sulated  for in  vitro  application  by polycaprolactone  (PCL)  polymer.  The  encapsulation  was  performed
using  modiﬁed  double  emulsion  solvent  evaporation  technique  with sonication.  Fluorescent  nanoparti-
cles  (20 nm)  were  incorporated  in  the inner aqueous  phase  of double  emulsion.  A  number  of  samples  were
fabricated  using  different concentrations  of  ﬂuorescent  contrast  agent. The contrast  agent-containing
submicron  particle  was characterized  by  a zetasizer  for  average  particle size,  SEM  and  TEM  for morphol-
ogy  observations  and  ﬂuorescence  spectrophotometer  for  encapsulation  efﬁciency. Moreover,  contrast
agent  distribution  in  the  PCL  matrix  was  determined by  confocal  microscopy.  The  incorporation  of  con-
trast  agent  in  different concentrations  did  not  affect the physicochemical properties of PCL  particles  and
the  average size  of  encapsulated  particles was  found  to  be in  the  submicron  range.
© 2015  Elsevier  B.V.  All  rights  reserved.
1. Introduction
Recently, biomedical imaging has received immense attention
due to its extensive applications in diagnosis of disease at  an
early stage [1,2], tracking of therapeutic carrier, monitoring dis-
ease changes and determining a proper end state to therapy [3].
In many cases, imaging is  performed for diagnosis of a disease
state prior to initiation of therapy. Several imaging techniques such
as,  computed X-ray tomography (CT), optical imaging, magnetic
resonance imaging (MRI), positron emission tomography (PET),
single-photon-emission computed tomography (SPECT), and ultra-
sound are being used for diagnosis of disease including cancer
and neurodegenerative diseases. These are noninvasive techniques
and allow the visualization of target tissues [4,5]. Various imaging
technologies (Magnetic resonance, optical etc) depend on con-
trast agent to visualize the organ of interest [6]. Contrast agents
could augment the efﬁciency of imaging techniques by highlight-
ing the differences between tissues [3], without contrast agent
∗ Corresponding author.
E-mail address: elaissari@lagep.univ-lyon1.fr (A.  Elaissari).
such information-rich images would be unobtainable. The con-
trast agents currently used for diagnosis faces problems of poor
target speciﬁcity, instability and low concentration at target site,
which consequently affect image quality. Thus, it is  essential to
deliver high payload of contrast agent speciﬁcally to an organ of
interest in order to obtain beneﬁcial images. Due to their spe-
ciﬁc size and shape, submicron particles offer multifunctional
capability. Polymeric particles, incorporated with contrast agents
(polymeric encapsulation of contrast agent) are emerging as a  new
class of imaging agent for detecting human diseases [7]. These
particles have shown many potential beneﬁts, such as, (i) they
restrict the delivery of imaging agent to a  small area thus reduc-
ing the systemic side effects (ii) they can deliver high payload
of imaging agent at  target site selectively (iii) they can travel
through blood vessels and protect the encapsulated agent until
delivery (iv) polymeric particles provide high surface area that
allows the attachment of appropriate targeting agent and enhance
the release properties (v) they can modify the biodistribution of
active agent in controlled manner. Moreover, polymeric materi-
als have the ability to encapsulate different contrast agents and
active molecules in a single particle enabling multifunctional par-
ticles possibilities [6–9], with a  capacity for targeted site imaging
and delivery of therapeutic agents [8]. Standard process allow
http://dx.doi.org/10.1016/j.colsurfb.2015.09.045
0927-7765/© 2015 Elsevier B.V. All  rights reserved.
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for the encapsulation of lipophilic molecules into a  multitude of
particulate materials, however their application to hydrophilic
compounds encapsulation is limited due to uncontrolled leakage
of entrapped compounds during the preparation process [10–12].
However, double emulsion technique is an appropriate method for
the  encapsulation of hydrophilic molecules as well as hydropho-
bic molecules, additionally, it allows ﬂexibility in particle size by
adjusting process parameters, the process is  independent of special
laboratory equipment, the operation costs are low and prefer-
able for low scale production [13,14]. Several polymeric materials
such as polystyrene, dextran, chitosan poly (lactic acid) and poly
(lactic-co-glycolic acid) has been used to develop multi-target and
multifunctional particle loaded with ﬂuorescent agent for optical
imaging [15]. The characteristics (size, surface charges, and struc-
tures) of these particles can be controlled by polymeric backbone
and process parameter during preparation, in order to improve
the ﬂuorescent agent entrapment, blood circulation time, target
site accumulation and target speciﬁcity of imaging particles probe
[16,17]. Polycaprolatone is a biodegradable polymer with low glass
transition temperature and melting point and the polymer metabo-
lites are eliminated from the body by innate metabolic process [18].
Due to biodegradable, biocompatible and non-toxic nature of PCL,
it  is extensively studied for control drug delivery system in sev-
eral formulations including nanoparticles, implants, nano-ﬁbers,
microspheres etc. Its compatibility with wide range of drug and
its slow degradation to release drug for extended period of time
(months–years) makes it an appropriate candidate for controlled
drug delivery systems. Moreover, PCL versatility is  due to the fact
that, it allows the modiﬁcation of its  physicochemical and mechan-
ical properties by copolymerization, which intern affect all other
properties of PCL such as solubility, ionic property and degradation
pattern [19–21]. Though, PCL has been extensive investigate in drug
delivery system [22–24], but its  applications in imaging technolo-
gies are studied too little, especially for encapsulation of contrast
agent in optical imaging techniques.
Confocal laser scanning microscopy (CLSM) can be used as
potential tool for characterization of polymeric particles. It allows
visualization of  structures not only on surface, but also inside the
particles without prior sample destruction and  can be used to visu-
alize the encapsulated compounds. CLSM has ability to acquire
in-focus images from selected depths, allowing three-dimensional
reconstructions of topologically complex objects, by assembling
several coplanar cross sections and already has been used for
evaluation of different formulations [25,26]. Conversely, SEM does
not  allow the visualization of internal structures (encapsulated
phase) of intact particle, and requires mechanical section of par-
ticle to observe the internal structures, which may  result in loss
of encapsulated phase. Moreover, CLSM enable us to evaluate
the encapsulation of ﬂuorescent contrast agent into submicron
particles as well as its  distribution in biological samples. dual
ﬂuorescence technique enable us to record images at two  individ-
ual wavelength couplets (excitation/emission), subsequently the
confocal images of ﬂuorescent particles (visualized under laser
scanning) can be superimposed on images of submicron carrier
particles (under normal observation) using the same sample plane
[27]. Hence, the main goal of this work was to develop a  poly-
meric submicron carrier for ﬂuorescent contrast agent that might
enhance stability, augment the imaging efﬁciency, and restrict
contrast agent accumulation to speciﬁc area and could be used
for delivery of imaging agent and therapeutic agent simultane-
ously. We  studied the encapsulation of contrast agents in/on to
PCL particles using double emulsion evaporation technique. Several
formulations with different concentrations of contrast agent were
characterized regarding particles size, morphology, zeta potential,
encapsulation efﬁciency etc. Average size of particles was found to
be  in submicron range with smooth surfaces, spherical shapes and
high encapsulation efﬁciency. We  also evaluated the penetration of
the  particles into excised human skin.
2. Materials and methods
2.1.  Materials
Polycaprolactone (PCL) (Mw  =  14000 g/mol), polyvinyl alcohol
(PVA) (Mowiol® 4–88, Mw = 31000 g/mol), and dichloromethane
(DCM) were obtained from Sigma–Aldrich, Germany and used
as such. Water was  deionized using (Aquadem® from Veolia
Water, France). Ultrasonic homogenizer system “CY-500” ivymen®
(500W, 20 kHz) from SELECTA GROUP, Switzerland. Analytical
balance (Acculab ALC-110.4) was  supplied by Sartorius group,
Germany. Hitachi S-800 FEG Scanning Electron Microscope from
Hitachi Japan, Zetasizer Nano-ZS (Malvern, UK), red ﬂuorescent
(580/605) labeled carboxyl-functionalized polystyrene particles
(FluoSpheres®) was  purchased from Molecular Probes® F-8786
(Oregon, USA). CM 120 Transmission electron microscope was
obtained from Philips, Netherlands. Eppendorf 5415C Centrifuge,
was obtained from Eppendorf, Germany, and Rotary Evapora-
tor (1500 W)  was supplied by Nahita. Cary Eclipse Fluorescence
Spectrophotometer (Fluorometer) was obtained from Agilent Tech-
nologies (Malaysia).
2.2.  Methods
2.2.1. Preparation of submicron particles incorporated with
contrast  agent
The  ﬂuorescent contrast agent was encapsulated by the mod-
iﬁed double emulsion (W1/O/W2) solvent evaporation process,
via two-step emulsiﬁcation technique using power ultrasound as
described by Iqbal et al. [28]. Brieﬂy, before preparing the ﬁrst
emulsion, the inner aqueous phase (W1), was  prepared by incor-
porating different concentrations of ﬂuorescent contrast agent
(FluoSpheres®) in deionized water and the volume was made up to
1.5  ml.  Similarly, oil phase was  prepared by  dissolving 3  g of poly-
caprolactone (PCL) in 12 ml of dichloromethane properly to form
a  clear solution. And PVA solution (0.5%) was  prepared to be used
as outer aqueous phase (W2), by taking 5 g of PVA in 1000 ml  ﬂask
and sufﬁcient amount of deionized water was  added to make up
the volume. PVA was dissolved under magnetic stirring at  60 ◦C for
40 min, which resulted in a  clear PVA solution.
Then,  in the ﬁrst step of emulsiﬁcation, the inner aqueous phase
(W1) was  added to PCL solution and this mixture was homoge-
nized properly to form a  primary emulsion (W1/O) using ultrasonic
homogenizer “CY-500” ivymen® at a 70% amplitude for 5 min. In
the second step, the primary emulsion (W1/O) was dispersed in
150 ml of the outer aqueous phase (W2) containing 0.5% PVA as
stabilizer in a 250 ml glass beaker. This mixture was  homogenized
by an ultrasonic probe at 70% amplitude for 8 min, to produce a dou-
ble  emulsion (W1/O/W2).  The ultrasonic horn was  positioned 2  mm
above the oil-water interface in the system. This position was kept
constant for all  the experiments. Afterward, the organic solvent
evaporation from the dispersion with the help of rotary evaporator
has led to the formation of solidiﬁed PCL particles. These dispersed
particles were then recovered by centrifugation at 10000 rpm for
10 min  and washed three times with deionized water properly. The
ultrasonic transducer (homogenizer) consisting of  titanium alloy
probe (5.6 mm diameter and 60 mm  height) used has power of
500W and frequency of 20 kHz. The above mentioned conditions
were same for all the experiments, only the concentration of ﬂuo-
rescent agent was changed in each formulation.
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2.3. Physicochemical characterization of  submicron particle
2.3.1.  Hydrodynamic size measurement
The hydrodynamic particles size (Dh) of the colloidal dispersions
was determined by dynamic light scattering using zetasizer from
Malvern Instrument at  room temperature (25 ◦C) and in 10−3 M
NaCl concentration. The mean hydrodynamic diameter is calcu-
lated by using the Stokes–Einstein’s equation:
Dh =
kT
3D
(1)
where,  k is the Boltzmann constant, T  is the absolute temperature,
 is the viscosity of the medium, and D is the diffusion coefﬁcient.
Each sample was prepared by adding one drop of submicron par-
ticles dispersion in about 1.5 ml of deionized water in quartz cell
and then the cell was placed in zetasizer for analysis. Mean particle
size was determined at  a  scattering angle of 90◦ using appropri-
ately diluted samples. For each preparation, the mean size of three
determinations was calculated.
2.3.2.  Zeta potential
Prepared  particles were also characterized with respect to elec-
tronic mobility and zeta  potential using a  zetasizer (Nano-ZS,
Malvern). Analysis was performed at  different pH values (pH 3, pH
5,  pH 7, pH 9 and pH 11) at  25 ◦C,  using Malvern autotitrator MPT-
2. All samples were appropriately diluted with 1 mM NaCl aqueous
dispersant in order to maintain constant ionic strength. For each
sample the mean value of three determinations were established.
Electrophoretic mobility is converted into zeta potential by using
Smoluchowski’s equation:
e = 4ς (2)
where,   is the dielectric constant,  is  the viscosity of the medium,
and  is the zeta potential.
2.3.3.  Determination of  encapsulation efﬁciency
The encapsulation efﬁciency refers to the amount of ﬂuores-
cent contrast agent encapsulated into the PCL polymeric particles as
compared to the total amount of ﬂuorescent material added in for-
mulations. For determination of encapsulation efﬁciency, indirect
method was used i.e by measuring the amount of ﬂuorescent agent
that was not entrapped and, thus, remained in the supernatant
layer upon centrifugation of particulate dispersion. The encapsu-
lation efﬁciency of ﬂuorescent contrast agent in PCL particles was
then calculated in triplicate using indirectly method, as follow:
Encapsulation effeciency(%)  = Totat amount FC added −  Amount of recovered in supernatents
Total amount of Fluorescent agent added
×  100 (3)
where, FC is the ﬂuorescent contrast agent. For this purpose, spe-
ciﬁc amount of particulate dispersion were centrifuged (Eppendorf
5415C; Eppendorf, Germany) at  14000 for 10 min, and the super-
natant was then analyzed for ﬂuorescent intensity by adding about
2.5 ml  sample into ﬂuorometer’s covet. The excitation and emis-
sion wavelengths used were 580 nm and 605 nm respectively. All
the  samples were measured at  PMT  detector voltage of 600 V, with
emission and excitation slits width of 5 nm for each. Before encap-
sulation efﬁciency measurement of prepared particles, a  standard
curve was generated by preparing a  series of ﬂuorescent agent
dilutions in deionized water, these dilutions were analyzed for
ﬂuorescence intensity via ﬂuorometer and, the results obtained
were used to produce the standard curve. Afterward, the amount
of ﬂuorescent contrast agent (percent encapsulation efﬁciency)
in different formulations was quantiﬁed by using this standard
curve. When the ﬂuorescence spectra of contrast agent dispersed
in water was analyzed by  ﬂuorometer, their excitation and emis-
sion maxima were obtained at  580 nm and 606 nm respectively,
which is  almost the same as mentioned on  the label of FluoSpheres®
(ex =  580, em =  605).
2.3.4.  Particles morphology
Scanning  Electron Microscopy (SEM) and transmission electron
microscopy (TEM) were performed in order to determine the shape
and surface morphology of the ﬂuorescent-containing polymeric
particles. Scanning Electron Microscopy (SEM) morphological eval-
uation was performed with Hitachi S800 FEG microscope at  the
“Centre Technologique des Microstructures” (CT) at  the Univer-
sity of Lyon (Villeurbanne, France). A drop of diluted aqueous
suspension of submicron particles was deposited on a  ﬂat steel
holder and dried at  room temperature. The sample was  ﬁnally
coated under vacuum by cathodic sputtering with platinum (5  nm).
The samples were observed by SEM under an accelerating voltage
of 15 kV. Before deposition on steel holder, all samples of particle
were centrifuged at 1000 rpm for 10 min  and  washed three times
with deionized water. While, the transmission electron microscopy
(TEM) of the ﬂuorescent agent encapsulated particles were done
by a  Philips CM 120 Transmission electron microscope (CMEABG,
Claude Bernard University Lyon 1, France) at an electron accelerat-
ing voltage of 100 kV. A drop of highly diluted sample was deposited
onto a  copper grid covered with a  200 mesh and covered with form-
var carbon membrane and dried at room temperature before TEM
analysis.
2.3.5. Confocal laser scanning microscopy
Confocal laser scanning microscopy (CLSM) is  an  optical imag-
ing technique that can be used to achieve cellular resolution in
real-time and record depth section information of tissue with cel-
lular deﬁnition. CLSM allows the inspection of  internal structures
of ﬂuorescent-containing polymeric particles without prior sample
destruction and it  can be used for localization of encapsulated com-
pounds [26,29]. Fluorescence technique enable us to record images
at  two  individual wavelength couplets, subsequently the confocal
images of ﬂuorescent nanoparticles (visualized at  a speciﬁc wave-
length) can be overlaid on images of carrier particles (visualized
at white light) obtained in the same sample plane [27]. An ideal
ﬂuorescent agent selected for CLSM might possess good quantum
efﬁciency, high selectivity for target site, high resistance to photo-
bleaching, least disturbance to the sample and minimum cross-talk
when many contrast agents are used together. When a  ﬂuorescent
agent is  excited by light of speciﬁc wavelength, it remains in excited
state for only a few nanoseconds and then relaxes into its ground
state by emitting ﬂuorescence of  longer wavelength. The intensity
of energy emitted by ﬂuorescent agent at  its optimum excitation
wavelength can be described by quantum efﬁciency value (QE)
value of the ﬂuorescent agent [30,31].
QE = Energy emitted
Energy absorbed
(4)
Several  samples were prepared by incorporating different concen-
trations of ﬂuorescent contrast agent in the inner aqueous phase
(W1) of double emulsion. Additionally, one sample was prepared
without adding contrast agent (blank sample). After preparation
of all formulations, the particulate dispersion was  visualized by
confocal laser scanning microscopy (CLSM).
Confocal microscopy was  performed at the “Centre Tech-
nologique des Microstructures” (CT) at the University of Lyon
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(Villeurbanne, France), on  the Axiovert 200 LSM 510 Meta micro-
scope (Carl Zeiss, Jena, Germany) using a  63x oil immersion
objective of 1.4 Numeric Aperture (N.A.). The ﬂuorescence emis-
sion was collected with a pinhole at  136 m, the 543 nm laser was
set up at 70% of its maximum intensity and  the emission was  col-
lected from 560 nm and above. The contrast agent (FluoSpheres®)
used was red ﬂuorescent beads/nanoparticles, maximally excited
at 580 nm and their emission wavelength was 605 nm.  These par-
ticles were supplied as suspensions (2% solids content) in water,
with average diameter of 20 nm.
2.4.  Skin penetration of  particles
Fresh human skins from surgery of healthy Caucasians were
used. The surface was cleaned with water and 100 l of PCL parti-
cles were deposited. After application for 48 h,  discs of skin, 3  mm in
diameter, were punched out, frozen and embedded in Tissue-Tek®
O.C.T. Cryostat sections (10 m) perpendicular to the skin surface
were prepared and mounted on poly-lysine coated slides. Tissue
sections were examined by CLSM.
3. Results and discussion
The  physicochemical aspect of colloidal system such as, particle
size and zeta potential, are known to inﬂuence the physical sta-
bility of colloids, release rate and their interaction with cells and
biological environment [32]. The particles were characterized on
the basis of morphology, particle size, zeta potential, contrast agent
encapsulation efﬁciency and their localization.
3.1. Particles size
The  hydrodynamic particle size of each sample was  examined.
Each sample was highly diluted before any analysis. The presented
mean particle size was at least the average of 3  independent
measurements. The size range of particles produced by W1/O/W2
protocol can be adjusted depending on  the amplitude of sonotrode
and time duration of sonication [33]. The prepared particles were
analyzed via zetasizer and, their average size was found to be in
submicron range (Table 1). The presence of ﬂuorescent agent in PCL
particles did not affect the particle size when used in small concen-
trations (F2, F3 and F4), while, at relatively higher concentration
(F6 and F7) there was a slight increase in particle size but it was
insigniﬁcant (Table 1).  This can be attributed to the constant vol-
ume  of inner aqueous phase used in the all formulations. And the
results showed that the chemical composition of the inner aqueous
phase has no signiﬁcant effects on the ﬁnal particle size.
3.2.  Zeta potential (ZP)
The  zeta potential reﬂects the strength of the colloidal particles
electrical barrier and is used as a vital parameter in evaluating the
stability of colloidal dispersions [34]. In order to point out the effect
of pH on the particles surface charge density, the zeta potential of
PCL  particles was determined as a  function of pH, with different
concentrations of  contrast agent-containing samples and a  blank
sample. It was measured at  different pH values, and from the results
obtained it has been shown that, the zeta potential of contrast agent
loaded particles varied between 0.1 and −7.4, which could be con-
sidered near to zero. These results demonstrated that there was no
considerable variation in zeta potential of different formulations as
the  pH was increased (Fig. 1),  which can be attributed to uncharged
chemical nature of PCL as already reported in literature [35,36] and
also to the screening effect of PVA. Normally, for charged parti-
cles, the use of non-charged stabilizer leads to the surface charge
Fig. 1.  Zeta potential versus pH of Contrast agent-containing (CA) submicron parti-
cles.
( ) CA free particles, (  )  CA 0.06 g/g of PCL,  (  ) CA 0.16 g/g of PCL,  (  )  CA
0.33  g/g of PCL, (  ) CA 0.50 g/g of PCL, ( )  CA 0.66 g/g of PCL, (  ) CA 1.33 g/g
of  PCL.
screening effect and shift in sleeping plan position far from par-
ticles surface, which induce decreases in the absolute of the zeta
potential.
3.3. Morphology
Scanning electronic microscopy (SEM) was  used to visualize
the morphology of contrast agent-loaded PCL particles prepared
by W1/O/W2 double emulsion evaporation technique at  70% soni-
cation amplitude. Particles were evaluated on the basis of shape,
surface texture, smoothness and presence of inter-particulate
bridging. Under SEM observations, the submicron particles pro-
duced had smooth surfaces and spherical shapes (Fig. 2) with an
average particle size in submicron range. The average particle sizes
were also conﬁrmed by light scattering analysis (Table. 1). The rela-
tively smooth surface of the particle supported the assumption that
the  release of the encapsulated moiety may  be caused by matrix
erosion [37]. Moreover, rarely a split or  broken particles were seen
within all samples. The incorporation of  contrast agent in differ-
ent concentrations did not affect the morphology of submicron
particles. SEM Images showed slight bridging between some par-
ticles, this can be attributed to sticky nature of residual stabilizer
(PVA) used in the formulations; since, it is  difﬁcult to remove PVA
absolutely even after washing [38].
Additionally, TEM was  used to observe the produced particles
formed by double emulsion method. The loading of ﬂuorescent con-
trast  agent in various concentrations into the PCL particle did not
affect the morphology of the particles as shown in Fig. 3.  Under
TEM observations, no  inorganic impurities were found in the sam-
ples and, the submicron particle appeared to be spherical and fairly
detached from each other, as the samples were highly diluted prior
to TEM observation.
3.4.  Encapsulation efﬁciency (EE)
Encapsulation of ﬂuorescent contrast agents can be of wide
interest in optical imaging, because it decreases photobleaching,
prevent dye aggregation and increases ﬂuorescence per particle
by conﬁning large no of  ﬂuorescent molecule into a  small vol-
ume  [39]. Though once the ﬂuorescent material is incorporated
into polymeric particles, then dispersion medium is  not in direct
contact with ﬂuorescent agent, therefore, medium of dispersion
does not affect the ﬂuorescence spectra [40]. The encapsulation
efﬁciency of ﬂuorescent contrast agent into PCL submicron particles
was determined by indirect method using cary eclipse ﬂuorescence
spectrophotometer. All the measurements were performed in trip-
licate.
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Table 1
Composition of various formulations for preparation of submicron particle incorporated with ﬂuorescent contrast agent, particles were prepared via  two-step double emulsion
evaporation process. Double emulsion was  homogenized by sonication at 70% amplitude for 5 min  in the  ﬁrst step, and 8 min in the second step of emulsiﬁcation. Samples
were prepared by incorporating different concentrations of contrast agent (FluoSpheres®) along with one blank sample (F1)  i.e without contrast agent. The average particle
size and encapsulation efﬁciency (%) of these formulations are also tabulated.
Run FluoSpheres®(g/g of PCL) Inner aqueous phase (ml) PCL polymer (g) PVA solution (0.5%, ml)  Particle size (nm) Encapsulation efﬁciency (%)
F 1 0 1.5 3 150 342  NAa
F 2 0.06 1.5 3 150 346  84.4
F  3 0.16 1.5 3 150 354  86
F  4 0.33 1.5 3 150 347  89.8
F  5 0.50 1.5 3 150 322  88.6
F  6 0.66 1.5 3 150 371  90.2
F  7 1.33 1.5 3 150 375  91.4
a Not applicable.
Fig. 2. SEM images of PCL particles incorporated with different concentrations of contrast agent. (A)  0.06 g/g of PCL (B) 0.66 g/g of PCL (C) 1.33  g/g of PCL (D) blank
formulation. The scale bars represent 1 m.
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Fig. 3. TEM representative images of contrast agent-containing PCL particles. Contrast agent was incorporated in  different concentrations to various samples. (a) 0.16 g/g
of  PCL and (b) 0.66 g/g of PCL. Scale bar in A  represents 0.2 m,  while in C  it represents 0.5 m.
The average encapsulation efﬁciencies of the contrast agent
were found between 84.4% and 91.4% in various formulations
(Table. 1). The percentage encapsulation efﬁciency of formulation
F2 was found to be 84.4%, which slightly increased to 86%, 89.9%,
88.6%, 90.2% and 91.4% in the other formulations i.e. F3,  F4, F5, F6
and F7 respectively (Table. 1).  These results showed that encapsu-
lation efﬁciency were almost same for various concentrations of
contrast agent incorporated in different formulations. Also, with
an increase in concentration of contrast agent, there was  slight
increase in EE from 84.4% to 91.4% but it was insigniﬁcant. The opti-
cal spectra of ﬂuorescent agents are often affected by the change in
polarity of their medium, which cause change in dipole moment of
ﬂuorescent agent and subsequently shift of  peak maxima [41]. The
background intensity was also measured; which, was  found to be
11  arbitrary units (a.u.) for blank sample, and excluded from ﬁnal
values. The high encapsulation efﬁciency may  be due to high afﬁn-
ity of hydrophilic contrast agent (CA) toward inner aqueous phase
(W1). The CA is easily disposable in W1,  and its  homogenization
with PCL solution (in DCM) results in appropriate nanodroplets for-
mation during the ﬁrst step of emulsiﬁcation. In the second step of
emulsiﬁcation, the PCL in DCM solvent rapidly solidiﬁes and encap-
sulating the CA in the inner aqueous phase and  thus, preventing the
leakage of CA from W1 to outer aqueous phase (W2). The PCL pre-
cipitation in the second step is  induced by the diffusion of organic
solvent from dispersed nanodroplets to outer aqueous phase (W2).
3.5.  Confocal laser scanning microscopy
After the encapsulation efﬁciency of contrast agent analysis
by ﬂuorescence microscopy, the localization and distribution of
contrast agent was observed with respect to PCL particles in the
system (background) with the help of CLSM. Moreover, the inﬂu-
ence of contrast agent concentration on the ﬂuorescence images
(brightness) in different samples was also visualized. The confo-
cal microscopy can be used either in ﬂuorescence mode, which
collect the light generated by a  ﬂuorescence contrast agent or in
reﬂectance mode (to observe structural and morphological infor-
mation of the background under white light) [42].
All  samples were visualized in ﬂuorescence mode (Fig. 4) and
direct observation; afterward, these images were overlaid with the
help  of Zeiss LSM confocal software. The contrast agent-loaded par-
ticles of size 300-400 nm were easily visible under CLSM when
excited at a proper wavelength (nm) of  light. Fig. 4  shows the distri-
bution of contrast agent (ex =  580, em =  605) encapsulated by PCL
particles.  From the overlaid images for the same sample (Fig. 4B3,
C3, D3), one can see that the ﬂuorescent contrast agents are only
localized at  PCL particles positions, which indicate that all parti-
cles are labeled, showing proper encapsulation of contrast agent
by polycaprolactone-based particles. Moreover, from CLSM images,
the ﬂuorescence can be observed quantitatively on  the basis of
images brightness. For example, image 4c is brighter (due to high
ﬂuorescence) than image 4b, which conﬁrmed the high concentra-
tion of ﬂuorescent contrast agent incorporated in 4c formulation
(0.66 g/g of PCL) as compared to 4b (0.06 g/g PCL) (Fig. 4). On the
other hand the lack of ﬂuorescence emission in image 4a  (blank for-
mulation) veriﬁed the absence of contrast agent in this formulation
(blank sample).
3.6.  Skin penetration of  formulated particles
Several studies using in vitro and ex vivo models have demon-
strated that nanoparticles have the potential to penetrate across
the skin barrier or  the follicular structure [27,43].
Fig. 5 shows the penetration pattern of particles in the skin and
in the hair  follicle. The red ﬂuorescence allowed easy identiﬁcation
of particles. PLC particles remained on the surface of both stratum
corneum (Fig. 5A) and hair follicle (Fig. 5B). Therefore, under passive
diffusion conditions, no penetration of particles was found.
The  main barrier to cutaneous molecule absorption is the imper-
meability of the stratum corneum. Another important issue is the
mechanical stress applied to the skin when investigating the pene-
tration behavior. In future works, we  will evaluate the impact of the
removal of the stratum corneum and  the application of a mechanical
stimulation.
4. Conclusion
The biodegradable polymer PCL is an extremely useful nano-
and micro carrier for several imaging contrast agents that can be
used for theranostic purpose and targeting of diseased tissue. Here,
PCL submicron particles loaded with imaging contrast agent were
successfully prepared via double emulsion technique in order to
restrict its delivery to a  speciﬁc area, prevent contrast agent aggre-
gation and improve its stability, which could enhance the efﬁciency
of imaging techniques. It was observed that the presence of  ﬂuo-
rescent agent in formulation has no signiﬁcant inﬂuence on the
colloidal properties of the ﬁnal particles.
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Fig. 4. Representative CLSM images of PCL particles containing different concentrations of ﬂuorescent contrast agent (a) blank formulation (b) 0.06 g/g PCL (c)  0.66 g/g
PCL prepared by double emulsion process. All images were taken with 63x oil immersion objective of 1.4 numeric aperture in ﬂuorescence mode (left panel) along with their
corresponding direct observation images (middle panel), afterward, these images were overlaid (right panel). The scale bars represent 10 m.
Fig. 5. Representative CLSM images of skin treated for 48 h with PCL particles. Images were taken with 20x objective in ﬂuorescence mode along with their corresponding
direct observation images, afterward, these images were overlaid (A: skin; B: follicular region). The scale bars represent 100 m.
The prepared particles were analyzed for average particle size
and it was found that the presence of ﬂuorescent agent in par-
ticles did not affect the particle size when used in different
concentrations. Also, zeta potential of various formulations was
stable at different pH values.
Under  TEM observation the submicron particle appeared
to be spherical and fairly detached from each other and no
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impurities were observed in TEM images. The SEM images revealed
that nanoparticles produced were in submicron size (<400 nm)
with spherical shape and  smooth surface. The relatively smooth
surface of the particle supported the assumption that the release
of the encapsulated moiety may  be caused by matrix erosion. The
incorporation of contrast agent in different concentrations did not
affect the morphology of submicron particles. The average encap-
sulation efﬁciencies of  the contrast agent were found in-between
84.4% to 91.4% in various formulations. The encapsulation efﬁciency
was almost same for all the formulations containing various con-
centrations of contrast. Also, with an  increase in concentration of
contrast agent, there was insigniﬁcant increase in EE from 84.4%
to 91.4%. Furthermore, CLSM images showed that all particles are
labeled and contrast agents are dispersed in polymer matrix.
Though,  there has been signiﬁcant research progress in the
ﬁeld of synthesis polymeric particle and their imaging application,
but still faces some challenges to be focused like active target-
ing, burst release, toxicity, stability of contrast agent and solubility
of polymeric material. As demonstrated here contrast agent-
containing imaging particles can be prepared by double emulsion
solvent evaporation technique. Furthermore, future application
could include encapsulation of hydrophilic/hydrophobic or  both
drugs along with one or more ﬂuorescent contrast agent can be
incorporated in these particles simultaneously i.e for theranos-
tic purpose. And, with the help of  imaging technique, tracking
of loaded drug, and drug distribution in target tissues would be
possible. Moreover, there could be possibility to add molecu-
lar recognition capability to this particulate system by adding a
targeting agent to the particle scheme. This technique for encapsu-
lation of contrast agent can be extended to other imaging agents,
hydrophilic drugs and hydrophobic drugs.
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 General summary 
Preparation of gold nanoparticle and evaluation of its colloidal properties is presently 
a very dynamic area of research. New techniques are cautiously evolving that provide more 
control over the particle size, size distribution and shape of nanoparticles which make these 
particles very attractive for various applications. Gold nanoparticles have been investigated 
for many years because of their extensive use in various applications such as catalysis, 
photonics, electronics, optoelectronics, diagnostic, delivery, chemical, biological and 
biomedical sensing, surface plasmon resonance and surface-enhanced raman scattering 
(SERS) detection. The characteristic red color of the gold nanoparticle is due to the collective 
oscillation of the electrons in the conduction band, called surface plasmon resonance, which 
mainly depend on the shape, size and aggregation of the nanoparticle and dielectric constant 
of the surrounding medium. Classically, gold nanoparticles exhibit a single absorption peak 
in the visible range between 510 nm and 550 nm and with an increase in particle size, the 
absorption peak shifts to a longer wavelength. The width of the absorption spectra usually 
depends on the size distribution of the nanoparticles. The properties such as photostability, 
nontoxicity, surface plasmon resonance (SPR), easy surface functionalization, and their 
biocompatibility make these probes highly advantageous for biological  imaging,  cancer  
therapy,  and  drug  delivery,  immunoassay,  protein  assay,  and detection of cancer cells. 
There are two commonly used approaches for preparation of metallic nanoparticles, 
namely, “the bottom up approach”, which involves the association of atoms to fabricate 
nanoparticles, and “the top down method” which involves the constant division of bulk 
metals into nanoparticles. Currently, various techniques have been used for the preparation of 
gold nanoparticles such as, chemical, electrochemical, irradiation, sonochemical, 
photochemical and laser ablation. However the Turkevich citrate reduction method (reported 
in 1951), is still one of the most applied procedures, in which, sodium citrate reduces 
[AuCl4]- in hot aqueous solution to give colloids of 15-20 nm. In this method the size 
distribution of nanoparticles can be controlled by adjusting ration of gold salt to reducing 
agent, the temperature, and the order of addition of the reagents. Transmission electron 
microscopy (TEM) is the most common technique for characterization in term of average 
gold nanoparticles size and size distribution. Another very useful technique is UV-vis 
spectroscopy, which allows estimation of gold nanoparticles size, concentration, and 
aggregation level. Moreover, UV−vis spectrophotometers are present in most laboratories, 
the analysis does not alter the sample, and the registration of the spectrum requires short 
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 times. The extinction spectra of gold particles recorded by this technique can be analyzed 
using the Mie theory. 
In this study, gold nanoparticles were prepared by NaBH4 reduction method. Briefly, 
100 ml of HAuCl4 aqueous solution (0.25 mM) were taken in 250 ml flask with magnetic 
stirring at 750 rpm and 0.1 M reducing agent (NaBH4) solution was added drop by drop with 
continuous stirring. The color of HAuCl4 solution changed from pale yellow to dark red over 
several minutes. Stirring process was continued for another 10 minutes for complete 
homogenization. After preparation of the particles, the dispersions were centrifuge at 14000 
rpm for 15 min and the collected particles were redispersed in deionized water before any 
characterization. Several formulations were prepared by changing the concentration of 
reducing agent only, while all other parameters were kept constant. The average size of gold 
nanoparticles in various formulations were determined via different techniques such as 
dynamic light scattering, transmission electron microscopy, UV spectrum using standard 
curve and particles size calculated by using Mie theory and UV-vis spectrum of gold 
dispersion. Additionally, the polydispersity index was calculated from TEM images and 
effects of reducing agent concentrations were reported. 
 It was found that concentration of reducing agent did not affect the particle size and 
size distribution of gold nanodispersion up to certain limit (6.9 mM), however, when NaBH4  
was used in excess, the particle size was increased with relatively broad size distribution. The 
NaBH4 concentration had slight effect on particle morphology too, and TEM images showed 
that by increasing reducing agent the practice color become darker and also probability of 
aggregations increases due to excessive reduction of gold salt. As the gold nanoparticle size 
increases, the the absorption peak shifts to a longer wavelength and full dark color of gold 
nanoparticle dispersion is the indication of high aggregation tendency of particle. Moreover, 
when the particle size was analyzed by UV standard curve based technique using standard 
curve, the obtained results were in agreement with particle size measured by DLS in samples 
where narrow size distribution. The UV standard curve based technique works better for fully 
monodispersed preparations. The nanoparticle size was found to be smaller when measured 
by TEM as compared to hydrodynamic particle size determined by DLS technique. 
Nanoparticle size was also determined by using Mie theory based approach, optical 
absorption spectra of each sample were fitted using Lorentz equation and the particle size was 
found between 8 nm and 19 nm and almost in good agreement with those deduced from 
standard UV curve and TEM analysis. Thus gold nanoparticles can be prepared by NaBH4
reduction method. And the average gold nanoparticle size can be evaluated by methods based 
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 on the fitting of   their   UV−vis   spectra   by   the   Mie   model   for   spheres,   DLS,   TEM   
and   UV-vis spectrophotometer. 
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 Abstract
Gold nanoparticles have been used in various applications covering both electronics, 
biosensors, in vivo biomedical imaging and in vitro biomedical diagnosis. As a general 
requirement, gold nanoparticles should be prepared in large scale, easy to be functionalized 
by chemical compound of by specific ligands or biomolecules. In this study, gold 
nanoparticles were prepared by using different concentrations of reducing agent (NaBH4) in 
various formulations and their effect on the particle size, size distribution and morphology 
was investigated. Moreover, special attention has been dedicated to comparison of particles 
size measured by various techniques, such as, light scattering, transmission electron 
microscopy, UV spectrum using standard curve and particles size calculated by using Mie 
theory and UV spectrum of gold nanoparticles dispersion. Particle size determined by 
various techniques can be correlated for monodispersed particles and excess of reducing 
agent leads to increase in the particle size.
Keywords: A. Metals; A. Nanostructures: A. optical materials; B. Optical properties; C. 
Transmission electron microscopy 
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 1. Introduction 
Over the last three decades, nanoparticles research has received an increasing interest. 
This is due to the unique size dependent properties of nanoparticles, which are often thought 
as a separate and intermediate state of matter between individual atoms and bulk material 
(Schmid, 2006). Metal nanostructures present a wide variety of remarkable physical and 
chemical properties, which can be modified by changing their size, morphology, 
composition, and various preparation parameters (Abdelhalim and M. Mady, 2012; Schmid 
and Corain, 2003). Gold nanostructure have attracted considerable attention for many years 
because of their extensive use in various applications such as catalysis, photonics, 
electronics, optoelectronics, diagnostic, delivery, chemical, biological and biomedical 
sensing, photothermal therapy, surface plasmon resonance and surface-enhanced raman
scattering (SERS) detection (Basu et al., 2012; Doria et al., 2012; Iodice et al., 2016; Kamiar 
et al., 2013; Kaya, 2011; Long et al., 2009; Lu et al., 2012; Sardar et al., 2009). Gold 
nanoparticles (AuNPs) are considered as good candidate for labeling applications due to its 
ability of strong interaction with visible light. Upon interaction with light, the excitation of 
free electrons in gold atoms lead to a state of collective oscillation called surface plasmon 
resonance (SPR), which provide gold the ability to absorb and scatter visible light depending 
upon its size, shape and agglomeration state (Huang et al., 2006; Kumar et al., 2007).
AuNPs can be targeted and accumulated at specific tissue of interest thus enable 
visualization of that area under study. They can be detected by several techniques including 
phase contrast optical microscopy, dark field microscopy, photothermal imaging (Lim et al., 
2011; Roth, 1996) and confocal scanning optical microscopy (Li et al., 2009; Sokolov et al., 
2003). AuNPs have been reported to lack the capability to induce adverse and acute toxicity, 
thus, they are considered biocompatible device for biomedical applications (Connor et al., 
2005; Costa Lima and Reis, 2015; Shukla et al., 2005; Singh et al., 2015). These properties 
of nanoparticles result from the extremely high proportion of surface atoms, this factor is 
directly dependent on the size of the nanoparticle. Indeed, the possibility to control these 
properties by adjusting the size of the nanoparticle, has been the cause of extensive 
investigation. Contrary to bulk materials that have constant physical properties regardless of 
mass, nanoparticles offer unique opportunities to control the electrical, magnetic and optical 
properties by modifying their diameter.
Nanoparticles can be prepared from various materials by relatively simple methods. 
In recent years, several types of methods have been published and reviewed. Currently, there 
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 are two kinds of approaches commonly used to prepare nanoparticles, the “top down 
approach”, which involves the constant division of bulk metals into nanoparticles and the 
“bottom-up approach”, which involves the building up of nanoparticles from the atomic 
level (metal ions) (Iqbal et al., 2015; Kaya, 2011; Schmid and Corain, 2003). Various 
techniques such as, chemical, electrochemical, irradiation, sonochemical, solvothermal,
photochemical and laser ablation have been used to prepare nanoparticles from metal ions 
precursors in the presence or absence of a capping agent (Ahmad et al., 2013; Akhavan et 
al., 2010; Fattori et al., 2013; Long et al., 2009; Okitsu et al., 2005; Wender et al., 2011).
Michael Faraday was the first to study the formation of colloidal gold particles from a 
scientific point of view and used phosphorus agent for the reduction of [AuCl4]- ions 
(Faraday, 1857). During the last century, numerous easy to handle reducers were found, 
such as sodium borohydride, thiosulfate, or organic ones like, sodium citrate, ascorbic acid, 
alcohols (polyalcohol) and amines (Li et al., 2011; Lloret et al., 2013; Long et al., 2009; Paul
H. Davis et al., 2008; Salcedo and Sevilla III, 2013; Tabrizi et al., 2009). The Turkevich 
method is still one of the most applied procedures, in which, sodium citrate reduces [AuCl4]-
in hot aqueous solution to give colloids of 15-20 nm (Turkevich et al., 1951). Citrate itself
and its oxidation products can act as protecting agents, even if no other stabilizer is used. 
However one of the most popular methods for preparation of gold nanoparticles of various 
sizes comes from Brust et al. It uses NaBH4 to reduce gold salts in the presence of 
alkanethiols to yield gold particles of 1-3 nm. And, by varying the thiol concentration, the 
particles sizes can be controlled between 2 and 5 nm (Brust et al., 1994).
Characterization methods for analysis and measurement of nanomaterials are essential 
in the development of nanotechnology; as the sizes, shapes, and structures of nanomaterials
influence their physicochemical properties. The most common technique used for 
characterization of metallic nanoparticles is high-resolution transmission electron 
microscopy (HRTEM), which generates a photomicrograph of the core of the nanoparticles, 
providing information regarding the particle size, size distribution and polydispersity of the 
samples. UV-visible (optical) spectroscopy is used for analysis of the intensely colored 
colloidal dispersions having characteristic surface plasmon absorption (Abdelhalim and M. 
Mady, 2012; Ibraheem et al., 2014; Iqbal et al., 2014). In a given preparation of 
nanoparticles, there is usually a mixture of different size particles, which, have characteristic 
surface plasmon resonance peaks and thus their UV-visible spectra are usually significantly 
different, which may help in determining the nanoparticle size (Haiss et al., 2007).
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 The aim of this work is to characterize the prepared nanoparticles in terms of 
morphology, size and size distribution. Special attention was dedicated to comparison of 
particles size measured by light scattering, transmission electron microscopy, by UV using 
standard curve and the particles size was calculated using Mie theory and UV spectrum of 
gold dispersion.
2. Materials and methods
2.1. Materials
Gold (III) chloride hydrate (≥99.999%) was purchased from Sigma Aldrich, and 
sodium borohydride (NaBH4), 98+%, was purchased from Acros Organics. Water was 
deionized using (Aquadem® from Veolia Water, France). Nitric acid (68%) and Hydrochloric 
Acid (35%) were obtained from BDH Prolabo-VWR International. 
2.2. Preparation of gold nanoparticles
The preparation of gold nanoparticles was performed by NaBH4 reduction method as 
described in literature (Selvakannan et al., 2003). Briefly, 10 mg of HAuCl4 was dissolved in 
100 ml of deionized water (≈ 0.25 mM), and shaken properly to mix the solution. And, 0.1 M 
solution of reducing agent (NaBH4) was prepared by dissolving 1.891 g of NaBH4 in 500 ml 
of deionized water. Then, 100 ml of HAuCl4 (0.25 mM) were taken in 250 ml flask with 
magnetic stirring at 750 rpm (230 V, IKA® RET, Germany) and the reducing agent solution 
was added drop by drop with continuous stirring. The color of HAuCl4 solution changed from 
pale yellow to dark red over several minutes. Stirring process was continued for another 10 
minutes for complete homogenization. Since the HAuCl4 is corrosive, a glass spatula was 
used to avoid the contact with metal. In the preparation of gold nanoparticles, cleaning of 
glassware is very crucial. Thus, all the glassware and stir magnetic bars were thoroughly 
cleaned in freshly prepared aqua regia (HCl/HNO3 3:1, v/v) and then rinse with distilled 
water and dried, to avoid aggregation of residual gold particle and to avoid unwanted 
nucleation during synthesis. After preparation of the particles, the dispersions were centrifuge 
at 14000 rpm for 15 min and the collected particles were redispersed in deionized water 
before any characterization. All the gold nanoparticles batches were store in the dark to 
minimize the photo induced oxidation.
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 Fig. 1. Schematic illustration of gold nanoparticles preparation process using NaBH4 as 
reducing agent
2.3. Physicochemical characterization of nanoparticles.
2.3.1. Hydrodynamic particle size measurement
The hydrodynamic particles size (Dh) of the colloidal dispersions was determined by 
dynamic light scattering (DLS) using zetasizer from Malvern (England) at room temperature 
(25 C°). The mean hydrodynamic diameter is calculated by using the Stokes–Einstein’s 
equation: 
  ܦ݄ ൌ ௞்ଷగఎ஽ (1)
Where, k is the Boltzmann constant, T is the absolute temperature, η is the viscosity of the 
medium, and D is the diffusion coefficient. Each sample was prepared by adding 2 ml of the 
prepared nanoparticles dispersion in quartz cell and then the cell was placed in zetasizer for 
analysis. Mean particle size was determined at a scattering angle of 90° for all the samples. 
The particle size was determined in triplicate for all samples, and then averaged.
2.3.2. Transmission electron microscopy morphology and particles size analysis
Transmission electron microscopy (TEM) was performed with a Philips CM120 
microscope at the “Centre Technologique des Microstructures” (CTμ) at the University of 
Lyon (Villeurbanne, France). A small drop of suspension was deposited of a microscope grid 
(copper support covered with carbon) and slowly dried in open air. The dry samples were 
observed by TEM under 120 kV acceleration voltages. The average gold nanoparticles 
diameter and polydispersity index (PDI) were calculated for each sample by averaging 200 
HAuCl4 
solution 
Magnetic 
stirrer 
AuNPs 
dispersion 
NaBH4 
Stirring 
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 particles from the TEM images using ImageJ software (image processing program developed 
at the National Institutes of Health) 
2.3.3. Size determination using reported standard curve
The absorbance of gold nanoparticles dispersions was examined using 
spectrophotometer (UV-1800 Shimadzu, Japan). The washed dispersions were redisposed in 
deionized water and the absorbance was recorded from 190 nm to 750 nm as a function of 
wavelength using quartz cell with a path length of 1 cm. Two major information were 
extracted from the obtained spectrum i.e the maximum wavelength (λmax) and full width at 
half maximum (FWHM). The obtained λmax were used for particle size estimation by using 
standard curve (Ghosh et al., 2004) and the deduced λmax and FWHMused for the calculation 
of particles using Mie theory. Various dispersions of gold nanoparticles were prepared and 
then analyzed by a double beam UV-vis spectrophotometer (Shimadzu UV-1800) in the 
range of 190 nm to 750 nm. From the obtained spectra, maximum wavelength were extracted 
and used to estimate the particle size from the reported standard curve from Ghosh et 
al.(Ghosh et al., 2004) to access to the gold nanoparticle’s size.
Table 1 
Data from Ghosh et al.(Ghosh et al., 2004) in which particle size and maximum wavelengths 
absorption of gold nanoparticles are reported as a function of trisodium citrate concentration.  
Run HAuCl4 solution 
(10mM, mL)
Trisodium 
citrate solut-
ion (1%, mL)
Color λmax Average diameter (nm)
Reported Observed
A 1.25 2.000 Dark red 518 - 8.00
B 1.25 1.600 Red 519 - 10.0
C 1.25 1.300 Red 520 - 13.0
D 1.25 1.000 Red 522 16.0 16.0
E 1.25 0.875 Red 526 - 20.0
F 1.25 0.750 Red 528 24.5 25.0
G 1.25 0.625 Pinkish 
red
529 - 32.0
H 1.25 0.500 Pink 532 41.0 41.0
I 1.25 0.400 Pink 534 - 55.0
J 1.25 0.300 Orange 545 71.5 73.0
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 In order to determine the particles size of our samples, the data reported in Table 1 is used to 
establish the standard curve reported in Fig. 2. 
Fig. 2. Standard curve of particle size versus wavelength (nm) deduced from Table 1.
The reported data in Fig. 1 is fitted by the following linear equation: 
d (nm) = 2.511 λmax (nm) - 1294.8. (2)
This equation gives the relation between nanoparticles size and maximum wavelength that 
will be used to estimate the particle size of the gold prepared particles. 
2.3.4. Size determination using UV-vis Spectroscopy and Mie theory
The size, concentration, and, in some cases, aggregation level of AuNP are key points for 
nanoparticles  applications because they determine chemical, optical , electrical and 
biological properties (Amendola and Meneghetti, 2009; Schmid and Corain, 2003). The 
estimation of the average size of gold nanoparticles based on the fitting of their UV-vis 
spectra by the Mie model for sphere was used and explored in this study (Amendola and 
Meneghetti, 2009; Haiss et al., 2007). In fact, the average diameter d of various  noble metal 
(Ag, Au, Pt) can be estimated from electromagnetic theory of Mie (Akbari, 2011; Amendola 
and Meneghetti, 2009; Desai et al., 2012; Prikhodko et al., 2014) using the half-width of 
resonance optical absorption peak and characteristic wave length of plasmon resonance “λp”.
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 Where “vf” is the electron velocity corresponding to the fermi energy of the metal, “c” is the 
velocity of light, ∆λ is the full width at half maximum of absorption band, λp is the 
characteristic wave length at which SPR occurs (Manikandan et al., 2003) .  In order to find 
all these parameters; (full width at half maximum -FWHM, SPR position, absorbance 
intensity) spectra were fitted to Lorentzians. We have employed “ORIGIN 8.0” software. 
Utilization of the Mie model consists in an estimation of the average radius by fitting the 300-
800 nm spectral regions. 
3. Results and discussion
As above mentioned, various gold nanoparticles samples are prepared using the same 
recipe but not the same amount of reducing agent in order to know the effect of reducing 
agent concentration on particle size, size distribution and morphology. The obtained gold 
dispersions were characterized in term of hydrodynamic particles size, size distribution using 
light scattering. The morphology, the particle size and polydispersity were calculated from 
TEM image. The intrinsic photophysical property of the prepared gold nanoparticles was 
examined by spectrophotometry and the particles size was then examined using reported
standard curve or by using Mie theory. The obtained results are reported in Table 2 as a 
function of used method, approach and recipe. 
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 Table 2 
Composition of various formulations for preparation of gold nanoparticles. The concentration 
of HAuCl4 was fixed (0.25mM, 100 ml) for all formulations; only the concentration of 
reducing agent (NaBH4) agent was modified by changing volume of  NaBH4 (0.1M). The 
nanoparticles sizes determined by using different techniques are tabulated.
The physicochemical aspect of colloidal system such as, particle size and zeta potential, are 
known to influence the physical stability of colloids, release rate and their interaction with 
cells and biological environment. The particles were characterized on the basis of 
morphology, particle size and size distribution. 
3.1. Transmission Electron Microscopy morphology analysis
Transmission electronic microscopy (TEM) was performed in order to visualize the 
morphology of nanoparticles prepared by NaBH4 reduction of chloroauric acid solution.
Particles were evaluated on the basis of shape, size, size distribution, and presence of 
interparticles bridging and aggregation. Under TEM observations, the nanoparticles produced 
had spherical shapes (Fig. 4), with an average particle size smaller than 30 nm. The average 
particle sizes were also confirmed by light scattering analysis (Table 2). TEM Images showed 
slight aggregation between some particles (Fig. 4(F7a) and (F7b)), this can be attributed to 
Formula
tion code
Concentra
tion(mM) 
of HAuCl4
Concentrat
ion(mM) of 
NaBH4
λmax 
(nm)
PDI Particle size (nm) calculation versus 
used methods
DLS UV TEM Theore
-tical
F1 0.25 2.9 520 1.034 15.4 10.9 11.4 13.10
F2 0.25 3.8 525 1.059 18.8 23.5 13.7 8.42
F3 0.25 4.7 520 1.054 17.0 10.9 14.6 9.76
F4 0.25 6.5 523 1.035 19.4 18.5 10.1 9.70
F5 0.25 7.4 533 1.044 18.2 43.6 16.2 14.14
F6 0.25 6.9 523 1.049 17.7 18.5 15.6 8.10
F7 0.25 11.5 536.5 1.104 30.3 52.4 22.3 19.22
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 excessive reduction of gold salt solution; since comparatively high concentration of reducing 
agent was used in this formulation. However, at low reducing agent concentrations the 
particles were fairly detached and homogeneous (Fig. 4(F6a) and (F6b)).
Fig. 3. TEM micrograph of formulations prepared with different concentration of reducing 
agent (F1) 2.9 mM, (F2) 3.8 mM, (F3) 4.7 mM, (F4) 6.5 mM, (F5) 7.4 mM, (F6a,b) 6.9 mM,
and (F7a,b) 11.5 mM. Scale bars represent 50 nm in F2 and F3, 100 nm in F6a and 20 nm in 
all of the rest.
3.2. Particle size analysis via various methods
3.2.1. Light scattering and TEM Particles size and size distribution analysis 
Different dispersions of gold nanoparticles were prepared using various 
concentrations of reducing agent, while the concentrations of HAuCl4 were kept constant 
F3
F4
F2
F7a
F5 F6a
F6b
F1
F7b
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 throughout all formulations. Seven samples (F1, F2, F3, F4, F5, F6, and F7) were prepared by 
using freshly prepared reducing agent solution (NaBH4). From the obtained results, it was 
found that, by increasing the concentration of reducing agent from 2.9 mM (F1) to 7.4 mM 
(F5), there was no significant effect on particle size in all formulations and the average 
particle size was found between 15.4 nm and 19.4 nm when measured by using DLS 
technique (Table 2). However, at high concentration of reducing agent (11.5 mM) the particle 
was increased to 30.3 nm. Similar trend of slight increase in particles size was also found, 
when it was calculated from TEM images. The average particle size calculated from TEM, 
was smaller compare to hydrodynamic particle size as shown in Table 2, which is logical 
because, usually hydrodynamic particle size is larger than TEM particle size. The obtained 
results showed that particle size increases with an increase in reducing agent concentration.
This may be due to aggregation and over reduction of gold salt in the presence of excess of 
reducing agent. Though, Ghosh et al reported a decrease in particle size with an increase in 
reducing agent amount, however, they prepared NP via Frens’ method by using sodium 
citrate as reducing agent instead of NaBH4 with adsorbed pyrene on their surface (Ghosh et 
al., 2004). The polydispersity index (PDI) was calculated for each sample from the TEM 
images using ImageJ software and PDI was found between 1.034 and 1.104 (Table 2). The 
formulation F7 showed relatively high PDI due to slight attachments of particles.
The particle size distribution, which reflects the polydispersity of colloidal system, 
was also examined. It was observed that, with an increasing in NaBH4 concentration, there 
was slight increase is size distribution graph as shown in Fig. 4(C). This is also evident from 
TEM images, which shows some particle aggregation in Fig. 4(F7a) and (F7b). This may be 
due to high degree of gold salt reduction leading to slight aggregation, as no stabilizing agent 
was used in all formulations. Increase in particle size and size distribution by increasing 
reducing agent concentration has been already reported (Tabrizi et al., 2009). The high
surface energy of AuNPs makes them very reactive, which mostly leads to aggregation of 
particles without protection of their surfaces (Guo and Wang, 2007). However, at low 
reducing agent concentration (F6) the size distribution plot was narrow (Fig. 4(A) and (B))
with homogenous particle size.
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Fig. 4. Particle size distribution of various formulations prepared with different concentration 
of reducing agent (A, B and C represent sample F4, F6 and F7 respectively).
3.2.2. Particles size analysis by UV standard curve based method
For determination of particle size of our samples, we used the Eq. 2, which was 
derived from the standard curve (Fig. 2) based on the data taken from Table 1 (Ghosh et al., 
2004). For this purpose, first, the wavelength of maximum absorbance (λmax) for each 
sample of prepared nanoparticle dispersion was determined by using UV spectrophotometer 
(Table 2). Subsequently, the particle size was calculated for each formulation by putting their 
respective λmax values in Eq. 2, which relates the λmax with particle size (diameter).
Each formulation showed specific maximum wavelength (λmax), which reflect their 
photochemical characteristics. The λmax of different formulations was found between 520 
nm and 536.5 nm (Fig. 5), and the particles size calculated were in the range of 10.97 nm to 
52.40 nm (Table 2). A tendency of an increase in absorbance was found as the particle size 
increase, which were in agreement to those previously reported (Iwamoto et al., 2005; Njoki 
et al., 2007). The absorbance increase is due to the progressive increase in particle size; larger 
B 
A 
C 
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 particles have larger molar extinction coefficient values(Kuo et al., 2004; Link and El-Sayed, 
1999; Verma et al., 2014). Moreover, the particle size obtained from this calculation was in 
agreement with particle size determined by DLS (Table 2) in case of samples F2, F4 and F6, 
whereas slight deviations are shown in samples F5 and F7. The particle size calculated by this 
technique was large than DLS results, this may be due to partial aggregation of particles, 
especially in sample F7, which can also be seen from TEM images (Fig. 3(F7)). This 
equation (Eq. 2) can be ideal for completely monodispersed preparations and can be used to 
obtain information regarding nanoparticles polydispersity.
Fig. 5. Absorption spectra of gold nanoparticles dispersion prepared with different 
concentration of reducing agent. 
3.2.3. Size determination using UV-vis Spectroscopy and Mie theory
AuNPs show strong plasmon resonance absorption that is dependent on the particle 
size, shape and agglomeration. For almost spherical gold nanoparticles, the plasmon band 
maximum is generally between 520 and 530 nm. (Jana et al., 2001a, 2001b; Shimizu et al., 
2003). In order to determine the particle size, the obtained data of optical absorption spectra 
of each sample were fitted using Lorentz equation as below illustrated in Fig. 6 (for sample 
F6) in which optical absorption spectra was presented and mathematically fitted.
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 Fig. 6. Optical absorption spectra of the prepared gold nanoparticle (Lorentz fit of sample F6)
best fit of the optical surface plasmon absorption spectra using Mie equation.
The results of particles size estimation deduced from the best fitting using Mie theory 
are listed in Table 2. The determined diameters are in between 8 nm to 19 nm and almost in 
good agreement with those deduced from standard UV curve and TEM analysis. This method 
is more accurate and more establish theory compared to UV standard-based method. This 
Mie theory based approach has been already examined and totally approved as already 
reported (Haiss et al., 2007). The reported results showed that for the particle size larger than 
25 nm, both the theoretical and experimental peak positions precisely fit better compared to 
particle size smaller than 25 nm. This may be attributed to the proclaimed increase of the 
ratio of the surface atoms to bulk atoms for particle diameter smaller than 20 nm. Amendola 
et al. (Amendola and Meneghetti, 2009) show that the size of free or functionalized gold 
nanoparticles in water and other solvents, with diameters in between 4 and 25 nm, can be 
measured with an accuracy of about 6%. The literature value for Plasmon bands is usually in 
between 520 and 530 nm for spherical gold nanoparticles (Schmid and Corain, 2003). The 
maximum and the bandwidth of the plasmon band are both strongly dependent on the size 
and interactions with the surrounding medium. One can see that the SPR width increases for 
decreasing sizes in the 4-28 nm intervals.
4. Conclusion
In this study, the gold nanoparticles were fabricated that can be used for biomedical 
applications as imaging contrast agent both in vitro and in vivo. The effect of reducing agent 
concentration on the particle size, size distribution and morphology was investigated and also 
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 the particle size was determined via different techniques such as, DLS, TEM, UV-vis 
spectrophotometry and Mie theory. It was found that concentration of reducing agent did not 
affect the particle size and size distribution of gold nanodispersion up to specific 
concentration (F6), however, when NaBH4 was used in excess, the particle size was increased 
with relatively broad size distribution at  high concentration of reducing agent.  The reducing 
agent concentration had slight effect on particle morphology too, and TEM images showed 
that by increasing reducing agent the practice color become darker with distinct boundaries of 
particles and also probability of aggregations increases due to excessive reduction of gold 
salt. Moreover, when the particle size was analyzed by UV standard curve based technique 
using standard curve, the obtained results were in agreement with particle size measured by
DLS in samples where low concentration of reducing agent was used, however, at high 
concentration of NaBH4 the particle size calculated was larger than those of DLS technique 
because of slight particles aggregation in the sample as already reported in literature, that UV
standard curve based technique works better for fully monodispersed preparations. The 
nanoparticle size was also determined by using TEM images, and the average particle size 
was found to be smaller as compared to hydrodynamic particle size determined by DLS 
technique. Nanoparticle size was also determined by using Mie theory based approach, 
optical absorption spectra of each sample were fitted using Lorentz equation and the particle 
size was found between 8 nm and 19 nm and almost in good agreement with those deduced 
from standard UV curve and TEM analysis. 
From this study, it was concluded that the gold nanoparticles can be prepared 
successfully by NaBH4 reduction of HAuCl4, and their particle size can be verified through 
different methods. Furthermore, these particles can be used in biomedical imaging techniques 
as contrast agent such as MRI to visualize different tissues both for in vivo and in vitro 
applications and AuNPs can be surface functionalized for other potential applications in 
several field. These particles can be co-encapsulated with anticancer active agent for 
theranostic purpose.  
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Discussion and conclusion 
Nanotechnology has great potential for early detection, accurate diagnosis, and 
personalized treatment of many fetal diseases. Its application in biomedicine has been extensively 
studied over the last decade. Due to their specific size and shape, nanoparticles offer 
multifunctional capability by overcoming the numerous biological, biophysical, and biomedical 
barriers, which may revolutionize diagnosis and treatment of several diseases. It can offer 
unprecedented interactions with various biomolecules both on the surface of and inside the cells, 
and can offer platforms for efficient and targeted delivery of drugs and imaging agents for in 
vitro and ex vivo applications. The first step is the selection of appropriate technique for 
preparation of nanoparticle with required characteristics for intended application. Here, modified 
double emulsion solvent evaporation method was used for preparation of polymeric particle. This 
technique is appropriate for the encapsulation of both hydrophilic drugs and hydrophobic drugs. 
Moreover, it allows flexibility in particle size by adjusting various process parameters, the 
process is independent of special laboratory equipment, cost effective and preferable for low 
scale   production.   Conversely,   single   emulsion   process   allow   for   the   encapsulation   of 
hydrophobic molecules into a multitude of particulate materials, yet their application in 
hydrophilic compounds encapsulation is limited due to uncontrolled leakage of entrapped 
compounds during particles preparation. Polycaprolactone was selected as polymer due to its 
desirable properties such as biocompatibility, biodegradability and non-toxic nature. It has low 
glass transition temperature and melting point (60 °C), and the polymer metabolites are removed 
from the body by innate metabolic process and do not produce acidic environment as in case of 
PLA and PLGA. Its compatibility with variety of drugs, and its slow degradation rate to release 
drug for prolonged period of time makes it a suitable candidate for controlled drug delivery 
systems. Moreover, it allows the modification of its physicochemical and mechanical properties 
by copolymerization, which intern affect all other properties of polycaprolactone including 
solubility, ionic property and degradation pattern. Dichloromethane was chosen as solvent due to 
low boiling point (39.6 °C), immiscibility with water and its ability to dissolve polycaprolactone 
properly. 
As drug carriers, the large surface area of nanoparticles can enhance drug dissolution and 
they are capable to improve controlled release compared to micron-sized drug carriers. Though, 
their tendencies of aggregate are the potential problems to be overcome, therefore an appropriate 
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stabilizer may be needed to avoid aggregations. Poly vinyl alcohol (PVA) is a common stabilizer 
that has been used as an excipient in a wide range of pharmaceutical formulations. Here, PVA 
was used as stabilizer in the second step of emulsification process in order to facilitate 
homogenization and to prevent aggregation. It was used in different concentration in order to 
investigate  the  optimum  concentration  of  PVA,  and  0.5%  concentration  of  PVA  showed 
desirable results. Since, the physicochemical properties of the polymeric particle prepared via 
modified double emulsion are affected by the process parameters therefore various parameters 
were thoroughly investigated and the optimized parameter were used for the encapsulation of 
contrast agents and active drugs.  Polycaprolactone particle were prepared via double emulsion 
process by using two homogenization technique i.e mechanical (ultra-turrax) homogenization and 
sonication homogenization.  In utra-turrax process, the effects of stirring time and stirring speed 
in both, the first step and the second step of emulsification were investigated. Moreover, the 
effects of PCL amount, PVA concentration and outer aqueous phase volume, on particle size, size 
distribution and zeta potential were investigated. The size of obtained particles through this 
technique was in micron range.  Since, our goal was to obtain sub-micron particle therefore, we 
adopted sonication hominization for preparation of double emulsion. And, the effects of 
sonication process parameters were investigated in order to point out the relationship between the 
used conditions and the colloidal properties of obtained dispersion. The studied parameters were 
included, ultrasound exposure time in the first step and the second step of emulsification, 
sonication amplitude, polymer amount, PVA concentration and outer aqueous phase volume 
ratio. The particles obtained via double emulsion sonication homogenization were in submicron 
range (300-500 nm). Ultrasound exposure time is a key parameter affecting ultrasonic 
emulsification process.  In both, the first and the second step of emulsification, 2, 4, 6, 8, and 10 
min sonication time was used. In the first step, sonication time had no significant effect on the 
particle size and morphology while in the second step, the particle size gradually decreased with 
the increase in ultrasound exposure time. The ultrasound amplitudes used in this study were 50%, 
60%, 70%, 80%, and 90%. Initially, when 50% of amplitude was used, no homogenization was 
observed and both, the oily phase and the aqueous phase of double emission were distinctly 
visible. This was probably due to insufficient energy transmitted to the emulsion system to induce 
cavitation. Once cavitation threshold was reached, by increasing amplitude to 60% and above, 
then a proper homogenization of the system was achieved. There was tendency of decrease in 
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particle size with the increase in amplitude and the smallest particles were obtained at 90 % 
sonication amplitude.  Various formulations were prepared with different amount of polymer in 
order to study its effect and we found that by increasing the polymer amount the particle size also 
increases and the particle with good morphology were obtained at 3 g of PLC.  This increase in 
particle size with increase in PCL solid content can be attributed to increased viscosity of the 
primary emulsion, which leads to less particle size reduction during second step of 
emulsification. The addition of suitable stabilizer plays an important role in colloidal dispersions. 
The nature and concentration of stabilizer affect the colloidal stability of the prepared dispersion. 
In this study, concentration effect of PVA in the outer aqueous phase over average hydrodynamic 
particle size and morphology of particles were evaluated. When PVA concentration was 
decreased beyond 0.2% there was drastic increase in particle size, this may be due to coalescence 
of droplets, since, this amount of PVA was insufficient to cover properly the nanoparticles 
surfaces and no homogenization was achieved in the absence of PVA. There was no significant 
effect of PVA concentration above 0.2 %, and optimal morphology of particles was found at 
0.5% of PVA concentration. 
Generally, imaging is performed for diagnosis of a disease state before therapy of several 
diseases like cancer by using proper imaging technique. Several imaging technologies (Magnetic 
resonance, optical etc.) depend on contrast agent, highlighting the differences between tissues 
thus, allows efficient visualization of the tissues of interest. Contrast agents are encapsulated in 
order  to  enhance  their  stability  and  to  deliver  high  payload  of  contrast  agents  to  target 
specifically. In the light of these optimized parameters, the fluorescent contrast agent 
(FluoSpheres®) was loaded into polycaprolactone particles in different concentration. The 
contrast agent-containing submicron particle was characterized in term of average particle size, 
morphology and encapsulation efficiency. Moreover, contrast agent distribution in the PCL 
matrix was determined by confocal microscopy. The incorporation of contrast agent in different 
concentrations did not affect the physicochemical properties of PCL particles and the average 
size of loaded particles was found to be in the submicron range. However, the particles loaded 
with high fluorescent argent concentration showed high fluorescence intensity when visualized 
by confocal microscopy, which show their proper encapsulation into PCL matrix. The average 
size of loaded particle were about 322-375 nm and it was not affected by variation in loaded 
fluorescent agent amount. The encapsulation efficiency was found to be high enough i.e from 
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84% to 91% in different formulations. The skin penetration study was performed and red 
fluorescence allowed easy identification of loaded particles on the surface of skin and hair 
follicles. PLC particles remained on the surface of both stratum corneum and under passive 
diffusion conditions, no penetration of particles was found. Since, impermeability of the stratum 
corneum is the main barrier to cutaneous molecule absorption. Another important issue is the 
mechanical stress applied to the skin when investigating the penetration behavior. Therefore the 
application of a mechanical stimulation to the skin may be used to enhance its permeability. The 
zeta potential was found near to zero this may be due to non-charged nature of the 
polycaprolactone polymer. 
Another contrast agent frequently used for imaging in biomedical applications targeting 
theranostic is gold nanoparticles. They play an important role in in vitro assays, ex vivo and in 
vivo imaging, and drug delivery. A multifunctional platform based on gold nanoparticles have 
several capability such as, targeting , multimodal imaging, delivery of therapeutic moieties, thus,  
holds the promise for a “magic gold bullet” against cancer and other fetal disease. First, gold 
nanoparticles were prepared by NaBH4 reduction technique. 100 ml of HAuCl4 (0.25 mM) 
solution in deionized water was reduced by adding NaBH4 dropwise and stirred via magnetic 
stirring at 750 rpm. The relationship of various NaBH4 concentrations in different formulations, 
with respect to the nanoparticle size and morphology was evaluated. The average sizes of gold 
nanoparticle were about 20 nm at low concentration of NaBH4 (3-7 mM) however at 11.5 mM of 
NaBH4 the particle size was increased to 30 nm and the color of dispersion was changed from 
dark red to dark, which show that over reduction of gold salt leads to aggregation of particle. The 
gold nanoparticle size was measured by using various approaches such as, dynamic light 
scattering, transmission electron microscopy, UV spectrophotometry using standard curve and 
calculated particles size using Mie theory and UV spectrum of gold dispersion and the obtained 
results were compared with each other. 
After well characterization, the prepared gold nanoparticles were then encapsulated by 
polycaprolactone matrix, to be used as MRI or optical contrast agent. And in the next step, the 
PCL submicron particles were loaded with gold nanoparticles as contrast agent, a hydrophilic 
drug (Nefopam) and a lipophilic drug (benzyl benzoate) simultaneous to fabricate a 
multifunctional particle. The encapsulation efficiency of benzyl benzoate was almost 100 percent 
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as it is a lipophilic drug thus, having no affinity of leakage from polymeric matrix to outer 
aqueous phase. 
Perspectives: 
In future, further study will be conducted regarding pharmacokinetic and 
pharmacodynamics  of  the  contrast  agents  and  the  drug  encapsulated  via  double  emulsion 
process. For skin penetration study of contrast agent loaded particle, we will evaluate the impact 
of the removal of the stratum corneum and the application of a mechanical stimulation.  The 
obtained results provide valuable information regarding particles preparation and encapsulation 
via modified double emulsion process and their possible application in cancer therapy. In light of 
this study, various drugs and imaging agent will be encapsulated for different diseases using 
theranostic approach.  It will be applied to other route of administrations.  Since, 
multifunctionality is the key feature of theranostic agents. Therefore, targeting ligands, imaging 
labels, multiple therapeutic drugs, and other functionalities can all be integrated to allow for 
targeted molecular imaging and therapy of various diseases via theranostic approach.  The 
successful achievement of all these goals will be helpful in timely and better management of 
various fetal diseases. 
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Préparation de particules submicroniques pour applications théranostiques: imagerie et 
thérapie 
Résumé 
L'objectif de cette étude était de préparer et de caractériser les particules submicroniques 
multifonctionnelles utilisables simultanément pour le diagnostic et le traitement de plusieurs maladies 
mortelles telles que le cancer. Pour ce faire, une étude systématique a été réalisée afin de comprendre 
les mécanismes impliqués et d'optimiser les paramètres du procédé   de double émulsion-évaporation 
de solvant pour la préparation de ces particules. Pour l’imagerie in vitro, des nanoparticules 
polymériques fluorescentes (FluoSpheres®) ont  été encapsulées dans une matrice polycaprolactone 
dégradable en utilisant le procédé de l’émulsion double-évaporation de solvant. Pour l’imagerie in-
vivo, des nanoparticules d'or colloïdal ont été préparées et encapsulées via le même procédé et 
parfaitement caractérisées. Enfin, pour application theranostic, les nanoparticules d'or (comme agent 
de contraste) et un actif moléculaire (hydrophile Nefopam et hydrophobe benzoate de benzyle) ont été 
encapsulés simultanément dans des  particules de polycaprolactone. Ces particules multifonctionnelles 
ont été caractérisées et évaluées in vitro comme model de pénétration cutané 
Mots clés: Encapsulation, les particules submicroniques, Imaging, Théranostic, Double émulsion, les 
nanoparticules d'or, Agent de contraste. 
 
Preparation of submicron particles for theranostic applications: imaging and therapy 
Summary 
The objective of this study was to prepare and characterize multifunctional submicron particles that 
can be used for diagnosis and therapy of several fatal diseases including cancer (i.e theranostic). For 
this purpose, a systematic study was performed in order to optimize the process parameters for 
preparation of polymeric particle that can be used as a platform for effective delivery of drugs and 
imaging labels. The imaging agent (FluoSpheres®) was encapsulated via double emulsion solvent 
evaporation technique to be used fluorescent contrast agent and their in vitro evaluation was 
performed. Then, gold nanoparticles were prepared by using NaBH4 reduction method, characterized 
and encapsulated by polycaprolactone polymer for in vitro applications. Finally, the gold nanoparticle 
were loaded into polycaprolactone particle along with a hydrophilic drug (Nefopam) and a 
hydrophobic drug (benzyl benzoate) simultaneously. The prepared particles were then characterized 
physicochemically and in vitro skin penetration study was performed. 
Keywords: Encapsulation, Submicron particles, Imaging, Theranostic, Double emulsion, Gold 
nanoparticles, Contrast agent. 
 
